NITRONE HERBICIDES FIELD OF THE DISCLOSURE

This disclosure relates to certain nitrone compounds, N-oxides thereof, and salts of the nitrones and N-oxides; compositions comprising such nitrones, N-oxides and salts; processes for making such nitrones, N-oxides, salts and compositions; and methods for using such nitrones, N-oxides, salts and compositions to control undesirable vegetation.

BACKGROUND

The control of undesired vegetation is extremely important in achieving high crop efficiency. Achievement of selective control of the growth of weeds especially in such useful crops as rice, soybean, sugar beet, maize, potato, wheat, barley, tomato and plantation crops, among others, is very desirable. Unchecked weed growth in such useful crops can cause significant reduction in productivity and thereby result in increased costs to the consumer. The control of undesired vegetation in noncrop areas is also important. Many products are commercially available for these purposes, but the need continues for new compounds that are more effective, less costly, less toxic, environmentally safer or have different sites of action.

SUMMARY

This disclosure relates, in part, to compounds of Formula 1 (including all

stereoisomers), N-oxides of such compounds, and salts of such compounds and N-oxides:

wherein

Q ¹ is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with up to 4 substituents independently selected from R ⁷ ; or a 4- to 7-membered heterocyclic ring; or an 8- to 10-membered bicyclic ring system, each ring or ring system containing ring members selected from carbon atoms and 1 to 5 heteroatoms independently selected from up to 2 O, up to 2 S and up to 5 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently selected from S(=O) _u (=NR ⁸ ) _v , each ring or ring system optionally substituted with up to 5 substituents independently selected from R ⁷ on carbon atom ring members and selected from R ⁹ on nitrogen atom ring members; or

Q ¹ is C ₂ –C ₁₀ alkenylene, C ₂ –C ₁₀ alkynylene, C ₂ –C ₁₀ haloalkenylene, C ₂ –C ₁₀

haloalkynylene, C ₄ –C ₁₀ cycloalkenylene, C ₄ –C ₁₀ halocycloalkenylene, C ₂ –C ₈ alkylenecarbonyl or C ₂ –C ₈ alkoxyalkylene;

T is H; or

T is J ¹ -A-, wherein the free bond projecting to the right next to A indicates the

connecting point of J ¹ -A- to Q ¹ ; or

T is R ¹⁷ ON=CR ^17a -, (R ¹⁸ ) ₂ C=NO-, (R ¹⁹ ) ₂ NN=CR ^17a -, (R ¹⁸ ) ₂ C=NNR ²¹ ,

R ²⁰ N=CR ^17a -, (R ¹⁸ ) ₂ C=N-, R ¹⁷ ON=CR ^17a C(R ²² ) ₂ - or (R ¹⁸ ) ₂ C=NOC(R ²³ ) ₂ -, wherein the free bond projecting to the right indicates the connecting point to Q ¹ ; T is R ⁷ , provided T is bonded to a carbon ring member of Q ¹ ; or

T is R ⁹ , provided T is bonded to a nitrogen ring member of Q ¹ ;

A is a saturated, partially unsaturated or fully unsaturated chain containing 1 to 3

atoms selected from up to 3 carbon, up to 1 O, up to 1 S and up to 2 N atoms, the chain optionally substituted with up to 2 substituents independently selected from R ¹⁵ on carbon atoms and R ¹⁶ on nitrogen atoms;

Q ² is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with up to 5 substituents independently selected from R ¹⁰ ; or a 4- to 7-membered heterocyclic ring or an 8- to 10-membered bicyclic ring system, each ring or ring system containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 5 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently selected from S(=O) _u (=NR ⁸ ) _v , each ring or ring system optionally substituted with up to 5 substituents independently selected from R ¹⁰ on carbon atom ring members and selected from R ¹¹ on nitrogen atom ring members; or

Q ² is C ₂ –C ₁₀ alkenyl, C ₂ –C ₁₀ alkynyl, C ₂ –C ₁₀ haloalkenyl, C ₂ –C ₁₀ haloalkynyl, C ₄ -C ₁₀ cycloalkenyl, C ₄ –C ₁₀ halocycloalkenyl, C ₂ –C ₈ alkylcarbonyl or C ₂ –C ₈ alkoxyalkyl;

J ¹ is a phenyl ring or a naphthalenyl ring system, each ring or ring system optionally substituted with up to 5 substituents independently selected from R ^7a ; or a 4- to 6-membered heterocyclic ring or an 8- to 10-membered bicyclic ring system, each ring or ring system containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently selected from S(=O) _u (=NR ⁸ ) _v , each ring or ring system optionally substituted with up to 5 substituents independently selected from R ^7a on carbon atom ring members and selected from R ⁹ on nitrogen atom ring members; or

J ¹ is C ₄ –C ₁₀ cycloalkylalkoxy, C ₄ –C ₁₀ cycloalkylalkyl, C ₂ –C ₈ alkenyloxy, C ₂ –C ₈ haloalkenyloxy, C ₂ –C ₈ alkoxyalkoxy, C ₂ –C ₈ alkylthioalkyl, C ₂ –C ₈

alkylsulfinylalkyl, C ₂ –C ₈ alkylsulfonylalkyl, C ₁ –C ₈ alkylsulfonyloxy, C ₁ –C ₈ haloalkylsulfonyloxy, C ₁ –C ₈ alkylthio, C ₁ –C ₈ haloalkylthio, C ₃ –C ₈

cycloalkylthio, C ₁ –C ₈ alkylsulfinyl, C ₁ –C ₈ haloalkylsulfinyl, C ₁ –C ₈ alkylsulfonyl, C ₁ –C ₈ haloalkylsulfonyl, C ₂ –C ₈ alkynyl, C ₂ –C ₈ haloalkynyl, C ₂ -C ₈ alkoxyalkyl, C ₂ –C ₈ haloalkoxyalkyl, C ₃ –C ₈ haloalkoxyalkoxy, C ₂ –C ₈ haloalkoxyhaloalkyl, C ₁ –C ₈ haloalkyl, C ₃ –C ₈ halocycloalkyl, C ₂ –C ₈ alkylcarbonyloxy or C ₂ –C ₈ haloalkylcarbonyloxy;

J ² is (–CR ² R ³ –) _z ,–NR ^2b – or–O–;

Y is O, S or NR ¹² ;

R ¹ is H, hydroxy, amino, cyano, formyl, C ₃ –C ₈ alkylcarbonylalkyl, -C(C ₁ –C ₄

alkyl)=N-O(C ₁ –C ₄ alkyl), -C(O)NH ₂ , C ₁ –C ₆ alkyl, C ₁ –C ₆ haloalkyl, C ₂ –C ₆ alkenyl, C ₃ –C ₆ alkynyl, C ₂ –C ₆ cyanoalkyl, C ₃ –C ₆ cycloalkyl, C ₃ –C ₈ cycloalkenyl, C ₄ –C ₈ cycloalkylalkyl, C ₂ –C ₈ alkoxyalkyl, C ₃ –C ₈

alkoxyalkoxyalkyl, C ₂ –C ₈ haloalkoxyalkyl, C ₂ –C ₈ haloalkenylalkyl, C ₂ –C ₈ alkylthioalkyl, C ₂ –C ₈ alkylsulfinylalkyl, C ₂ –C ₈ alkylsulfonylalkyl, C ₅ –C ₁₀ cycloalkylcarbonylalkyl, C ₁ –C ₆ alkoxy, C ₁ –C ₆ alkylthio, C ₁ –C ₆ haloalkylthio, C ₃ –C ₈ cycloalkylthio, C ₁ –C ₆ alkylsulfinyl, C ₁ –C ₆ haloalkylsulfinyl, C ₃ –C ₈ cycloalkylsulfinyl, C ₁ –C ₆ alkylsulfonyl, C ₁ –C ₆ haloalkylsulfonyl, C ₃ –C ₈ cycloalkylsulfonyl, C ₁ –C ₆ alkylaminosulfonyl, C ₂ –C ₈ dialkylaminosulfonyl, C ₃ –C ₁₀ trialkylsilyl; or -CPh=N-O(C ₁ –C ₄ alkyl), each optionally substituted on ring members with up to 5 substituents independently selected from R ¹³ ; or G ¹ ; or W ¹ G ¹ ;

R ^2b is C ₁ –C ₆ alkyl, C ₂ –C ₆ alkenyl, C ₃ –C ₆ alkynyl or C ₁ –C ₆ alkoxy; or

R ¹ and R ^2b are taken together as C ₃ –C ₆ alkylene or–CH ₂ OCH ₂ –;

each R ² and R ³ , bonded to the same carbon atom, is independently H, halogen,

hydroxy, C ₁ –C ₄ alkyl, C ₁ –C ₄ haloalkyl or C ₁ –C ₄ alkoxy; or

R ² and R ³ , together with the carbon atom to which they are both bonded, form a C ₃ -C ₇ cycloalkyl ring;

each R ² and R ³ bonded to the same carbon atom is defined independent of any R ² and R ³ bonded to a different carbon atom;

R ⁴ and R ⁵ are each independently H, halogen, hydroxy, C ₁ –C ₄ alkoxy, C ₁ –C ₄

haloalkyl or C ₁ –C ₄ alkyl; R ⁶ is H, hydroxy, amino, C ₁ –C ₆ alkyl, C ₁ –C ₆ haloalkyl, C ₂ –C ₆ alkenyl, C ₃ –C ₆ alkynyl, C ₂ –C ₈ alkoxyalkyl, C ₂ –C ₈ haloalkoxyalkyl, C ₂ –C ₈ alkylthioalkyl, C ₂ -C ₈ alkylsulfinylalkyl, C ₂ –C ₈ alkylsulfonylalkyl, C ₂ –C ₈ alkylcarbonyl, C ₂ –C ₈ haloalkylcarbonyl, C ₄ –C ₁₀ cycloalkylcarbonyl, C ₂ –C ₈ alkoxycarbonyl, C ₂ –C ₈ haloalkoxycarbonyl, C ₄ –C ₁₀ cycloalkoxycarbonyl, C ₂ –C ₈ alkylaminocarbonyl, C ₃ –C ₁₀ dialkylaminocarbonyl, C ₄ –C ₁₀ cycloalkylaminocarbonyl, C ₁ –C ₆ alkoxy, C ₁ –C ₆ alkylthio, C ₁ –C ₆ haloalkylthio, C ₃ –C ₈ cycloalkylthio, C ₁ –C ₆

alkylsulfinyl, C ₁ –C ₆ haloalkylsulfinyl, C ₃ –C ₈ cycloalkylsulfinyl, C ₁ –C ₆ alkylsulfonyl, C ₁ –C ₆ haloalkylsulfonyl, C ₃ –C ₈ cycloalkylsulfonyl, C ₁ –C ₆ alkylaminosulfonyl, C ₂ –C ₈ dialkylaminosulfonyl or C ₃ –C ₁₀ trialkylsilyl or G ¹ ; or

R ⁶ and Q ² are taken together with the nitrogen atom to which they are both bonded to form an 8- to 10-membered bicyclic ring system, each ring or ring system containing ring members selected from carbon atoms and 1 to 4 heteroatoms independently selected from up to 2 O, up to 2 S and up to 4 N atoms, wherein up to 3 carbon ring members are independently selected from C(=O) and C(=S), and the sulfur atom ring members are independently selected from

S(=O) _u (=NR ⁸ ) _v , each ring or ring system optionally substituted with up to 5 substituents independently selected from R ⁷ on carbon atom ring members and selected from R ¹¹ on nitrogen atom ring members;

each R ⁷ is independently halogen, hydroxy, cyano, nitro, amino, C ₁ –C ₈ alkyl, C ₁ –C ₈ cyanoalkyl, C ₁ –C ₈ cyanoalkoxy, C ₁ –C ₈ haloalkyl, C ₁ –C ₈ nitroalkyl, C ₂ –C ₈ alkenyl, C ₂ –C ₈ haloalkenyl, C ₂ –C ₈ nitroalkenyl, C ₂ –C ₈ alkynyl, C ₂ –C ₈ haloalkynyl, C ₂ –C ₈ alkoxyalkyl, C ₃ –C ₈ alkoxyalkoxyalkyl, C ₂ –C ₈

haloalkoxyalkyl, C ₂ –C ₈ haloalkoxyhaloalkoxy, C ₃ –C ₆ cycloalkyl,

cyclopropylmethyl, 1-methylcyclopropyl, 2-methylcyclopropyl, C ₄ –C ₁₀ cycloalkylalkyl, C ₄ –C ₁₀ halocycloalkylalkyl, C ₅ –C ₁₂ alkylcycloalkylalkyl, C ₅ -C ₁₂ cycloalkylalkenyl, C ₅ –C ₁₂ cycloalkylalkynyl, C ₃ –C ₈ cycloalkyl, C ₃ –C ₈ halocycloalkyl, C ₄ –C ₁₀ alkylcycloalkyl, C ₆ –C ₁₂ cycloalkylcycloalkyl, C ₃ –C ₈ cycloalkenyl, C ₃ –C ₈ halocycloalkenyl, C ₂ –C ₈ haloalkoxyalkoxy, C ₂ –C ₈ alkoxyalkoxy, C ₄ –C ₁₀ cycloalkoxyalkyl, C ₃ –C ₁₀ alkoxyalkoxyalkyl, C ₂ –C ₈ alkylthioalkyl, C ₂ –C ₈ alkylsulfinylalkyl, C ₂ –C ₈ alkylsulfonylalkyl, C ₁ –C ₈ alkylamino, C ₂ –C ₈ dialkylamino, C ₂ –C ₈ halodialkylamino, C ₂ –C ₈

alkylaminoalkyl, C ₂ –C ₈ haloalkylaminoalkyl, C ₄ –C ₁₀ cycloalkylaminoalkyl, C ₃ –C ₁₀ dialkylaminoalkyl, -CHO, C ₂ –C ₈ alkylcarbonyl, C ₂ –C ₈

haloalkylcarbonyl, C ₄ –C ₁₀ cycloalkylcarbonyl, -C(=O)OH, C ₂ –C ₈

alkoxycarbonyl, C ₂ –C ₈ haloalkoxycarbonyl, C ₄ –C ₁₀ cycloalkoxycarbonyl, C ₅ -C ₁₂ cycloalkylalkoxycarbonyl, -C(=O)NH ₂ , C ₂ –C ₈ alkylaminocarbonyl, C ₄ -C ₁₀ cycloalkylaminocarbonyl, C ₃ –C ₁₀ dialkylaminocarbonyl, C ₁ –C ₈ alkoxy, C ₁ –C ₈ haloalkoxy, C ₂ –C ₈ alkoxyalkoxy, C ₂ –C ₈ alkenyloxy, C ₂ –C ₈

haloalkenyloxy, C ₃ –C ₈ alkynyloxy, C ₃ –C ₈ haloalkynyloxy, C ₃ –C ₈ cycloalkoxy, C ₃ –C ₈ halocycloalkoxy, C ₄ –C ₁₀ cycloalkylalkoxy, C ₃ –C ₁₀ alkylcarbonylalkoxy, C ₂ –C ₈ alkylcarbonyloxy, C ₂ –C ₈ haloalkylcarbonyloxy, C ₄ –C ₁₀

cycloalkylcarbonyloxy, C ₁ –C ₈ alkylsulfonyloxy, C ₁ –C ₈ haloalkylsulfonyloxy, C ₁ –C ₈ alkylthio, C ₁ –C ₈ haloalkylthio, C ₃ –C ₈ cycloalkylthio, C ₁ –C ₈

alkylsulfinyl, C ₁ –C ₈ haloalkylsulfinyl, C ₁ –C ₈ alkylsulfonyl, C ₁ –C ₈

haloalkylsulfonyl, C ₃ –C ₈ cycloalkylsulfonyl, formylamino, C ₂ –C ₈

alkylcarbonylamino, C ₂ –C ₈ haloalkylcarbonylamino, C ₃ –C ₈ cycloalkylamino, C ₂ –C ₈ alkoxycarbonylamino, C ₁ –C ₆ alkylsulfonylamino, C ₁ –C ₆

haloalkylsulfonylamino, -SF ₅ , -SCN, SO ₂ NH ₂ , C ₃ –C ₁₂ trialkylsilyl, C ₄ –C ₁₂ trialkylsilylalkyl, C ₄ –C ₁₂ trialkylsilylalkoxy or C ₁ –C ₆ haloalkylamino; or G ² ; or each R ⁷ is independently R ²⁶ S(=O)=N–, R ²⁶ S(=O) ₂ NR ²⁵ –C(=O)–,

R ²⁶ (R ²⁵ N=) _q S(=O) _p –, wherein the free bond projecting to the right indicates the connecting point to Q ¹ ; or

two adjacent R ⁷ , are taken together with the carbon atoms to which they are bonded to form a C ₃ –C ₇ cycloalkyl ring;

each R ^7a is independently halogen, hydroxy, cyano, nitro, C ₁ –C ₈ alkyl, C ₂ –C ₄

alkoxyalkyl, C ₃ –C ₈ alkoxyalkoxyalkyl, C ₁ –C ₄ cyanoalkyl, C ₁ –C ₄ cyanoalkoxy, C ₁ –C ₈ haloalkyl, C ₁ –C ₈ nitroalkyl, C ₂ –C ₈ alkenyl, C ₂ –C ₈ haloalkenyl, C ₂ –C ₈ nitroalkenyl, C ₂ –C ₈ alkynyl, C ₂ –C ₈ haloalkynyl, C ₄ –C ₁₀ cycloalkylalkyl, C ₄ -C ₁₀ halocycloalkylalkyl, C ₅ –C ₁₂ alkylcycloalkylalkyl, C ₅ –C ₁₂

cycloalkylalkenyl, C ₅ –C ₁₂ cycloalkylalkynyl, C ₃ –C ₈ cycloalkyl, C ₃ –C ₈ halocycloalkyl, C ₄ –C ₁₀ alkylcycloalkyl, C ₆ –C ₁₂ cycloalkylcycloalkyl, C ₃ –C ₈ cycloalkenyl, C ₃ –C ₈ halocycloalkenyl, C ₂ –C ₈ alkoxyalkyl, C ₂ –C ₈

haloalkoxyalkyl, C ₄ –C ₁₀ cycloalkoxyalkyl, C ₃ –C ₁₀ alkoxyalkoxyalkyl, C ₂ –C ₈ alkylthioalkyl, C ₂ –C ₈ alkylsulfinylalkyl, C ₂ –C ₈ alkylsulfonylalkyl, C ₂ –C ₈ alkylaminoalkyl, C ₂ –C ₈ haloalkylaminoalkyl, C ₄ –C ₁₀ cycloalkylaminoalkyl, C ₃ –C ₁₀ dialkylaminoalkyl, -CHO, C ₂ –C ₈ alkylcarbonyl, C ₂ –C ₈

haloalkylcarbonyl, C ₄ –C ₁₀ cycloalkylcarbonyl, -C(=O)OH, C ₂ –C ₈

alkoxycarbonyl, C ₂ –C ₈ haloalkoxycarbonyl, C ₄ –C ₁₀ cycloalkoxycarbonyl, C ₅ -C ₁₂ cycloalkylalkoxycarbonyl, -C(=O)NH ₂ , C ₂ –C ₈ alkylaminocarbonyl, C ₄ -C ₁₀ cycloalkylaminocarbonyl, C ₃ –C ₁₀ dialkylaminocarbonyl, C ₁ –C ₈ alkoxy, C ₁ –C ₈ haloalkoxy, C ₂ –C ₈ alkoxyalkoxy, C ₂ –C ₈ alkenyloxy, C ₂ –C ₈

haloalkenyloxy, C ₃ –C ₈ alkynyloxy, C ₃ –C ₈ haloalkynyloxy, C ₃ –C ₈ cycloalkoxy, C ₃ –C ₈ halocycloalkoxy, C ₄ –C ₁₀ cycloalkylalkoxy, C ₃ –C ₁₀ alkylcarbonylalkoxy, C ₂ –C ₈ alkylcarbonyloxy, C ₂ –C ₈ haloalkylcarbonyloxy, C ₄ –C ₁₀ cycloalkylcarbonyloxy, C ₁ –C ₈ alkylsulfonyloxy, C ₁ –C ₈ haloalkylsulfonyloxy, C ₁ –C ₈ alkylthio, C ₁ –C ₈ haloalkylthio, C ₃ –C ₈ cycloalkylthio, C ₁ –C ₈

alkylsulfinyl, C ₁ –C ₈ haloalkylsulfinyl, C ₁ –C ₈ alkylsulfonyl, C ₁ –C ₈

haloalkylsulfonyl, C ₃ –C ₈ cycloalkylsulfonyl, amino, C ₁ –C ₈ alkylamino, C ₁ -C ₆ haloalkylamino, C ₃ –C ₈ cycloalkylamino, C ₂ –C ₈ dialkylamino, C ₂ –C ₈ halodialkylamino, formylamino, C ₂ –C ₈ alkylcarbonylamino, C ₂ –C ₈

haloalkylcarbonylamino, C ₁ –C ₆ alkylsulfonylamino, C ₁ –C ₆

haloalkylsulfonylamino, -SF ₅ , -SCN, C ₃ –C ₁₂ trialkylsilyl, C ₄ –C ₁₂

trialkylsilylalkyl, C ₄ –C ₁₂ trialkylsilylalkoxy; or

two adjacent R ^7a , are taken together with the carbon atoms to which they are bonded to form a C ₃ –C ₇ cycloalkyl ring;

each R ⁸ is independently H, cyano, C ₂ –C ₃ alkylcarbonyl or C ₂ –C ₃ haloalkylcarbonyl; each R ⁹ and R ¹¹ are independently cyano, C ₁ –C ₃ alkyl, C ₂ –C ₃ alkenyl, C ₂ –C ₃

alkynyl, C ₃ –C ₆ cycloalkyl, C ₂ –C ₃ alkoxyalkyl, C ₁ –C ₃ alkoxy, C ₂ –C ₃ alkylcarbonyl, C ₂ –C ₃ alkoxycarbonyl, C ₂ –C ₃ alkylaminoalkyl or C ₃ –C ₄ dialkylaminoalkyl;

each R ¹⁰ is independently halogen, hydroxy, cyano, nitro, amino, C ₁ –C ₈ alkyl, C ₁ –C ₈ cyanoalkyl, C ₁ –C ₈ cyanoalkoxy, C ₁ –C ₈ haloalkyl, C ₁ –C ₈ nitroalkyl, C ₂ –C ₈ alkenyl, C ₂ –C ₈ haloalkenyl, C ₂ –C ₈ nitroalkenyl, C ₂ –C ₈ alkynyl, C ₂ –C ₈ haloalkynyl, C ₂ –C ₈ alkoxyalkyl, C ₃ –C ₈ alkoxyalkoxyalkyl, C ₂ –C ₈

haloalkoxyalkyl, C ₂ –C ₈ haloalkoxyhaloalkoxy, C ₃ –C ₆ cycloalkyl,

cyclopropylmethyl, 1-methylcyclopropyl, 2-methylcyclopropyl, C ₄ –C ₁₀ cycloalkylalkyl, C ₄ –C ₁₀ halocycloalkylalkyl, C ₅ –C ₁₂ alkylcycloalkylalkyl, C ₅ -C ₁₂ cycloalkylalkenyl, C ₅ –C ₁₂ cycloalkylalkynyl, C ₃ –C ₈ cycloalkyl, C ₃ –C ₈ halocycloalkyl, C ₄ –C ₁₀ alkylcycloalkyl, C ₆ –C ₁₂ cycloalkylcycloalkyl, C ₃ –C ₈ cycloalkenyl, C ₃ –C ₈ halocycloalkenyl, C ₂ –C ₈ haloalkoxyalkoxy, C ₂ –C ₈ alkoxyalkoxy, C ₄ –C ₁₀ cycloalkoxyalkyl, C ₃ –C ₁₀ alkoxyalkoxyalkyl, C ₂ –C ₈ alkylthioalkyl, C ₂ –C ₈ alkylsulfinylalkyl, C ₂ –C ₈ alkylsulfonylalkyl, C ₁ –C ₈ alkylamino, C ₂ –C ₈ dialkylamino, C ₂ –C ₈ halodialkylamino, C ₂ –C ₈

alkylaminoalkyl, C ₂ –C ₈ haloalkylaminoalkyl, C ₄ –C ₁₀ cycloalkylaminoalkyl, C ₃ –C ₁₀ dialkylaminoalkyl, -CHO, C ₂ –C ₈ alkylcarbonyl, C ₂ –C ₈

haloalkylcarbonyl, C ₄ –C ₁₀ cycloalkylcarbonyl, -C(=O)OH, C ₂ –C ₈

alkoxycarbonyl, C ₂ –C ₈ haloalkoxycarbonyl, C ₄ –C ₁₀ cycloalkoxycarbonyl, C ₅ -C ₁₂ cycloalkylalkoxycarbonyl, -C(=O)NH ₂ , C ₂ –C ₈ alkylaminocarbonyl, C ₄ -C ₁₀ cycloalkylaminocarbonyl, C ₃ –C ₁₀ dialkylaminocarbonyl, C ₁ –C ₈ alkoxy, C ₁ –C ₈ haloalkoxy, C ₂ –C ₈ alkoxyalkoxy, C ₂ –C ₈ alkenyloxy, C ₂ –C ₈

haloalkenyloxy, C ₃ –C ₈ alkynyloxy, C ₃ –C ₈ haloalkynyloxy, C ₃ –C ₈ cycloalkoxy, C ₃ –C ₈ halocycloalkoxy, C ₄ –C ₁₀ cycloalkylalkoxy, C ₃ –C ₁₀ alkylcarbonylalkoxy, C ₂ –C ₈ alkylcarbonyloxy, C ₂ –C ₈ haloalkylcarbonyloxy, C ₄ –C ₁₀

cycloalkylcarbonyloxy, C ₁ –C ₈ alkylsulfonyloxy, C ₁ –C ₈ haloalkylsulfonyloxy, C ₁ –C ₈ alkylthio, C ₁ –C ₈ haloalkylthio, C ₃ –C ₈ cycloalkylthio, C ₁ –C ₈ alkylsulfinyl, C ₁ –C ₈ haloalkylsulfinyl, C ₁ –C ₈ alkylsulfonyl, C ₁ –C ₈

haloalkylsulfonyl, C ₃ –C ₈ cycloalkylsulfonyl, formylamino, C ₂ –C ₈

alkylcarbonylamino, C ₂ –C ₈ haloalkylcarbonylamino, C ₃ –C ₈ cycloalkylamino, C ₂ –C ₈ alkoxycarbonylamino, C ₁ –C ₆ alkylsulfonylamino, C ₁ –C ₆

haloalkylsulfonylamino, -SF ₅ , -SCN, SO ₂ NH ₂ , C ₃ –C ₁₂ trialkylsilyl, C ₄ –C ₁₂ trialkylsilylalkyl, C ₄ –C ₁₂ trialkylsilylalkoxy, C ₁ –C ₆ haloalkylamino, C ₁ –C ₈ hydroxalkyl or G ² ; or

each R ¹⁰ is independently R ¹⁷ ON=CR ^17a –, (R ¹⁸ ) ₂ C=NO–, (R ¹⁹ ) ₂ NN=CR ^17a –,

(R ¹⁸ ) ₂ C=NNR ²¹ –, R ²⁰ N=CR ^17a –, (R ¹⁸ ) ₂ C=N–, R ¹⁷ ON=CR ^17a C(R ²² ) ₂ –, (R ¹⁸ ) ₂ C=NOC(R ²³ ) ₂ –, R ²⁶ S(=O)=N–, R ²⁶ S(=O) ₂ NR ²⁵ –C(=O)– or

R ²⁶ (R ²⁵ N=) _q S(=O) _p –, wherein the free bond projecting to the right of any such substituent indicates the connecting point to Q ² ; or

two adjacent R ¹⁰ , are taken together with the carbon atoms to which they are bonded form a C ₃ –C ₇ cycloalkyl ring;

each R ¹² is independently H, cyano, hydroxy, CHO, C ₁ –C ₄ alkyl, C ₁ –C ₄ haloalkyl, C ₁ –C ₄ alkoxy, C ₁ –C ₄ haloalkoxy, C ₂ –C ₆ alkylcarbonyl, C ₂ –C ₆

haloalkylcarbonyl, -(C=O)CH ₃ or -(C=O)CF ₃ ;

each G ¹ is independently phenyl, phenylmethyl (i.e. benzyl), pyridinylmethyl,

phenylcarbonyl (i.e. benzoyl), phenylcarbonylalkyl, phenoxy, phenylethynyl, phenylsulfonyl or a 5- or 6-membered heterocyclic ring, each optionally substituted on ring members with up to 5 substituents independently selected from R ¹³ ;

each G ² is independently phenyl, phenylmethyl (i.e. benzyl), pyridinylmethyl,

phenylcarbonyl (i.e. benzoyl), phenylcarbonylalkyl, phenoxy, phenylethynyl, phenylsulfonyl or a 5- or 6-membered heterocyclic ring, each optionally substituted on ring members with up to 5 substituents independently selected from R ¹³ ;

W ¹ is C ₁ –C ₃ alkylene, C ₂ –C ₄ alkenylene, C ₂ –C ₄ alkynylene,–(C ₁ –C ₂

alkylene)C(=O)–,–C(=O)(C ₁ –C ₂ alkylene)–,–CH ₂ O–,–CH ₂ NH–,–OCH ₂ –, –NCH ₂ –,–N–,–O–,–S–,–SO– or–SO ₂ – wherein the free bond projecting to the left indicates the connecting point of W ¹ to N and the free bond projecting to the right indicates the connecting point of W ¹ to G ¹ ;

each R ¹³ is independently halogen, cyano, hydroxy, amino, nitro, -CHO,

-C(=O)OH, -C(=O)NH ₂ , -SO ₂ NH ₂ , C ₁ –C ₆ alkyl, C ₁ –C ₆ haloalkyl, C ₂ –C ₆ alkenyl, C ₂ –C ₆ alkynyl, C ₂ –C ₈ alkylcarbonyl, C ₂ –C ₈ haloalkylcarbonyl, C ₂ –C ₈ alkoxycarbonyl, C ₄ –C ₁₀ cycloalkoxycarbonyl, C ₅ –C ₁₂

cycloalkylalkoxycarbonyl, C ₂ –C ₈ alkylaminocarbonyl, C ₃ –C ₁₀

dialkylaminocarbonyl, C ₁ –C ₆ alkoxy, C ₁ –C ₆ haloalkoxy, C ₂ –C ₈

alkylcarbonyloxy, C ₁ –C ₆ alkylthio, C ₁ –C ₆ haloalkylthio, C ₁ –C ₆ alkylsulfinyl, C ₁ –C ₆ haloalkylsulfinyl, C ₁ –C ₆ alkylsulfonyl, C ₁ –C ₆ haloalkylsulfonyl, C ₁ –C ₆ alkylaminosulfonyl, C ₂ –C ₈ dialkylaminosulfonyl, C ₃ –C ₁₀ trialkylsilyl, C ₁ –C ₆ alkylamino, C ₂ –C ₈ dialkylamino, C ₂ –C ₈ alkylcarbonylamino, C ₁ –C ₆ alkylsulfonylamino, phenyl, pyridinyl or thienyl;

each R ¹⁵ is independently halogen, cyano, hydroxy, C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₁ -C ₄ alkoxy, C ₁ -C ₄ haloalkoxy, C ₂ -C ₄ alkoxyalkyl, C ₂ -C ₄ alkylcarbonyl, C ₂ -C ₄ alkoxycarbonyl or C ₃ -C ₆ cycloalkyl;

each R ¹⁶ is independently H, cyano, C ₁ -C ₄ alkyl, C ₁ -C ₄ haloalkyl, C ₁ -C ₄ alkoxy, C ₂ -C ₄ alkylcarbonyl, C ₂ -C ₄ alkoxycarbonyl or C ₃ -C ₆ cycloalkyl;

each R ¹⁷ is independently H, C ₁ –C ₆ alkyl, C ₃ –C ₈ cycloalkyl, C ₄ –C ₈ cycloalkylalkyl, C ₁ –C ₆ haloalkyl, C ₂ –C ₆ alkenyl, C ₃ –C ₆ alkynyl, C ₂ –C ₈ alkoxyalkyl, C ₂ –C ₈ haloalkoxyalkyl, C ₂ –C ₈ alkylthioalkyl, C ₂ –C ₈ alkylsulfinylalkyl, C ₂ –C ₈ alkylsulfonylalkyl, C ₂ –C ₈ alkylcarbonyl, C ₂ –C ₈ haloalkylcarbonyl, C ₄ –C ₁₀ cycloalkylcarbonyl, C ₂ –C ₈ alkoxycarbonyl, C ₂ –C ₈ haloalkoxycarbonyl, C ₄ – C ₁₀ cycloalkoxycarbonyl, C ₂ –C ₈ alkylaminocarbonyl, C ₃ –C ₁₀

dialkylaminocarbonyl, C ₄ –C ₁₀ cycloalkylaminocarbonyl, C ₁ –C ₆ alkylsulfinyl, C ₁ –C ₆ haloalkylsulfinyl, C ₃ –C ₈ cycloalkylsulfinyl, C ₁ –C ₆ alkylsulfonyl, C ₁ – C ₆ haloalkylsulfonyl, C ₃ –C ₈ cycloalkylsulfonyl, C ₁ –C ₆ alkylaminosulfonyl, C ₂ –C ₈ dialkylaminosulfonyl, C ₃ –C ₁₀ trialkylsilyl or G ¹ ;

each R ^17a is independently H, C ₁ –C ₆ alkyl, C ₃ –C ₈ cycloalkyl, C ₄ –C ₈ cycloalkylalkyl, C ₁ –C ₆ haloalkyl, C ₂ –C ₆ alkenyl, C ₃ –C ₆ alkynyl, C ₂ –C ₈ alkoxyalkyl, C ₂ –C ₈ haloalkoxyalkyl, C ₂ –C ₈ alkylthioalkyl, C ₂ –C ₈ alkylsulfinylalkyl, C ₂ –C ₈ alkylsulfonylalkyl, C ₁ –C ₆ alkoxy, C ₁ –C ₆ alkylthio, C ₁ –C ₆ haloalkylthio, C ₃ – C ₈ cycloalkylthio, C ₃ –C ₁₀ trialkylsilyl or G ¹ ;

each R ¹⁸ is independently H, hydroxy, C ₁ –C ₆ alkyl, C ₃ –C ₈ cycloalkyl, C ₄ –C ₈

cycloalkylalkyl, C ₁ –C ₆ haloalkyl, C ₂ –C ₆ alkenyl, C ₃ –C ₆ alkynyl, C ₂ –C ₈ alkoxyalkyl, C ₂ –C ₈ haloalkoxyalkyl, C ₂ –C ₈ alkylthioalkyl, C ₂ –C ₈ alkylsulfinylalkyl, C ₂ –C ₈ alkylsulfonylalkyl, C ₂ –C ₈ alkylcarbonyl, C ₂ –C ₈ haloalkylcarbonyl, C ₄ –C ₁₀ cycloalkylcarbonyl, C ₂ –C ₈ alkoxycarbonyl, C ₂ –C ₈ haloalkoxycarbonyl, C ₄ –C ₁₀ cycloalkoxycarbonyl, C ₂ –C ₈

alkylaminocarbonyl, C ₃ –C ₁₀ dialkylaminocarbonyl, C ₄ –C ₁₀

cycloalkylaminocarbonyl, C ₁ –C ₆ alkoxy, C ₁ –C ₆ alkylthio, C ₁ –C ₆

haloalkylthio, C ₃ –C ₈ cycloalkylthio, C ₁ –C ₆ alkylsulfinyl, C ₁ –C ₆

haloalkylsulfinyl, C ₃ –C ₈ cycloalkylsulfinyl, C ₁ –C ₆ alkylsulfonyl, C ₁ –C ₆ haloalkylsulfonyl, C ₃ –C ₈ cycloalkylsulfonyl, C ₁ –C ₆ alkylaminosulfonyl, C ₂ – C ₈ dialkylaminosulfonyl, C ₃ –C ₁₀ trialkylsilyl or G ¹ ;

each R ¹⁹ is independently H, C ₁ –C ₆ alkyl, C ₃ –C ₈ cycloalkyl, C ₄ –C ₈ cycloalkylalkyl, C ₁ –C ₆ haloalkyl, C ₂ –C ₆ alkenyl, C ₃ –C ₆ alkynyl, C ₂ –C ₈ alkoxyalkyl, C ₂ –C ₈ haloalkoxyalkyl, C ₂ –C ₈ alkylthioalkyl, C ₂ –C ₈ alkylsulfinylalkyl, C ₂ –C ₈ alkylsulfonylalkyl, C ₂ –C ₈ alkylcarbonyl, C ₂ –C ₈ haloalkylcarbonyl, C ₄ –C ₁₀ cycloalkylcarbonyl, C ₂ –C ₈ alkoxycarbonyl, C ₂ –C ₈ haloalkoxycarbonyl, C ₄ –C ₁₀ cycloalkoxycarbonyl, C ₂ –C ₈ alkylaminocarbonyl, C ₃ –C ₁₀

dialkylaminocarbonyl, C ₄ –C ₁₀ cycloalkylaminocarbonyl, C ₁ –C ₆ alkoxy, C ₁ –C ₆ alkylsulfinyl, C ₁ –C ₆ haloalkylsulfinyl, C ₃ –C ₈ cycloalkylsulfinyl, C ₁ –C ₆ alkylsulfonyl, C ₁ –C ₆ haloalkylsulfonyl, C ₃ –C ₈ cycloalkylsulfonyl, C ₁ –C ₆ alkylaminosulfonyl, C ₂ –C ₈ dialkylaminosulfonyl, C ₃ –C ₁₀ trialkylsilyl or G ¹ ; each R ²⁰ is independently H, hydroxy, amino, C ₁ –C ₆ alkyl, C ₃ –C ₈ cycloalkyl, C ₄ –C ₈ cycloalkylalkyl, C ₁ –C ₆ haloalkyl, C ₂ –C ₆ alkenyl, C ₃ –C ₆ alkynyl, C ₂ –C ₈ alkoxyalkyl, C ₂ –C ₈ haloalkoxyalkyl, C ₂ –C ₈ alkylthioalkyl, C ₂ –C ₈

alkylsulfinylalkyl, C ₂ –C ₈ alkylsulfonylalkyl, C ₂ –C ₈ alkylcarbonyl, C ₂ –C ₈ haloalkylcarbonyl, C ₄ –C ₁₀ cycloalkylcarbonyl, C ₂ –C ₈ alkoxycarbonyl, C ₂ –C ₈ haloalkoxycarbonyl, C ₄ –C ₁₀ cycloalkoxycarbonyl, C ₂ –C ₈ alkylaminocarbonyl, C ₃ –C ₁₀ dialkylaminocarbonyl, C ₄ –C ₁₀ cycloalkylaminocarbonyl, C ₁ –C ₆ alkoxy, C ₁ –C ₆ alkylsulfinyl, C ₁ –C ₆ haloalkylsulfinyl, C ₃ –C ₈ cycloalkylsulfinyl, C ₁ –C ₆ alkylsulfonyl, C ₁ –C ₆ haloalkylsulfonyl, C ₃ –C ₈ cycloalkylsulfonyl, C ₁ –C ₆ alkylaminosulfonyl, C ₂ –C ₈ dialkylaminosulfonyl, C ₃ –C ₁₀ trialkylsilyl or G ¹ ; each R ²¹ is independently H, C ₁ –C ₆ alkyl, C ₃ –C ₈ cycloalkyl, C ₄ –C ₈ cycloalkylalkyl, C ₁ –C ₆ haloalkyl, C ₂ –C ₆ alkenyl, C ₃ –C ₆ alkynyl, C ₂ –C ₈ alkoxyalkyl, C ₂ –C ₈ haloalkoxyalkyl, C ₂ –C ₈ alkylthioalkyl, C ₂ –C ₈ alkylsulfinylalkyl, C ₂ –C ₈ alkylsulfonylalkyl, C ₁ –C ₆ alkoxy, C ₃ –C ₁₀ trialkylsilyl or G ¹ ;

each R ²² is independently H, halogen, cyano, hydroxy, C ₁ –C ₄ alkyl, C ₃ –C ₈

cycloalkyl, C ₄ –C ₈ cycloalkylalkyl, C ₁ –C ₄ haloalkyl, C ₁ –C ₄ alkoxy, C ₁ –C ₄ haloalkoxy, C ₂ –C ₄ alkoxyalkyl, C ₂ –C ₄ alkylcarbonyl, C ₂ –C ₄ alkoxycarbonyl or C ₃ –C ₆ cycloalkyl;

each R ²³ is independently H, C ₁ –C ₄ alkyl, C ₃ –C ₈ cycloalkyl, C ₄ –C ₈ cycloalkylalkyl, C ₁ –C ₄ haloalkyl, C ₁ –C ₄ alkoxy, C ₁ –C ₄ haloalkoxy, C ₂ –C ₄ alkoxyalkyl, C ₂ –C ₄ alkylcarbonyl, C ₂ –C ₄ alkoxycarbonyl or C ₃ –C ₆ cycloalkyl;

each R ²⁵ is independently H, cyano, C ₂ –C ₃ alkylcarbonyl or C ₂ –C ₃ haloalkylcarbonyl; each R ²⁶ is independently H, C ₁ –C ₆ alkyl, C ₃ –C ₈ cycloalkyl, C ₄ –C ₈ cycloalkylalkyl, C ₁ –C ₆ haloalkyl, C ₂ –C ₆ alkenyl, C ₃ –C ₆ alkynyl, C ₂ –C ₈ alkoxyalkyl, C ₂ –C ₈ haloalkoxyalkyl, C ₂ –C ₈ alkylthioalkyl, C ₂ –C ₈ alkylsulfinylalkyl, C ₂ –C ₈ alkylsulfonylalkyl, C ₁ –C ₆ alkoxy, C ₃ –C ₁₀ trialkylsilyl or G ¹ ; each u and v are independently 0, 1 or 2 in each instance of S(=O) _u (=NR ⁸ ) _v , provided that the sum of u and v is 0, 1 or 2;

each p and q are independently 0, 1 or 2 in each instance of R ²⁶ (R ²⁵ N=) _q S(=O) _p –, provided that the sum of p and q is 0, 1 or 2; and

z is 1, 2 or 3.

This disclosure also relates, in part, to an agricultural composition (generally herbicidal) comprising such a compound, N-oxide or salt in a herbicidally effective amount and at least one component selected from the group consisting of surfactants, solid diluents and liquid diluents, the composition optionally further comprising at least one additional active ingredient selected from the group consisting of other herbicides and herbicide safeners.

This dislcosure also relates, in part, to a herbicidal mixture comprising (a) a compound selected from Formula 1, N-oxides, and salts thereof, and (b) at least one additional active ingredient selected from (b1) through (b16); and salts of compounds of (b1) through (b16), as described below.

This disclosure also relates, in part, to processes for making the above-identified compounds, N-oxides, salts and compositions.

This disclosure also relates, in part, to methods for controlling the growth of undesired vegetation comprising contacting the vegetation or its environment with a herbicidally effective amount of an above-identified compound, N-oxide, salt or composition.

DETAILED DESCRIPTION

As used herein, the terms“comprises,”“comprising,”“includes,”“incl uding,”“has,” “having,”“contains”,“containing,”“characterize d by” or any other variation thereof, are intended to cover a non-exclusive inclusion, subject to any limitation explicitly indicated. For example, a composition, mixture, process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, mixture, process, method, article, or apparatus.

The transitional phrase“consisting of” excludes any element, step, or ingredient not specified. If in the claim, such would close the claim to the inclusion of materials other than those recited except for impurities ordinarily associated therewith. When the phrase “consisting of” appears in a clause of the body of a claim, rather than immediately following the preamble, it limits only the element set forth in that clause; other elements are not excluded from the claim as a whole.

The transitional phrase“consisting essentially of” is used to define a composition, method or apparatus that includes materials, steps, features, components, or elements, in addition to those literally disclosed, provided that these additional materials, steps, features, components, or elements do not materially affect the basic and novel characteristic(s) of the claimed disclosure. The term“consisting essentially of” occupies a middle ground between “comprising” and“consisting of”.

Where applicants have defined an disclosure or a portion thereof with an open-ended term such as“comprising,” it should be readily understood that (unless otherwise stated) the description should be interpreted to also describe such an disclosure using the terms “consisting essentially of” or“consisting of.”

Further, unless expressly stated to the contrary,“or” refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).

Also, the indefinite articles“a” and“an” preceding an element or component of the disclosure are intended to be nonrestrictive regarding the number of instances (i.e. occurrences) of the element or component. Therefore“a” or“an” should be read to include one or at least one, and the singular word form of the element or component also includes the plural unless the number is obviously meant to be singular.

As referred to herein, the term“seedling”, used either alone or in a combination of words means a young plant developing from the embryo of a seed.

As referred to herein, the term“broadleaf” used either alone or in words such as “broadleaf weed” means dicot or dicotyledon, a term used to describe a group of angiosperms characterized by embryos having two cotyledons.

In the above recitations, the term“alkyl”, used either alone or in compound words such as“alkylthio” or“haloalkyl” includes straight-chain or branched alkyl, such as, methyl, ethyl, n-propyl, i-propyl, or the different butyl, pentyl or hexyl isomers. “Alkenyl” includes straight-chain or branched alkenes such as ethenyl, 1-propenyl, 2-propenyl, and the different butenyl, pentenyl and hexenyl isomers. “Alkenyl” also includes polyenes such as 1,2-propadienyl and 2,4-hexadienyl.“Alkynyl” includes straight-chain or branched alkynes such as ethynyl, 1-propynyl, 2-propynyl and the different butynyl, pentynyl and hexynyl isomers. “Alkynyl” can also include moieties comprised of multiple triple bonds such as 2,5-hexadiynyl. “Alkylene” denotes a straight-chain or branched alkanediyl. Examples of “alkylene” include CH ₂ , CH ₂ CH ₂ , CH(CH ₃ ), CH ₂ CH ₂ CH ₂ , CH ₂ CH(CH ₃ ) and the different butylene isomers.“Alkenylene” denotes a straight-chain or branched alkenediyl containing one olefinic bond. Examples of“alkenylene” include CH=CH, CH ₂ CH=CH and CH=C(CH ₃ ). “Alkynylene” denotes a straight-chain or branched alkynediyl containing one triple bond. Examples of“alkynylene” include C≡C, CH ₂ C≡C, C≡CCH ₂ and the different butynylene isomers.

“Alkoxy” includes, for example, methoxy, ethoxy, n-propyloxy, isopropyloxy and the different butoxy, pentoxy and hexyloxy isomers.“Alkoxyalkyl” denotes alkoxy substitution on alkyl. Examples of“alkoxyalkyl” include CH ₃ OCH ₂ -, CH ₃ OCH ₂ CH ₂ -, CH ₃ CH ₂ OCH ₂ -, CH ₃ CH ₂ CH ₂ CH ₂ OCH ₂ - and CH ₃ CH ₂ OCH ₂ CH ₂ -. “Aloxyalkoxyalkyl” denotes alkoxy substitution on the alkoxy moiety of an alkoxyalkyl moiety. Examples of“alkoxyalkoxyalkyl” include CH ₃ OCH ₂ OCH ₂ -, CH ₃ CH ₂ O(CH ₃ )CHOCH ₂ - and (CH ₃ O) ₂ CHOCH ₂ -. “Alkoxyalkoxy” denotes alkoxy substitution on alkoxy. Examples of“alkoxyalkoxy” include CH ₃ OCH ₂ O-, CH ₃ OCH ₂ (CH ₃ O)CHCH ₂ O- and (CH ₃ ) ₂ CHOCH ₂ CH ₂ O-. “Alkenyloxy” includes straight-chain or branched alkenyloxy moieties. Examples of“alkenyloxy” include H ₂ C=CHCH ₂ O-, (CH ₃ ) ₂ C=CHCH ₂ O-, (CH ₃ )CH=CHCH ₂ O-, (CH ₃ )CH=C(CH ₃ )CH ₂ O- and CH ₂ =CHCH ₂ CH ₂ O-.“Alkynyloxy” includes straight-chain or branched alkynyloxy moieties. Examples of“alkynyloxy” include HC≡CCH ₂ O-, CH ₃ C≡CCH ₂ O- and CH ₃ C≡CCH ₂ CH ₂ O-. “Alkylthio” includes branched or straight-chain alkylthio moieties such as methylthio, ethylthio, and the different propylthio, butylthio, pentylthio and hexylthio isomers. “Alkylsulfinyl” includes both enantiomers of an alkylsulfinyl group. Examples of “alkylsulfinyl” include CH ₃ S(O)-, CH ₃ CH ₂ S(O)-, CH ₃ CH ₂ CH ₂ S(O)-, (CH ₃ ) ₂ CHS(O)- and the different butylsulfinyl, pentylsulfinyl and hexylsulfinyl isomers. Examples of “alkylsulfonyl” include CH ₃ S(O) ₂ -, CH ₃ CH ₂ S(O) ₂ -, CH ₃ CH ₂ CH ₂ S(O) ₂ -, (CH ₃ ) ₂ CHS(O) ₂ -, and the different butylsulfonyl, pentylsulfonyl and hexylsulfonyl isomers.“Alkylthioalkyl” denotes alkylthio substitution on alkyl. Examples of“alkylthioalkyl” include CH ₃ SCH ₂ -, CH ₃ SCH ₂ CH ₂ -, CH ₃ CH ₂ SCH ₂ -, CH ₃ CH ₂ CH ₂ CH ₂ SCH ₂ - and CH ₃ CH ₂ SCH ₂ CH ₂ -. “Alkylsulfinylalkyl” denotes alkylsulfinyl substitution on alkyl. Examples of “alylsulfinylalkyl” include CH ₃ S(=O)CH ₂ -, CH ₃ S(=O)CH ₂ CH ₂ -, CH ₃ CH ₂ S(=O)CH ₂ - and CH ₃ CH ₂ S(=O)CH ₂ CH ₂ -. “Alkylamino” “dialkylamino”, and the like, are defined analogously to the above examples.“Alkylaminoalkyl” denotes a straight-chain or branched alkyl moieties bonded to a nitrogen atom of amino(straight-chain or branched)alkyl moiety. Examples of “alkylaminoalkyl” include CH ₃ NHCH ₂ -, (CH ₃ ) ₂ CHNHCH ₂ - and CH ₃ NHCH(CH ₃ )-. “Haloalkylaminoalkyl” denotes an halogen group substituted with alkylaminoalkyl group.“Haloalkylaminoalkyl” includes halogen group attached any alkyl groups as well as nitrogen. Examples of “haloalkylaminoalkyl” include CH ₃ NHCHCl-, (CH ₃ ) ₂ CClNHCH ₂ - and CH ₃ NClCH(CH ₃ )-.“Dialkylaminoalkyl” denotes two independent straight-chain or branched alkyl moieties bonded to a nitrogen atom of amino(straight-chain or branched)alkyl moiety. Examples of “dialkylaminoalkyl” include (CH ₃ ) ₂ NCH ₂ -, (CH ₃ ) ₂ NC(CH ₃ )H- and (CH ₃ )(CH ₃ )NCH ₂ -.“Cyanoalkyl” denotes an alkyl group substituted with one cyano group. Examples of “cyanoalkyl” include NCCH ₂ -, NCCH ₂ CH ₂ - and CH ₃ CH(CN)CH ₂ -.“Cyanoalkoxy” denotes an alkoxy group substituted with one cyano group. Examples of “cyanoalkoxy” include NCCH ₂ O-, NCCH ₂ CH ₂ O- and CH ₃ CH(CN)CH ₂ O-. “Alkenylthio”, “alkenylsulfinyl”, “alkenylsulfonyl”, “alkynylthio”, “alkynylsulfinyl”, “alkynylsulfonyl”, and the like, are defined analogously to the above examples. “Alkylcarbonyl” denotes a straight-chain or branched alkyl moieties bonded to a C(=O) moiety. Examples of “alkylcarbonyl” include CH ₃ C(=O)-, CH ₃ CH ₂ CH ₂ C(=O)- and (CH ₃ ) ₂ CHC(=O)-. An example of“cycloalkylcarbonyl” is cyclopentyl-C(=O)-. Examples of “haloalkylcarbonyl” include C(O)CF ₃ , C(O)CCl ₃ , C(O)CH ₂ CF ₃ and C(O)CF ₂ CF ₃ . Examples of “alkylcarbonylalkoxy” include CH ₃ C(=O)CH ₂ O-, CH ₃ CH ₂ CH ₂ C(=O)CH ₂ O- and (CH ₃ ) ₂ CHC(=O)CH ₂ O-. “Alkylcarbonyloxy” denotes an alkylcarbonyl moiety linked through an oxygen atom attached to the carbonyl. Examples of“alkylcarbonyloxy” include CH ₃ C(=O)O-, CH ₃ CH ₂ CH ₂ C(=O)O- and (CH ₃ ) ₂ CHC(=O)O-. Examples of “cycloalkylcarbonyloxy” include cyclopentyl-C(=O)O-. Examples of “alkoxycarbonyl” include CH ₃ OC(=O)-, CH ₃ CH ₂ OC(=O)-, CH ₃ CH ₂ CH ₂ OC(=O)-, (CH ₃ ) ₂ CHOC(=O)- and the different butoxy- or pentoxycarbonyl isomers. Examples of“alkylaminocarbonyl” include CH ₃ NHC(O)-, (CH ₃ ) ₂ CHNHC(O)- and CH ₃ CH ₂ NHC(O)-. Examples of “dialkylaminocarbonyl” include (CH ₃ ) ₂ NC(=O)-, (CH ₃ CH ₂ ) ₂ NC(=O)-, CH ₃ CH ₂ (CH ₃ )NC(=O)-, (CH ₃ ) ₂ CHN(CH ₃ )C(=O)- and CH ₃ CH ₂ CH ₂ (CH ₃ )NC(=O)-. “Cycloalkylalkoxycarbonyl” denotes a cycloalkylalkyl moiety bonded to a oxygen atom of alkoxycarbonyl moiety. Examples of “cycloalkylalkoxycarbonyl” include cyclopropyl- CH ₂ OC(=O)-, cyclopropyl-CH(CH ₃ )OC(=O)- and cyclopentyl-CH ₂ OC(=O)-. An example of“alkylcarbonylamino” includes NHC(O)CH ₃ . The terms“alkoxycarbonylamino” denotes a straight-chain or branched alkoxy moieties bonded to a C(=O) moiety of carbonylamino group. Examples of “alkoxycarbonylamino” include CH ₃ OC(=O)NH- and CH ₃ CH ₂ OC(=O)NH-. Examples of “alkylsulfonylamino” include CH ₃ S(O) ₂ NH-, CH ₃ CH ₂ S(O) ₂ NH-, CH ₃ CH ₂ CH ₂ S(O) ₂ NH-, (CH ₃ ) ₂ CH ₂ (O) ₂ NH-, and the different butylsulfonylamino, pentylsulfonylamino and hexylsulfonylamino isomers. Examples of “alkylsulfonyloxy” include CH ₃ S(O) ₂ O-, CH ₃ CH ₂ S(O) ₂ O-, CH ₃ CH ₂ CH ₂ S(O) ₂ O-, (CH ₃ ) ₂ CHS(O) ₂ O-, and the different butylsulfonyloxy, pentylsulfonyloxy and hexylsulfonyloxy isomers.“Alkylsulfonylalkyl” denotes alkylsulfonyl substitution on alkyl. Examples of “alkylsulfonylalkyl” include CH ₃ S(=O) ₂ CH ₂ -, CH ₃ S(=O) ₂ CH ₂ CH ₂ -, CH ₃ CH ₂ S(=O) ₂ CH ₂ - and CH ₃ CH ₂ S(=O) ₂ CH ₂ CH ₂ -. An example of“alkylaminosulfonyl” is CH ₃ NHS(O) ₂ -. An example of“dialkylaminosulfonyl” is (CH ₃ ) ₂ NS(O) ₂ -.

“Cycloalkyl” includes, for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term“alkylcycloalkyl” denotes alkyl substitution on a cycloalkyl moiety and includes, for example, methylcyclopropyl, ethylcyclopropyl, i-propylcyclobutyl, 3- methylcyclopentyl and 4-methylcyclohexyl. The term“cycloalkylalkyl” denotes cycloalkyl substitution on an alkyl moiety. Examples of“cycloalkylalkyl” include cyclopropylmethyl, cyclopentylethyl, and other cycloalkyl moieties bonded to straight-chain or branched alkyl groups.“Halocycloalkylalkyl” denotes halogen substitution on cycloalkyl group, alkyl group or both of cycloalkylalkyl moiety. Examples of “halocycloalkylalkyl” include 2- chlorocyclopropylmethyl, cyclopentyl-1-chloroethyl, and 3-chlorocyclopentyl-1-chloroethyl. The term“cycloalkoxy” denotes cycloalkyl linked through an oxygen atom such as cyclopentyloxy and cyclohexyloxy. “Cycloalkylalkoxy” denotes cycloalkylalkyl linked through an oxygen atom attached to the alkyl chain. Examples of“cycloalkylalkoxy” include cyclopropylmethoxy, cyclopentylethoxy, and other cycloalkyl moieties bonded to straight-chain or branched alkoxy groups. “Cycloalkoxyalkyl” denotes cycloalkoxy substitution on an alkyl moiety. Examples of “cycloalkoxyalkyl” include cyclopropoxymethyl, cyclopentoxyethyl, and other cycloalkoxy moieties bonded to straight- chain or branched alkyl groups.“Cycloalkenyl” includes groups such as cyclopentenyl and cyclohexenyl as well as groups with more than one double bond such as 1,3- and 1,4-cyclohexadienyl. “Cycloalkylalkenyl” denotes cycloalkyl substitution on an alkenyl moiety. An example of “cycloalkylalkenyl” is cyclopropylethenyl. “Cycloalkylalkynyl” denotes cycloalkyl substitution on an alkynyl moiety. An example of“cycloalkylalkynyl” is cyclopropylethynyl.“Cycloalkylamino” denotes an NH radical substituted with cycloalkyl. Examples of“cycloalkylamino” include groups such as cyclopropylamino, cyclobutylamino, cyclopentylamino and cyclohexylamino. Examples of “alkoxycarbonylamino” include CH ₃ OC(=O)NH- and CH ₃ CH ₂ OC(=O)NH-. The term“cycloalkylaminoalkyl” denotes cycloalkylamino substitution on an alkyl group. Examples of“cycloalkylaminoalkyl” include cyclopropylaminomethyl, cyclopentylaminoethyl, and other cycloalkylamino moieties bonded to straight-chain or branched alkyl groups. “Cycloalkylalkoxycarbonyl” denotes a cycloalkylalkyl moiety bonded to an oxygen atom of an alkoxycarbonyl moiety. Examples of “cycloalkylalkoxycarbonyl” include cyclopropyl-CH ₂ OC(=O)-, cyclopropyl- CH(CH ₃ )OC(=O)- and cyclopentyl-CH ₂ OC(=O)-. “Cycloalkoxycarbonyl” denotes cycloalkoxy bonded to a C(=O) moiety. Examples of “cycloalkoxycarbonyl” include cyclopentyl-OC(=O)-. “Alkylcycloalkyalkyl” denotes an alkyl group substituted with alkylcycloalkyl. Examples of“alkylcycloalkylalkyl” include 1-, 2-, 3- or 4-methyl or -ethyl cylohexylmethyl. The term“cycloalkylcycloalkyl” denotes cycloalkyl substitution on another cycloalkyl ring, wherein each cycloalkyl ring independently has from 3 to 7 carbon atom ring members. Examples of“cycloalkylcycloalkyl” include cyclopropylcyclopropyl (such as 1,1’- bicyclopropyl-1-yl, 1,1’-bicyclopropyl-2-yl), cyclohexylcyclopentyl (such as 4- cyclopentylcyclohexyl) and cyclohexylcyclohexyl (such as 1,1—bicyclohexyl-1-yl), and the different cis- and trans-cycloalkylcycloalkyl isomers, (such as (1R,2S)-1,1’-bicyclopropyl-2- yl and (1R,2R)-1,1’-bicyclopropyl-2-yl). An example of“cycloalkylthio” is cyclopentyl-S-. An example of “cycloalkylsufinyl” is cyclopentyl-S(=O)-. An example of “cycloalkylsulfonyl” is cyclopentyl-S(O) ₂ -.

The term“halogen”, either alone or in compound words such as“haloalkyl”, or when used in descriptions such as“alkyl substituted with halogen” includes fluorine, chlorine, bromine or iodine. Further, when used in compound words such as“haloalkyl”, or when used in descriptions such as“alkyl substituted with halogen” said alkyl may be partially or fully substituted with halogen atoms which may be the same or different. Examples of“haloalkyl” or“alkyl substituted with halogen” include F ₃ C-, ClCH ₂ -, CF ₃ CH ₂ - and CF ₃ CCl ₂ -. The terms “haloalkenyl”,“haloalkynyl”,“halocycloalkyl”,“ halocycloalkenyl”,“haloalkylcarbonyl”, “haloalkylcarbonyloxy”, “haloalkoxy”, “halocycloalkoxy”, “haloalkoxyalkyl”, “haloalkoxyhaloalkyl”, “haloalkoxyalkoxy”, “haloalkoxycarbonyl”, “haloalkoxylhaloalkoxy”, “haloalkenyloxy”, “haloalkynyloxy”, “haloalkylthio”, “haloalkylsulfinyl”, “haloalkylsulfonyl”, “haloalkylsulfonyloxy”, “halodialkylamino”, “haloalkylaminoalkyl”,“haloalkylcarbonylamino”,“ha loalkylsulfonylamino” and the like, are defined analogously to the term“haloalkyl”. Examples of “haloalkenyl” include (Cl) ₂ C=CHCH ₂ - and CF ₃ CH ₂ CH=CHCH ₂ -. Examples of “haloalkynyl” include HC≡CCHCl-, CF ₃ C≡C-, CCl ₃ C≡C- and FCH ₂ C≡CCH ₂ -. Examples of“haloalkoxy” include CF ₃ O-, CCl ₃ CH ₂ O-, HCF ₂ CH ₂ CH ₂ O- and CF ₃ CH ₂ O-.“Haloalkoxyalkyl” denotes at least one halogen group substituted with alkoxy moiety of alkoxyalkyl group. Examples of “haloalkoxyalkyl” include CH ₂ ClOCH ₂ -, CHCl ₂ OCH ₂ -, CF ₃ OCH ₂ -, ClCH ₂ CH ₂ OCH ₂ CH ₂ -, Cl ₃ CCH ₂ OCH ₂ - as well as branched alkyl derivatives. “Haloalkoxyhaloalkyl” denotes at least two halogen groups independently substituted with both alkoxy moiety and alkyl moiety of alkoxyalkyl group. Examples of “haloalkoxyhaloalkyl” include CH ₂ ClOCHCl- and CH ₂ FCH ₂ OCl ₂ C-. The term“haloalkoxyalkoxy” denotes halogen group substituted with first alkoxy moiety of alkoxyalkoxy group. Examples of “haloalkoxyalkoxy” include CF ₃ OCH ₂ O-, ClCH ₂ CH ₂ OCH ₂ CH ₂ O-, Cl ₃ CCH ₂ OCH ₂ O- as well as branched alkyl derivatives. Examples of“haloalkoxycarbonyl” include CF ₃ OC(O)-, ClCH ₂ CH ₂ OCH ₂ CH ₂ -, Cl ₃ CCH ₂ OCH ₂ OC(O)- as well as branched alkyl derivatives. The term “haloalkoxyhaloalkoxy” denotes halogen group independently substituted with both alkoxy moiety of alkoxyalkoxy group. Examples of“haloalkoxyhaloalkoxy” include CF ₃ OCHClO-, ClCH ₂ CH ₂ OCHClCH ₂ O-, Cl ₃ CCH ₂ OCHClO- as well as branched alkyl derivatives. Examples of “haloalkylthio” include CCl ₃ S-, CF ₃ S-, CCl ₃ CH ₂ S- and ClCH ₂ CH ₂ CH ₂ S-. Examples of “haloalkylsulfinyl” include CF ₃ S(O)-, CCl ₃ S(O)-, CF ₃ CH ₂ S(O)- and CF ₃ CF ₂ S(O)-. Examples of “haloalkylsulfonyl” include CF ₃ S(O) ₂ -, CCl ₃ S(O) ₂ -, CF ₃ CH ₂ S(O) ₂ - and CF ₃ CF ₂ S(O) ₂ -. An example of“haloalkylamino” is CH ₂ ClHN-. The term“halodialkylamino” denotes at least one halogen group substituted with any alkyl moiety of dialkylamino group. Examples of“halodialkylamino” include CF ₃ (CH ₃ )N-, (CF ₃ ) ₂ N- and CH ₂ Cl(CH ₃ )N-. “Haloalkylaminoalkyl” denotes a halogen group substituted with alkylaminoalkyl group.“Haloalkylaminoalkyl” includes halogen group attached to an alkyl group as well as nitrogen. Examples of “haloalkylaminoalkyl” include CH ₃ NHCHCl-, (CH ₃ ) ₂ CClNHCH ₂ - and CH ₃ NClCH(CH ₃ )-. An example of“haloalkylcarbonylamino” is NHC(O)CF ₃ .

“Trialkylsilyl” includes 3 branched and/or straight-chain alkyl radicals attached to and linked through a silicon atom, such as trimethylsilyl, triethylsilyl and tert-butyldimethylsilyl. “-CHO” means formyl.

When a compound is substituted with a substituent bearing a subscript that indicates the number of said substituents can exceed 1, said substituents (when they exceed 1) are independently selected from the group of defined substituents, e.g., ([(R ⁷ ) _n ], n is 1, 2, 3, 4 or 5). Further, when the subscript indicates a range, e.g. (R) _i–j , then the number of substituents may be selected from the integers between i and j inclusive. When a group contains a substituent which can be hydrogen, for example (R ¹ or R ² ), then when this substituent is taken as hydrogen, it is recognized that this is equivalent to said group being unsubstituted. When a variable group is shown to be optionally attached to a position, for example [(R ⁷ ) _n ] wherein n may be 0, then hydrogen may be at the position even if not recited in the variable group definition. When one or more positions on a group are said to be“not substituted” or “unsubstituted”, then hydrogen atoms are attached to take up any free valency.

The expression“fully saturated” in relation to a ring of atoms means that the bonds between the atoms of the ring are all single. The expression“fully unsaturated” in relation to a ring means that the bonds between the atoms in the ring are single or double bonds according to valence bond theory and furthermore the bonds between the atoms in the ring include as many double bonds as possible without double bonds being cumulative (i.e. no C=C=C, N=C=C, etc.). The term“partially unsaturated” in relation to a ring denotes a ring comprising at least one ring member bonded to an adjacent ring member though a double bond and which conceptually potentially accommodates a number of non-cumulated double bonds through adjacent ring members (i.e. in its fully unsaturated counterpart form) greater than the number of double bonds present (i.e. in its partially unsaturated form). When a fully unsaturated ring satisfies Hückel’s rule then it can also be described as aromatic.

Unless otherwise indicated, a“ring” or“ring system” as a component of Formula 1 (e.g., substituent Q ¹ ) is carbocyclic or heterocyclic. The term“ring system” denotes two or more fused rings. The terms“bicyclic ring system” and“fused bicyclic ring system” denote a ring system consisting of two fused rings, in which either ring can be saturated, partially unsaturated, or fully unsaturated unless otherwise indicated. The term“fused heterobicyclic ring system” denotes a fused bicyclic ring system in which at least one ring atom is not carbon. A“bridged bicyclic ring system” is formed by bonding a segment of one or more atoms to nonadjacent ring members of a ring. The term“ring member” refers to an atom or other moiety (e.g., C(=O), C(=S), S(O) or S(O) ₂ ) forming the backbone of a ring or ring system.

The terms“carbocyclic ring”,“carbocycle” or“carbocyclic ring system” denote a ring or ring system wherein the atoms forming the ring backbone are selected only from carbon. Unless otherwise indicated, a carbocyclic ring can be a saturated, partially unsaturated, or fully unsaturated ring. When a fully unsaturated carbocyclic ring satisfies Hückel’s rule, then said ring is also called an“aromatic ring”. “Saturated carbocyclic” refers to a ring having a backbone consisting of carbon atoms linked to one another by single bonds; unless otherwise specified, the remaining carbon valences are occupied by hydrogen atoms.

The terms“heterocyclic ring”,“heterocycle” or“heterocyclic ring system” denote a ring or ring system in which at least one atom forming the ring backbone is not carbon, e.g., nitrogen, oxygen or sulfur. Typically a heterocyclic ring contains no more than 4 nitrogens, no more than 2 oxygens and no more than 2 sulfurs. Unless otherwise indicated, a heterocyclic ring can be a saturated, partially unsaturated, or fully unsaturated ring. When a fully unsaturated heterocyclic ring satisfies Hückel’s rule, then said ring is also called a “heteroaromatic ring” or “aromatic heterocyclic ring”. Unless otherwise indicated, heterocyclic rings and ring systems can be attached through any available carbon or nitrogen by replacement of a hydrogen on said carbon or nitrogen.

“Aromatic” indicates that each of the ring atoms is essentially in the same plane and has a p-orbital perpendicular to the ring plane, and that (4n + 2) pi electrons, where n is a positive integer, are associated with the ring to comply with Hückel’s rule. The term“aromatic ring system” denotes a carbocyclic or heterocyclic ring system in which at least one ring of the ring system is aromatic. The term“aryl” can be used alone or in compound words such as “arylcarbonyl”.“Arylcarbonyl” denotes an aryl group bonded to a C(=O) moiety. The terms “arylalkenylalkyl” is defined similarly. The term“aromatic carbocyclic ring system” denotes a carbocyclic ring system in which at least one ring of the ring system is aromatic. The term “aromatic heterocyclic ring system” denotes a heterocyclic ring system in which at least one ring of the ring system is aromatic. The term“nonaromatic ring system” denotes a carbocyclic or heterocyclic ring system that may be fully saturated, as well as partially or fully unsaturated, provided that none of the rings in the ring system are aromatic. The term“nonaromatic carbocyclic ring system” in which no ring in the ring system is aromatic. The term “nonaromatic heterocyclic ring system” denotes a heterocyclic ring system in which no ring in the ring system is aromatic.

The term“optionally substituted” in connection with the heterocyclic rings refers to groups which are unsubstituted or have at least one non-hydrogen substituent that does not extinguish the biological activity possessed by the unsubstituted analog. As used herein, the following definitions shall apply unless otherwise indicated. The term "optionally substituted" is used interchangeably with the phrase“substituted or unsubstituted” or with the term “(un)substituted.” Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and each substitution is independent of the other.

When Q ¹ or Q ² is a 5- or 6-membered nitrogen-containing heterocyclic ring, it may be attached to the remainder of Formula 1 though any available carbon or nitrogen ring atom, unless otherwise described. As noted above, Q ¹ or Q ² can be (among others) phenyl optionally substituted with one or more substituents selected from a group of substituents as defined in the Summary. An example of phenyl optionally substituted with one to five substituents is the ring illustrated as U-1 in Exhibit 1, wherein R ^v is R ⁷ as defined in the Summary for Q ¹ or R ^v is R ¹⁰ as defined in the Summary for Q ² , and r is an integer (from 0 to 5).

As noted above, Q ¹ or Q ² can be (among others) 5- or 6-membered heterocyclic ring, which may be saturated or unsaturated, optionally substituted with one or more substituents selected from a group of substituents as defined in the Summary. Examples of a 5- or 6-membered unsaturated aromatic heterocyclic ring optionally substituted with from one or more substituents include the rings U-2 through U-61 illustrated in Exhibit 1 wherein R ^v is any substituent as defined in the Summary for Q ¹ or Q ² and r is an integer from 0 to 5, limited by the number of available positions on each U group. As U-29, U-30, U-36, U-37, U-38, U- 39, U-40, U-41, U-42 and U-43 have only one available position, for these U groups r is limited to the integers 0 or 1, and r being 0 means that the U group is unsubstituted and a hydrogen is present at the position indicated by (R ^v ) _r .

U-21 U-22 U-23 U-24 U-25

U-26 U-27 U-28 U-29 U-30

U-31 U-32 U-33 U-34 U-35

U-41 U-42 U-43 U-44 U-45

U-46 U-47 U-48 U-49 U-50

U-51 U-52 U-53 U-54 U-55

U-56 U-57 U-58 U-59 U-60

U-61 As noted above, Q ¹ and Q ² can be an 8- to 10-membered heterocyclic ring system optionally substituted with one or more substituents selected from a group of substituents as defined in the Summary for Q ¹ and Q ² . Examples of 8- to 10-membered heterocyclic ring system optionally substituted with from one or more substituents include the rings U-62 through U-102 illustrated in Exhibit 2 wherein R ^v is any substituent as defined in the Summary for Q ¹ or Q ² , and r is typically an integer from 0 to 5. The free bond denoted by a straight line can be located on either ring irregardless of where they are drawn. The free bond connected to (R ^v ) _r can be located on either ring irregardless of where they are drawn.

U-98 U-99 U-100

As noted above, R ⁶ and Q ² can be taken together with the nitrogen atom to which they are both bonded to form an 8- to 10-membered bicyclic ring system. Examples of R ⁶ and Q ² taken together are shown in Exhibit 3.

Exhibit 3 Some examples of a 4- to 6-membered saturated heterocyclic ring optionally substituted with one or more substituents include but not limited to the rings U-106 through U-110 illustrated in Exhibit 3 wherein R ^v is any substituent as defined in the Summary for Q ¹ or Q ² , and r is typically an integer from 0 to 4 or 5.

Exhibit 4

U-106 U-107 U-108 U-109 U-110 Although R ^v groups are shown in the structures U-1 through U-110, it is noted that they do not need to be present since they are optional substituents. Note that when R ^v is H when attached to an atom, this is the same as if said atom is unsubstituted. The nitrogen atoms that require substitution to fill their valence are substituted with H or R ^v . Note that when the attachment point between (R ^v ) _r and the U group is illustrated as floating, (R ^v ) _r can be attached to any available carbon atom or nitrogen atom of the U group. Note that when the attachment point on the U group is illustrated as floating, the U group can be attached to the remainder of Formula 1 through any available carbon or nitrogen of the U group by replacement of a hydrogen atom. In some embodiments, for greater herbicidal activity, the U group is attached to the remainder of Formula 1 through an available carbon or nitrogen on a fully unsaturated ring of the U group. Note that some U groups can only be substituted with less than 4 R ^v groups (e.g., U-2 through U-5, U-7 through U-48, and U-52 through U-61).

In the present disclosure, the term“nitrone” refers to the presence of an oxidized nitrogen species carrying a formal charge either as a substituent or as part of the ring.

A wide variety of synthetic methods are known in the art to enable preparation of aromatic and nonaromatic heterocyclic rings and ring systems; for extensive reviews see the eight volume set of Comprehensive Heterocyclic Chemistry, A. R. Katritzky and C. W. Rees editors-in-chief, Pergamon Press, Oxford, 1984 and the twelve volume set of Comprehensive Heterocyclic Chemistry II, A. R. Katritzky, C. W. Rees and E. F. V. Scriven editors-in-chief, Pergamon Press, Oxford, 1996.

Compounds of this disclosure can exist as one or more stereoisomers. The various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers. Stereoisomers are isomers of identical constitution but differing in the arrangement of their atoms in space and include enantiomers, diastereomers, cis-trans isomers (also known as geometric isomers) and atropisomers. Atropisomers result from restricted rotation about single bonds where the rotational barrier is high enough to permit isolation of the isomeric species. One skilled in the art will appreciate that one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate, enrich, and/or to selectively prepare said stereoisomers. The compounds of the disclosure may be present as a mixture of stereoisomers, individual stereoisomers or as an optically active form. Particularly when R ⁴ and R ⁵ are each H, the C(O)N(Q ² )(R ⁶ ) and Q ¹ substituents are typically mostly in the thermodynamically preferred trans configuration on the nitrone ring.

For example the C(Y)N(Q ² )(R ⁶ ) moiety (bonded to the carbon at the 2-position of the nitrone ring wherein Y is oxygen and J ² is–CR ² R ³ - and both R ² and R ³ are H) and Q ¹ (bonded to the carbon at the 3-position of the nitrone ring) are generally found in the trans configuration. These two carbon atoms (i.e. at the 2- and 3-positions of the central ring of Formula 1) both possess a chiral center. The two most prevelant pairs of enantiomers are depicted as Formula 1' and Formula 1" where the chiral centers are identified (i.e. as 2S,3R or as 2R,3S). The skilled artisan will undertand that in some Embodiments of the disclosure, the R or S designation is determined relative to other substituents around the same carbon and therefore a compound of the disclosure could also be given the 2S,3S or 2R,3R designation. In Synthesis Example 1, the compound trans-3-(4-chlorophenyl)-N-(2,3-difluorophenyl)-3,4-dihydro- 5-methyl-2H-pyrrole-2-carboxamide 1-oxide may also be referred to as rel-(2S,3R)-3-(4- chlorophenyl)-N-(2,3-difluorophenyl)-3,4-dihydro-5-methyl-2H -pyrrole-2-carboxamide 1- oxide, and the compounds prepared in Synthesis Examples 2, 3 and 4 may also be named in a similar manner. For a comprehensive discussion of all aspects of stereoisomerism, see Ernest L. Eliel and Samuel H. Wilen, Stereochemistry of Organic Compounds, John Wiley & Sons, 1994.

Molecular depictions drawn herein follow standard conventions for depicting stereochemistry. To indicate stereoconfiguration, bonds rising from the plane of the drawing and towards the viewer are denoted by solid wedges wherein the broad end of the wedge is attached to the atom rising from the plane of the drawing towards the viewer. Bonds going below the plane of the drawing and away from the viewer are denoted by dashed wedges wherein the narrow end of the wedge is attached to the atom further away from the viewer. Constant width lines indicate bonds with a direction opposite or neutral relative to bonds shown with solid or dashed wedges; constant width lines also depict bonds in molecules or parts of molecules in which no particular stereoconfiguration is intended to be specified.

This disclosure comprises racemic mixtures, for example, equal amounts of the enantiomers of Formulae 1' and 1". In addition, this disclosure includes compounds that are enriched compared to the racemic mixture in an enantiomer of Formula 1. Also included are the essentially pure enantiomers of compounds of Formula 1, for example, Formula 1' and Formula 1".

When enantiomerically enriched (i.e. enantio-enriched), one enantiomer is present in greater amounts than the other, and the extent of enrichment can be defined by an expression of enantiomeric excess (“ee”), which is defined as (2x–1)·100 %, where x is the mole fraction of the dominant enantiomer in the mixture (e.g., an ee of 20 % corresponds to a 60:40 ratio of enantiomers). The compounds of the disclosure can be prepared entantiomerically enriched (i.e. enantio-enriched) by utilizing a corresponding enantiomerically enriched intermediate during the course of synthesis. In these instances, the enantiomeric excess is not measured in the final product but is presumed to be“enantiomerically enriched” based on equivalent known chemical transformations in the literature.

Preferably the compositions of this disclosure have at least a 50 % enantiomeric excess; more preferably at least a 75 % enantiomeric excess; still more preferably at least a 90 % enantiomeric excess; and the most preferably at least a 94 % enantiomeric excess of the more active isomer. Of particular note are enantiomerically pure embodiments of the more active isomer.

Compounds of Formula 1 can comprise additional chiral centers. For example, substituents and other molecular constituents such as R ² and R ³ may themselves contain chiral centers. This disclosure comprises racemic mixtures as well as enriched and essentially pure stereoconfigurations at these additional chiral centers.

Compounds of this disclosure can exist as one or more conformational isomers due to restricted rotation about the amide bond (e.g., C(Y)N(Q ² )(R ⁶ )) in Formula 1. This disclosure comprises mixtures of conformational isomers. In addition, this disclosure includes compounds that are enriched in one conformer relative to others.

Compounds of Formula 1 typically exist in more than one form, and Formula 1 thus include all crystalline and non-crystalline forms of the compounds they represent. Non- crystalline forms include embodiments which are solids such as waxes and gums as well as embodiments which are liquids such as solutions and melts. Crystalline forms include embodiments which represent essentially a single crystal type and embodiments which represent a mixture of polymorphs (i.e. different crystalline types). The term“polymorph” refers to a particular crystalline form of a chemical compound that can crystallize in different crystalline forms, these forms having different arrangements and/or conformations of the molecules in the crystal lattice. Although polymorphs can have the same chemical composition, they can also differ in composition due the presence or absence of co-crystallized water or other molecules, which can be weakly or strongly bound in the lattice. Polymorphs can differ in such chemical, physical and biological properties as crystal shape, density, hardness, color, chemical stability, melting point, hygroscopicity, suspensibility, dissolution rate and biological availability. One skilled in the art will appreciate that a polymorph of a compound of Formula 1 can exhibit beneficial effects (e.g., suitability for preparation of useful formulations, improved biological performance) relative to another polymorph or a mixture of polymorphs of the same compound of Formula 1. Preparation and isolation of a particular polymorph of a compound of Formula 1 can be achieved by methods known to those skilled in the art including, for example, crystallization using selected solvents and temperatures. For a comprehensive discussion of polymorphism see R. Hilfiker, Ed., Polymorphism in the Pharmaceutical Industry, Wiley-VCH, Weinheim, 2006. One skilled in the art will appreciate that not all nitrogen-containing heterocycles can form N-oxides since the nitrogen requires an available lone pair for oxidation to the oxide; one skilled in the art will recognize those nitrogen-containing heterocycles which can form N-oxides. One skilled in the art will also recognize that tertiary amines can form N-oxides. Synthetic methods for the preparation of N-oxides of heterocycles and tertiary amines are very well known by one skilled in the art including the oxidation of heterocycles and tertiary amines with peroxy acids such as peracetic and m-chloroperbenzoic acid (MCPBA), hydrogen peroxide, alkyl hydroperoxides such as t-butyl hydroperoxide, sodium perborate, and dioxiranes such as dimethyldioxirane. These methods for the preparation of N-oxides have been extensively described and reviewed in the literature, see for example: T. L. Gilchrist in Comprehensive Organic Synthesis, vol. 7, pp 748–750, S. V. Ley, Ed., Pergamon Press; M. Tisler and B. Stanovnik in Comprehensive Heterocyclic Chemistry, vol. 3, pp 18–20, A. J. Boulton and A. McKillop, Eds., Pergamon Press; M. R. Grimmett and B. R. T. Keene in Advances in Heterocyclic Chemistry, vol. 43, pp 149–161, A. R. Katritzky, Ed., Academic Press; M. Tisler and B. Stanovnik in Advances in Heterocyclic Chemistry, vol.9, pp 285–291, A. R. Katritzky and A. J. Boulton, Eds., Academic Press; and G. W. H. Cheeseman and E. S. G. Werstiuk in Advances in Heterocyclic Chemistry, vol. 22, pp 390–392, A. R. Katritzky and A. J. Boulton, Eds., Academic Press.

One skilled in the art recognizes that because in the environment and under physiological conditions salts of chemical compounds are in equilibrium with their corresponding nonsalt forms, salts share the biological utility of the nonsalt forms. Thus a wide variety of salts of a compound of Formula 1 are useful for control of undesired vegetation (i.e. are agriculturally suitable). The salts of a compound of Formula 1 include acid-addition salts with inorganic or organic acids such as hydrobromic, hydrochloric, nitric, phosphoric, sulfuric, acetic, butyric, fumaric, lactic, maleic, malonic, oxalic, propionic, salicylic, tartaric, 4-toluenesulfonic or valeric acids. When a compound of Formula 1 contains an acidic moiety such as a carboxylic acid or phenol, salts also include those formed with organic or inorganic bases such as pyridine, triethylamine or ammonia, or amides, hydrides, hydroxides or carbonates of sodium, potassium, lithium, calcium, magnesium or barium. Accordingly, the present disclosure comprises compounds selected from Formula 1, N-oxides and agriculturally suitable salts thereof.

Embodiments of the present disclosure as described in the Summary include (where Formula 1 as used in the following Embodiments includes N-oxides and salts thereof):

Embodiment 1. A compound of Formula 1 wherein when Q ¹ is a phenyl ring optionally substituted with up to 4 substituents selected from R ⁷ ; or an 8- to 10-membered heteroaromatic bicyclic ring system optionally substituted with up to 5 substituents independently selected from R ⁷ on carbon atom ring members and selected from R ⁹ on nitrogen atom ring members.

Embodiment 2. A compound of Formula 1 or Embodiment 1 wherein Q ¹ is a phenyl ring or a benzodioxolane (i.e. U-81) ring optionally substituted with up to 4 substituents independently selected from R ⁷ .

Embodiment 3. A compound of Embodiment 2 wherein Q ¹ is a phenyl ring optionally substituted with 1 to 3 substituents or a benzodioxolane ring substituted with 1 to 3 substituents independently selected from R ⁷ .

Embodiment 4. A compound of Embodiment 3 wherein Q ¹ is a phenyl ring or a

benzodioxolane ring substituted with 1 to 2 substituents independently selected from R ⁷ .

Embodiment 5. A compound of Formula 1 or any one of Embodiments 1 through 4 wherein Q ¹ is a phenyl ring having at least one substituent selected from R ⁷ at the para (4-) position (and optionally other substituents).

Embodiment 6. A compound of Formula 1 or any one of Embodiments 1 through 4 wherein Q ¹ is a phenyl ring having at least one substituent selected from R ⁷ at the meta (3-) position (and optionally other substituents).

Embodiment 7. A compound of Formula 1 or any one of Embodiments 1 through 6 wherein when Q ¹ is a phenyl ring substituted with at least two substituents independently selected from R ⁷ , then one substituent is at the meta (3-) position and at least one other substituent is at a para position (of the phenyl ring).

Embodiment 8. A compound of Formula 1 or any one of Embodiments 1 through 7 wherein Q ² is a phenyl ring, a 5- to 6- membered heteroaromatic ring or an 8- to 10-membered heteroaromatic bicyclic ring system, each ring or ring system optionally substituted with up to 5 substituents independently selected from R ¹⁰ on carbon atom ring members and selected from R ¹¹ on nitrogen atom ring members.

Embodiment 9. A compound of Formula 1 or any one of Embodiments 1 through 8 wherein Q ² is a phenyl, pyridinyl or thiophenyl ring optionally substituted with 1 to 5 substituents independently selected from R ¹⁰ .

Embodiment 10. A compound of Embodiment 9 wherein Q ² is a phenyl, pyridinyl or thiophenyl ring substituted with 1 to 3 substituents independently selected from R ¹⁰ .

Embodiment 11. A compound of Embodiment 10 wherein Q ² is a phenyl, 2-pyridinyl, 3-pyridinyl or 3-thiophenyl ring substituted with 1 to 2 substituents

independently selected from R ¹⁰ . Embodiment 12. A compound of Formula 1 or any one of Embodiments 1 through 11 wherein Q ² is a phenyl ring having at least one substituent selected from R ¹⁰ at an ortho (e.g., 2-) position (and optionally other substituents).

Embodiment 13. A compound of Formula 1 or any one of Embodiments 1 through 11 wherein when Q ² is a phenyl ring substituted with at least two substituents independently selected from R ¹⁰ , then at least one substituent is at an ortho (e.g., 2-) position and at least one substituent is at an adjacent meta (e.g., 3-) position (of the phenyl ring).

Embodiment 14. A compound of Formula 1 or any one of Embodiments 1 through 13 wherein, each R ⁷ and R ¹⁰ is independently halogen, cyano, nitro, C ₁ –C ₄ alkyl, C ₁ –C ₄ haloalkyl, C ₂ –C ₄ alkenyl, C ₂ –C ₄ haloalkenyl C ₂ –C ₄ alkynyl, C ₂ –C ₄ haloalkynyl, C ₁ –C ₄ nitroalkyl, C ₂ –C ₄ nitroalkenyl, C ₂ –C ₄ alkoxyalkyl, C ₂ –C ₄ haloalkoxyalkyl, C ₃ –C ₄ cycloalkyl, C ₃ –C ₄ halocycloalkyl, cyclopropylmethyl, methylcyclopropyl, C ₁ –C ₄ alkoxy, C ₁ –C ₄ haloalkoxy, C ₂ -C ₄ alkenyloxy, C ₂ –C ₄ haloalkenyloxy, C ₃ –C ₄ alkynyloxy, C ₃ –C ₄ haloalkynyloxy, C ₃ –C ₄ cycloalkoxy, C ₁ –C ₄ alkylthio, C ₁ –C ₄ haloalkylthio, C ₁ -C ₄ alkylsulfinyl, C ₁ –C ₄

haloalkylsulfinyl, C ₁ –C ₄ alkylsulfonyl, C ₁ –C ₄ haloalkylsulfonyl, hydroxy, formyl, C ₂ –C ₄ alkylcarbonyl, C ₂ –C ₄ alkylcarbonyloxy, C ₁ –C ₄ alkylsulfonyloxy, C ₁ –C ₄ haloalkylsulfonyloxy, amino, C ₁ –C ₄ alkylamino, C ₂ –C ₄ dialkylamino, formylamino, C ₂ –C ₄ alkylcarbonylamino, -SF ₅ , -SCN, C ₃ –C ₄ trialkylsilyl, trimethylsilylmethyl or trimethylsilylmethoxy.

Embodiment 15. A compound of Embodiment 14 wherein each R ⁷ is independently halogen, cyano, C ₁ –C ₂ alkyl, C ₁ –C ₃ haloalkyl or C ₁ –C ₃ haloalkoxy.

Embodiment 16. A compound of Embodiment 15 wherein each R ⁷ is independently halogen, C ₁ –C ₂ alkyl or C ₁ –C ₂ haloalkyl.

Embodiment 17. A compound of Embodiment 16 wherein each R ⁷ is independently halogen, C ₁ alkyl or C ₁ haloalkyl.

Embodiment 18. A compound of Embodiment 17 wherein each R ⁷ is independently halogen, C ₁ alkyl or C ₁ fluoroalkyl.

Embodiment 19. A compound of Embodiment 18 wherein each R ⁷ is independently halogen, CH ₃ or CF ₃ .

Embodiment 20. A compound of Embodiment 19 wherein each R ⁷ is independently F, Cl, Br, CH ₃ or CF ₃ .

Embodiment 21. A compound of Embodiment 20 wherein each R ⁷ is independently F, CH ₃ or CF ₃ .

Embodiment 22. A compound of Embodiment 20 or 21 wherein when Q ¹ is phenyl at most only one CF ₃ substituent is present and is at the para position of the Q ¹ phenyl ring. Embodiment 23. A compound of any one of Embodiments 14 through 22 wherein each R ¹⁰ is independently halogen, cyano, C ₁ –C ₂ alkyl, C ₁ –C ₃ haloalkyl, C ₁ -C ₃ alkylthio, C ₁ –C ₃ alkylsulfinyl or C ₁ –C ₃ alkylsulfonyl.

Embodiment 24. A compound of Embodiment 23 wherein each R ¹⁰ is independently halogen or C ₁ –C ₂ haloalkyl.

Embodiment 25. A compound of Embodiment 24 wherein each R ¹⁰ is independently halogen or C ₁ haloalkyl.

Embodiment 26. A compound of Embodiment 25 wherein each R ¹⁰ is independently halogen or C ₁ fluoroalkyl.

Embodiment 27. A compound of Embodiment 26 wherein each R ¹⁰ is independently halogen or CF ₃ .

Embodiment 28. A compound of Embodiment 27 wherein each R ¹⁰ is independently F, Cl, Br or CF ₃ .

Embodiment 29. A compound of Embodiment 28 wherein each R ¹⁰ is independently F or CF ₃ .

Embodiment 30. A compound of Embodiment 29 wherein each R ¹⁰ is F.

Embodiment 31. A compound of Formula 1 or any one of Embodiments 1 through 30 wherein, each R ⁹ and R ¹¹ is independently C ₁ –C ₂ alkyl.

Embodiment 32. A compound of Embodiment 31 wherein, each R ⁹ and R ¹¹ is

independently CH ₃ .

Embodiment 33. A compound of Formula 1 or any one of Embodiments 1 through 32 wherein Y is O.

Embodiment 34. A compound of Formula 1 or any one of Embodiments 1 through 33 wherein T is H.

Embodiment 35. A compound of Formula 1 or any one of Embodiments 1 through 34 wherein R ¹ is H, CH ₃ or CF ₃ .

Embodiment 36. A compound of Embodiment 35 wherein R ¹ is CH ₃ .

Embodiment 37. A compound of Formula 1 or any one of Embodiments 1 through 36 wherein each R ² is independently H or CH ₃ .

Embodiment 38. A compound of Embodiment 37 wherein each R ² is H.

Embodiment 39. A compound of Formula 1 or any one of Embodiments 1 through 38 wherein each R ³ is independently H or CH ₃ .

Embodiment 40. A compound of Embodiment 39 wherein each R ³ is H.

Embodiment 41. A compound of Formula 1 or any one of Embodiments 1 through 40 wherein R ⁴ is H or CH ₃ .

Embodiment 42. A compound of Embodiment 41 wherein R ⁴ is H.

Embodiment 43. A compound of Formula 1 or any one of Embodiments 1 through 42 wherein R ⁵ is H, F or CH ₃ . Embodiment 44. A compound of Embodiment 43 wherein R ⁵ is H.

Embodiment 45. A compound of Embodiment 44 wherein R ⁶ is H.

Embodiment 46: A compound of Formula 1 or any one of Embodiments 1-45 wherein J ² is (-CR ₂ R ₃ -) _z and z is 1.

Embodiment 47. A compound of Formula 1 or any one of Embodiments 1 through 46 wherein Q ¹ is a benzodioxolane ring substituted with two R ⁷ both being F:

.

Embodiments of this disclosure, including Embodiments 1–47 above as well as any other embodiments described herein, can be combined in any manner, and the descriptions of variables in the embodiments pertain not only to the compounds of Formula 1 but also to the starting compounds and intermediate compounds useful for preparing the compounds of Formula 1. In addition, embodiments of this disclosure, including Embodiments 1–45 above as well as any other embodiments described herein, and any combination thereof, pertain to the compositions and methods of the present disclosure.

Combinations of Embodiments 1–45 are illustrated by:

Embodiment A. A compound of Formula 1 wherein

each R ⁷ and R ¹⁰ is independently halogen, cyano, nitro, C ₁ –C ₄ alkyl, C ₁ –C ₄

haloalkyl, C ₂ –C ₄ alkenyl, C ₂ –C ₄ haloalkenyl C ₂ –C ₄ alkynyl, C ₂ –C ₄ haloalkynyl, C ₁ –C ₄ nitroalkyl, C ₂ –C ₄ nitroalkenyl, C ₂ –C ₄ alkoxyalkyl, C ₂ -C ₄ haloalkoxyalkyl, C ₃ –C ₄ cycloalkyl, C ₃ –C ₄ halocycloalkyl, cyclopropylmethyl, methylcyclopropyl, C ₁ –C ₄ alkoxy, C ₁ –C ₄ haloalkoxy, C ₂ –C ₄ alkenyloxy, C ₂ –C ₄ haloalkenyloxy, C ₃ –C ₄ alkynyloxy, C ₃ –C ₄ haloalkynyloxy, C ₃ –C ₄ cycloalkoxy, C ₁ –C ₄ alkylthio, C ₁ –C ₄ haloalkylthio, C ₁ –C ₄ alkylsulfinyl, C ₁ –C ₄ haloalkylsulfinyl, C ₁ –C ₄ alkylsulfonyl, C ₁ –C ₄ haloalkylsulfonyl, hydroxy, formyl, C ₂ –C ₄ alkylcarbonyl, C ₂ –C ₄ alkylcarbonyloxy, C ₁ –C ₄ alkylsulfonyloxy, C ₁ –C ₄ haloalkylsulfonyloxy, amino, C ₁ –C ₄ alkylamino, C ₂ –C ₄ dialkylamino, formylamino, C ₂ –C ₄ alkylcarbonylamino, -SF ₅ , -SCN, C ₃ –C ₄ trialkylsilyl, trimethylsilylmethyl or trimethylsilylmethoxy; and

each R ⁹ and R ¹¹ is C ₁ –C ₂ alkyl.

Embodiment B. A compound of Embodiment A wherein

Y is O;

R ¹ is CH ₃ ; and T, R ² , R ³ , R ⁴ , R ⁵ and R ⁶ are each H.

Embodiment C. A compound of Embodiment B wherein

wherein Q ¹ is a phenyl ring optionally substituted with 1 to 3 substituents or a benzodioxolane ring substituted with 1 to 3 substituents independently selected from R ⁷ ; and

Q ² is a phenyl, pyridinyl or thiophenyl ring substituted with 1 to 3 substituents independently selected from R ¹⁰ .

Embodiment D. A compound of Embodiment C wherein

each R ⁷ is independently halogen, cyano, C ₁ –C ₂ alkyl, C ₁ –C ₃ haloalkyl or C ₁ –C ₃ haloalkoxy; and

each R ¹⁰ is independently halogen, cyano, C ₁ –C ₂ alkyl, C ₁ –C ₃ haloalkyl, C ₁ –C ₃ alkylthio, C ₁ –C ₃ alkylsulfinyl or C ₁ –C ₃ alkylsulfonyl.

Embodiment E. A compound of Embodiment D wherein

Q ¹ is a phenyl ring having at least one substituent selected from R ⁷ at the meta (3-) or the para (4-) position or substituted with at least two substituents independently selected from R ⁷ wherein one substituent is at the meta position and at least one other substituent is at a para position; and

Q ² is a phenyl, 2-pyridinyl, 3-pyridinyl or 3-thiophene ring substituted with 1 to 2 substituents independently selected from R ¹⁰ .

Embodiment F. A compound of Embodiment E wherein

each R ⁷ is independently F, CH ₃ or CF ₃ ; and

each R ¹⁰ is F.

Specific embodiments include compounds of Formula 1 selected from the group consisting of a compound of Formula 1 wherein Q ¹ is Ph(4-CF ₃ ), Q ² if Ph(2,3-di-F), R ¹ is CH ₃ , J ² is CH ₂ CH ₂ and T, R ⁴ , R ⁵ and R ⁶ are H; a compound of Formula 1 wherein Q ¹ is Ph(4-CH ₃ ), Q ² if Ph(2,3-di-F), R ¹ is CH ₃ , J ² is CH ₂ CH ₂ and T, R ⁴ , R ⁵ and R ⁶ are H, and a compound of Formula 1 wherein Q ¹ is Ph(4-Cl), Q ² is Ph(2,3-di-F), R ¹ is CH ₃ , J ² is CH ₂ CH ₂ and T, R ⁴ , R ⁵ and R ⁶ are H.

Specific embodiments include compounds of Formula 1 selected from the group consisting of:

rel-(2S,3R)-3-(4-chlorophenyl)-N-(2,3-difluorophenyl)-3,4-di hydro-5-methyl-2H- pyrrole-2-carboxamide 1-oxide (Compound 5; Example 1);

rel-(2S,3R)-N-(2,3-difluorophenyl)-3,4-dihydro-5-methyl-3-[4 - (trifluoromethyl)phenyl]-2H-pyrrole-2-carboxamide 1-oxide (Compound 2; Example 2); rel-(2S,3R)-N-(2-fluorophenyl)-3,4-dihydro-5-methyl-3-[4-(tr ifluoromethyl)phenyl]- 2H-pyrrole-2-carboxamide 1-oxide (Compound 26; Example 3);

rel-(2S,3R)-N-(2,3-Difluorophenyl)-3,4-dihydro-5-methyl-3-(4 -methylphenyl)-2H- pyrrole-2-carboxamide 1-oxide (Compound 6); rel-(2S,3R)-3-(2,2-Difluoro-1,3-benzodioxol-5-yl)-N-(2,3-dif luorophenyl)-3,4- dihydro-5-methyl-2H-pyrrole-2-carboxamide 1-oxide (Compound 25);

rel-(2S,3R)-3-(4-Difluoromethyl)phenyl)-N-(2,3-difluoropheny l) 3,4-dihydro-5- methyl-2H-pyrrole-2-carboxamide 1-oxide (Compound 93);

(2S,3R)-N-(2,3-Difluorophenyl)-3-[4-fluoro-3-(1,1,2,2-tetraf luoroethyoxy)phenyl]- 3,4-dihydro-5-methyl-2H-pyrrole-2-carboxamide 1-oxide (Compound 54);

rel-(2S,3R)-N-(2,6-Difluoro-3-pyridinyl)-3,4-dihydro-5-methy l-3-[4- (trifluoromethyl)phenyl]-2H-pyrrole-2-carboxamide 1-oxide (Compound 37);

rel-(2S,3R)-N-(2,3-Difluorophenyl)-3-[3-fluoro-4-(trifluorom ethyl)phenyl]-3,4- dihydro-5-methyl-2H-pyrrole-2-carboxamide 1-oxide (Compound 61);

(2S,3R)-3-(4-chlorophenyl)-N-(2,3-difluorophenyl)-3,4-dihydr o-5-methyl-2H-pyrrole- 2-carboxamide 1-oxide (Compound 40);

(2S,3R)-N-(2,3-difluorophenyl)-3,4-dihydro-5-methyl-3-[4-(tr ifluoromethyl)phenyl]- 2H-pyrrole-2-carboxamide 1-oxide (Compound 30); and

(2S,3R)-N-(2,3-Difluorophenyl)-3,4-dihydro-5-methyl-3-(4-met hylphenyl)-2H- pyrrole-2-carboxamide 1-oxide (Compound 42). This disclosure also relates to a method for controlling undesired vegetation comprising applying to the locus of the vegetation herbicidally effective amounts of the compounds of the disclosure (e.g., as a composition described herein). Of note as embodiments relating to methods of use are those involving the compounds of embodiments described above. Compounds of the disclosure are particularly useful for selective control of weeds in crops such as wheat, barley, maize, soybean, sunflower, cotton, oilseed rape and rice, and specialty crops such as sugarcane, citrus, fruit and nut crops.

Also noteworthy as embodiments are herbicidal compositions of the present disclosure comprising the compounds of embodiments described above.

This disclosure also includes a herbicidal mixture comprising (a) a compound selected from Formula 1, N-oxides, and salts thereof, and (b) at least one additional active ingredient selected from (b1) photosystem II inhibitors, (b2) acetohydroxy acid synthase (AHAS) inhibitors, (b3) acetyl-CoA carboxylase (ACCase) inhibitors, (b4) auxin mimics, (b5) 5-enol- pyruvylshikimate-3-phosphate (EPSP) synthase inhibitors, (b6) photosystem I electron diverters, (b7) protoporphyrinogen oxidase (PPO) inhibitors, (b8) glutamine synthetase (GS) inhibitors, (b9) very long chain fatty acid (VLCFA) elongase inhibitors, (b10) auxin transport inhibitors, (b11) phytoene desaturase (PDS) inhibitors, (b12) 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) inhibitors, (b13) homogentisate solenesyltransererase (HST) inhibitors, (b14) cellulose biosynthesis inhibitors, (b15) other herbicides including mitotic disruptors, organic arsenicals, asulam, bromobutide, cinmethylin, cumyluron, dazomet, difenzoquat, dymron, etobenzanid, flurenol, fosamine, fosamine-ammonium, hydantocidin, metam, methyldymron, oleic acid, oxaziclomefone, pelargonic acid and pyributicarb, and (b16) herbicide safeners; and salts of compounds of (b1) through (b16).

“Photosystem II inhibitors” (b1) are chemical compounds that bind to the D-1 protein at the Q _B -binding niche and thus block electron transport from Q _A to Q _B in the chloroplast thylakoid membranes. The electrons blocked from passing through photosystem II are transferred through a series of reactions to form toxic compounds that disrupt cell membranes and cause chloroplast swelling, membrane leakage, and ultimately cellular destruction. The Q _B -binding niche has three different binding sites: binding site A binds the triazines such as atrazine, triazinones such as hexazinone, and uracils such as bromacil, binding site B binds the phenylureas such as diuron, and binding site C binds benzothiadiazoles such as bentazon, nitriles such as bromoxynil and phenyl-pyridazines such as pyridate. Examples of photosystem II inhibitors include ametryn, amicarbazone, atrazine, bentazon, bromacil, bromofenoxim, bromoxynil, chlorbromuron, chloridazon, chlorotoluron, chloroxuron, cumyluron, cyanazine, daimuron, desmedipham, desmetryn, dimefuron, dimethametryn, diuron, ethidimuron, fenuron, fluometuron, hexazinone, ioxynil, isoproturon, isouron, lenacil, linuron, metamitron, methabenzthiazuron, metobromuron, metoxuron, metribuzin, monolinuron, neburon, pentanochlor, phenmedipham, prometon, prometryn, propanil, propazine, pyridafol, pyridate, siduron, simazine, simetryn, tebuthiuron, terbacil, terbumeton, terbuthylazine, terbutryn and trietazine.

“AHAS inhibitors” (b2) are chemical compounds that inhibit acetohydroxy acid synthase (AHAS), also known as acetolactate synthase (ALS), and thus kill plants by inhibiting the production of the branched-chain aliphatic amino acids such as valine, leucine and isoleucine, which are required for protein synthesis and cell growth. Examples of AHAS inhibitors include amidosulfuron, azimsulfuron, bensulfuron-methyl, bispyribac-sodium, cloransulam-methyl, chlorimuron-ethyl, chlorsulfuron, cinosulfuron, cyclosulfamuron, diclosulam, ethametsulfuron-methyl, ethoxysulfuron, flazasulfuron, florasulam, flucarbazone-sodium, flumetsulam, flupyrsulfuron-methyl, flupyrsulfuron-sodium, foramsulfuron, halosulfuron-methyl, imazamethabenz-methyl, imazamox, imazapic, imazapyr, imazaquin, imazethapyr, imazosulfuron, iodosulfuron-methyl (including sodium salt), iofensulfuron (2-iodo-N-[[(4-methoxy-6-methyl-1,3,5-triazin-2- yl)amino]carbonyl]benzenesulfonamide), mesosulfuron-methyl, metazosulfuron (3-chloro-4- (5,6-dihydro-5-methyl-1,4,2-dioxazin-3-yl)-N-[[(4,6-dimethox y-2- pyrimidinyl)amino]carbonyl]-1-methyl-1H-pyrazole-5-sulfonami de), metosulam, metsulfuron-methyl, nicosulfuron, oxasulfuron, penoxsulam, primisulfuron-methyl, propoxycarbazone-sodium, propyrisulfuron (2-chloro-N-[[(4,6-dimethoxy-2- pyrimidinyl)amino]carbonyl]-6-propylimidazo[1,2-b]pyridazine -3-sulfonamide), prosulfuron, pyrazosulfuron-ethyl, pyribenzoxim, pyriftalid, pyriminobac-methyl, pyrithiobac-sodium, rimsulfuron, sulfometuron-methyl, sulfosulfuron, thiencarbazone, thifensulfuron-methyl, triafamone (N-[2-[(4,6-dimethoxy-1,3,5-triazin-2-yl)carbonyl]-6- fluorophenyl]-1,1-difluoro-N-methylmethanesulfonamide), triasulfuron, tribenuron-methyl, trifloxysulfuron (including sodium salt), triflusulfuron-methyl and tritosulfuron.

“ACCase inhibitors” (b3) are chemical compounds that inhibit the acetyl-CoA carboxylase enzyme, which is responsible for catalyzing an early step in lipid and fatty acid synthesis in plants. Lipids are essential components of cell membranes, and without them, new cells cannot be produced. The inhibition of acetyl CoA carboxylase and the subsequent lack of lipid production leads to losses in cell membrane integrity, especially in regions of active growth such as meristems. Eventually shoot and rhizome growth ceases, and shoot meristems and rhizome buds begin to die back. Examples of ACCase inhibitors include alloxydim, butroxydim, clethodim, clodinafop, cycloxydim, cyhalofop, diclofop, fenoxaprop, fluazifop, haloxyfop, pinoxaden, profoxydim, propaquizafop, quizalofop, sethoxydim, tepraloxydim and tralkoxydim, including resolved forms such as fenoxaprop-P, fluazifop-P, haloxyfop-P and quizalofop-P and ester forms such as clodinafop-propargyl, cyhalofop-butyl, diclofop-methyl and fenoxaprop-P-ethyl.

Auxin is a plant hormone that regulates growth in many plant tissues.“Auxin mimics” (b4) are chemical compounds mimicking the plant growth hormone auxin, thus causing uncontrolled and disorganized growth leading to plant death in susceptible species. Examples of auxin mimics include aminocyclopyrachlor (6-amino-5-chloro-2-cyclopropyl-4- pyrimidinecarboxylic acid) and its methyl and ethyl esters and its sodium and potassium salts, aminopyralid, benazolin-ethyl, chloramben, clacyfos, clomeprop, clopyralid, dicamba, 2,4-D, 2,4-DB, dichlorprop, fluroxypyr, halauxifen (4-amino-3-chloro-6-(4-chloro-2-fluoro-3- methoxyphenyl)-2-pyridinecarboxylic acid), halauxifen-methyl (methyl 4-amino-3-chloro-6- (4-chloro-2-fluoro-3-methoxyphenyl)-2-pyridinecarboxylate), MCPA, MCPB, mecoprop, picloram, quinclorac, quinmerac, 2,3,6-TBA, triclopyr, and methyl 4-amino-3-chloro-6-(4- chloro-2-fluoro-3-methoxyphenyl)-5-fluoro-2-pyridinecarboxyl ate.

“EPSP synthase inhibitors” (b5) are chemical compounds that inhibit the enzyme, 5-enol-pyruvylshikimate-3-phosphate synthase, which is involved in the synthesis of aromatic amino acids such as tyrosine, tryptophan and phenylalanine. EPSP inhibitor herbicides are readily absorbed through plant foliage and translocated in the phloem to the growing points. Glyphosate is a relatively nonselective postemergence herbicide that belongs to this group. Glyphosate includes esters and salts such as ammonium, isopropylammonium, potassium, sodium (including sesquisodium) and trimesium (alternatively named sulfosate).

“Photosystem I electron diverters” (b6) are chemical compounds that accept electrons from Photosystem I, and after several cycles, generate hydroxyl radicals. These radicals are extremely reactive and readily destroy unsaturated lipids, including membrane fatty acids and chlorophyll. This destroys cell membrane integrity, so that cells and organelles“leak”, leading to rapid leaf wilting and desiccation, and eventually to plant death. Examples of this second type of photosynthesis inhibitor include diquat and paraquat.

“PPO inhibitors” (b7) are chemical compounds that inhibit the enzyme protoporphyrinogen oxidase, quickly resulting in formation of highly reactive compounds in plants that rupture cell membranes, causing cell fluids to leak out. Examples of PPO inhibitors include acifluorfen-sodium, azafenidin, benzfendizone, bifenox, butafenacil, carfentrazone, carfentrazone-ethyl, chlomethoxyfen, cinidon-ethyl, fluazolate, flufenpyr-ethyl, flumiclorac-pentyl, flumioxazin, fluoroglycofen-ethyl, fluthiacet-methyl, fomesafen, halosafen, lactofen, oxadiargyl, oxadiazon, oxyfluorfen, pentoxazone, profluazol, pyraclonil, pyraflufen-ethyl, saflufenacil, sulfentrazone, thidiazimin, trifludimoxazin (dihydro-1,5- dimehyl-6-thioxo-3-[2,2,7-trifluoro-3,4-dihydro-3-oxo-4-(2-p ropyn-1-yl)-2H-1,4- benzoxazin-6-yl]-1,3,5-triazine-2,4(1H,3H)-dione) and tiafenacil (methyl N-[2-[[2-chloro-5- [3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1(2H)-py rimidinyl]-4- fluorophenyl]thio]-1-oxopropyl]-β-alaninate).

“GS inhibitors” (b8) are chemical compounds that inhibit the activity of the glutamine synthetase enzyme, which plants use to convert ammonia into glutamine. Consequently, ammonia accumulates and glutamine levels decrease. Plant damage probably occurs due to the combined effects of ammonia toxicity and deficiency of amino acids required for other metabolic processes. The GS inhibitors include glufosinate and its esters and salts such as glufosinate-ammonium and other phosphinothricin derivatives, glufosinate-P ((2S)-2-amino- 4-(hydroxymethylphosphinyl)butanoic acid) and bilanaphos.

“VLCFA elongase inhibitors” (b9) are herbicides having a wide variety of chemical structures, which inhibit the elongase. Elongase is one of the enzymes located in or near chloroplasts which are involved in biosynthesis of VLCFAs. In plants, very-long-chain fatty acids are the main constituents of hydrophobic polymers that prevent desiccation at the leaf surface and provide stability to pollen grains. Such herbicides include acetochlor, alachlor, anilofos, butachlor, cafenstrole, dimethachlor, dimethenamid, diphenamid, fenoxasulfone (3- [[(2,5-dichloro-4-ethoxyphenyl)methyl]sulfonyl]-4,5-dihydro- 5,5-dimethylisoxazole), fentrazamide, flufenacet, indanofan, mefenacet, metazachlor, metolachlor, naproanilide, napropamide, napropamide-M ((2R)-N,N-diethyl-2-(1-naphthalenyloxy)propanamide), pethoxamid, piperophos, pretilachlor, propachlor, propisochlor, pyroxasulfone, and thenylchlor, including resolved forms such as S-metolachlor and chloroacetamides and oxyacetamides.

“Auxin transport inhibitors” (b10) are chemical substances that inhibit auxin transport in plants, such as by binding with an auxin-carrier protein. Examples of auxin transport inhibitors include diflufenzopyr, naptalam (also known as N-(1-naphthyl)phthalamic acid and 2-[(1-naphthalenylamino)carbonyl]benzoic acid). “PDS inhibitors” (b11) are chemical compounds that inhibit carotenoid biosynthesis pathway at the phytoene desaturase step. Examples of PDS inhibitors include beflubutamid, diflufenican, fluridone, flurochloridone, flurtamone norflurzon and picolinafen.

“HPPD inhibitors” (b12) are chemical substances that inhibit the biosynthesis of synthesis of 4-hydroxyphenyl-pyruvate dioxygenase. Examples of HPPD inhibitors include benzobicyclon, benzofenap, bicyclopyrone (4-hydroxy-3-[[2-[(2-methoxyethoxy)methyl]-6- (trifluoromethyl)-3-pyridinyl]carbonyl]bicyclo[3.2.1]oct-3-e n-2-one), fenquinotrione (2-[[8- chloro-3,4-dihydro-4-(4-methoxyphenyl)-3-oxo-2-quinoxalinyl] carbonyl]-1,3- cyclohexanedione), isoxachlortole, isoxaflutole, mesotrione, pyrasulfotole, pyrazolynate, pyrazoxyfen, sulcotrione, tefuryltrione, tembotrione, tolpyralate (1-[[1-ethyl-4-[3-(2- methoxyethoxy)-2-methyl-4-(methylsulfonyl)benzoyl]-1H-pyrazo l-5-yl]oxy]ethyl methyl carbonate), topramezone, 5-chloro-3-[(2-hydroxy-6-oxo-1-cyclohexen-1-yl)carbonyl]-1-( 4- methoxyphenyl)-2(1H)-quinoxalinone, 4-(2,6-diethyl-4-methylphenyl)-5-hydroxy-2,6- dimethyl-3(2H)-pyridazinone, 4-(4-fluorophenyl)-6-[(2-hydroxy-6-oxo-1-cyclohexen-1- yl)carbonyl]-2-methyl-1,2,4-triazine-3,5(2H,4H)-dione, 5-[(2-hydroxy-6-oxo-1-cyclohexen- 1-yl)carbonyl]-2-(3-methoxyphenyl)-3-(3-methoxypropyl)-4(3H) -pyrimidinone, 2-methyl-N- (4-methyl-1,2,5-oxadiazol-3-yl)-3-(methylsulfinyl)-4-(triflu oromethyl)benzamide and 2- methyl-3-(methylsulfonyl)-N-(1-methyl-1H-tetrazol-5-yl)-4-(t rifluoromethyl)benzamide. “HST inhibitors” (b13) disrupt a plant’s ability to convert homogentisate to 2-methyl-6-solanyl-1,4-benzoquinone, thereby disrupting carotenoid biosynthesis. Examples of HST inhibitors include haloxydine, pyriclor, 3-(2-chloro-3,6-difluorophenyl)-4-hydroxy-1- methyl-1,5-naphthyridin-2(1H)-one, 7-(3,5-dichloro-4-pyridinyl)-5-(2,2-difluoroethyl)-8- hydroxypyrido[2,3-b]pyrazin-6(5H)-one and 4-(2,6-diethyl-4-methylphenyl)-5-hydroxy-2,6- dimethyl-3(2H)-pyridazinone.

HST inhibitors also include compounds of Formulae A and B.

wherein R ^d1 is H, Cl or CF ₃ ; R ^d2 is H, Cl or Br; R ^d3 is H or Cl; R ^d4 is H, Cl or CF ₃ ; R ^d5 is CH ₃ , CH ₂ CH ₃ or CH ₂ CHF ₂ ; and R ^d6 is OH, or -OC(=O)-i-Pr; and R ^e1 is H, F, Cl, CH ₃ or CH ₂ CH ₃ ; R ^e2 is H or CF ₃ ; R ^e3 is H, CH ₃ or CH ₂ CH ₃ ; R ^e4 is H, F or Br; R ^e5 is Cl, CH ₃ , CF ₃ , OCF ₃ or CH ₂ CH ₃ ; R ^e6 is H, CH ₃ , CH ₂ CHF ₂ or C≡CH; R ^e7 is

OH, -OC(=O)Et, -OC(=O)-i-Pr or -OC(=O)-t-Bu; and A ^e8 is N or CH.

“Cellulose biosynthesis inhibitors” (b14) inhibit the biosynthesis of cellulose in certain plants. They are most effective when applied preemergence or early postemergence on young or rapidly growing plants. Examples of cellulose biosynthesis inhibitors include chlorthiamid, dichlobenil, flupoxam, indaziflam (N ² -[(1R,2S)-2,3-dihydro-2,6-dimethyl-1H-inden-1-yl]-6- (1-fluoroethyl)-1,3,5-triazine-2,4-diamine), isoxaben and triaziflam.

“Other herbicides” (b15) include herbicides that act through a variety of different modes of action such as mitotic disruptors (e.g., flamprop-M-methyl and flamprop-M-isopropyl), organic arsenicals (e.g., DSMA, and MSMA), 7,8-dihydropteroate synthase inhibitors, chloroplast isoprenoid synthesis inhibitors and cell-wall biosynthesis inhibitors. Other herbicides include those herbicides having unknown modes of action or do not fall into a specific category listed in (b1) through (b14) or act through a combination of modes of action listed above. Examples of other herbicides include aclonifen, asulam, amitrole, bromobutide, cinmethylin, clomazone, cumyluron, cyclopyrimorate (6-chloro-3-(2-cyclopropyl-6- methylphenoxy)-4-pyridazinyl 4-morpholinecarboxylate), daimuron, difenzoquat, etobenzanid, fluometuron, flurenol, fosamine, fosamine-ammonium, dazomet, dymron, ipfencarbazone (1-(2,4-dichlorophenyl)-N-(2,4-difluorophenyl)-1,5-dihydro-N -(1- methylethyl)-5-oxo-4H-1,2,4-triazole-4-carboxamide), metam, methyldymron, oleic acid, oxaziclomefone, pelargonic acid, pyributicarb and 5-[[(2,6-difluorophenyl)methoxy]methyl]- 4,5-dihydro-5-methyl-3-(3-methyl-2-thienyl)isoxazole.

“Herbicide safeners” (b16) are substances added to a herbicide formulation to eliminate or reduce phytotoxic effects of the herbicide to certain crops. These compounds protect crops from injury by herbicides but typically do not prevent the herbicide from controlling undesired vegetation. Examples of herbicide safeners include but are not limited to benoxacor, cloquintocet-mexyl, cumyluron, cyometrinil, cyprosulfamide, daimuron, dichlormid, dicyclonon, dietholate, dimepiperate, fenchlorazole-ethyl, fenclorim, flurazole, fluxofenim, furilazole, isoxadifen-ethyl, mefenpyr-diethyl, mephenate, methoxyphenone, naphthalic anhydride, oxabetrinil, N-(aminocarbonyl)-2-methylbenzenesulfonamide and N- (aminocarbonyl)-2-fluorobenzenesulfonamide, 1-bromo-4-[(chloromethyl)sulfonyl]benzene, 2-(dichloromethyl)-2-methyl-1,3-dioxolane (MG 191), 4-(dichloroacetyl)-1-oxa- 4-azospiro[4.5]decane (MON 4660), 2,2-dichloro-1-(2,2,5-trimethyl-3-oxazolidinyl)- ethanone and 2-methoxy-N-[[4-[[(methylamino)carbonyl]amino]phenyl]sulfony l]- benzamide.

The compounds of Formula 1 can be prepared by general methods known in the art of synthetic organic chemistry. Of note are the following methods described in Schemes 1–15 and variations thereof. The definitions of R ¹ , R ² , R ^2b , R ³ , R ⁴ , R ⁵ , R ⁶ , R ²⁰ , R ²¹ , Q ¹ , Q ² , T, Y and J ² in the compounds of Formulae 1 through 22 below are as defined above in the Summary unless otherwise noted. Formulae 1a–1d are various subsets of a compound of Formula 1. Substituents for each subset formula are as defined above for its parent formula unless otherwise noted.

As shown in Scheme 1 compounds of Formula 1a (i.e. Formula 1 wherein Y is O) can be prepared by reaction of acids of Formula 2 with amines of Formula 3 in the presence of a dehydrative coupling reagent such as propylphosphonic anhydride, dicyclohexylcarbodiimide, N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide, N,N'-carbonyldiimidazole, 2-chloro-l,3- dimethylimidazolium chloride or 2-chloro-l-methylpyridinium iodide. Polymer-supported reagents, such as polymer-supported cyclohexylcarbodiimide, are also suitable. These reactions are typically run at temperatures ranging from 0–60 °C in a solvent such as dichloromethane, acetonitrile, N,N-dimethylformamide or ethyl acetate in the presence of a base such as triethylamine, N,N-diisopropylamine, or 1,8-diazabicyclo[5.4.0]undec-7-ene. See Organic Process Research & Development 2009, 13, 900–906 for coupling conditions employing propylphosphonic anhydride. The method of Scheme 1 utilizing propylphosphonic anhydride is illustrated by Step D of Synthesis Example 2. Substituents in the 2- and 3- positions of the dihydropyrrolium oxide ring of compounds of Formula 1a, i.e. C(O)N(Q ² )(R ⁶ ) and Q ¹ T, respectively, are predominantly in the trans configuration. In some instances, the presence of minor amounts of the cis isomer can be detected by NMR.

Scheme 1

As shown in Scheme 2 compounds of Formula 1a can be prepared by reaction of alkyl esters of Formula 4 with amines of Formula 3 in the presence of an organometallic compound. Suitable organometallic compounds for the reaction include, but are not limited to, trialkylaluminum reagents such as trimethylaluminum, diorganoaluminum hydrides such as diisobutylaluminum hydride and organomagnesium halides such as methylmagnesium bromide. A wide variety of solvents are suitable for the reaction including, but not limited to, toluene, benzene, dichloromethane, 1,2-dichloroethane, diethyl ether and tetrahydrofuran. The reaction is conducted at temperatures ranging from–20 °C to the boiling point of the solvent, and typically from 0 to 120 °C. See Journal of the American Chemical Society 2010, 132, 1740–1740 for coupling conditions employing trimethylaluminum and Journal of the American Chemical Society 2015, 137, 13492–13495 for coupling conditions employing methylmagnesium bromide. The method of Scheme 2 is illustrated by Step A of Synthesis Example 3.

Scheme 2

As shown in Scheme 3 compounds of Formula 1 can be prepared by oxidation of dihydropyrroles of Formula 5 by methods well known to those skilled in the art. Oxidation is carried out with an oxidant, optionally in the presence of a catalyst and typically in the presence of a co-solvent. Suitable oxidants for the reaction include, but are not limited to, urea hydrogen peroxide, hydrogen peroxide, peracids such as m-chloroperbenzoic acid and dioxiranes such as dimethyldioxirane. Suitable catalysts for the reaction include, but are not limited to, sodium tungstate and methyltrioxorhenium. A wide variety of co-solvents are suitable for the reaction including, but not limited to, water, ethanol, methanol, acetone, chloroform and dichloromethane. The reaction is conducted at temperatures ranging from -20 °C to the boiling point of the solvent, and typically from 0 to 50 °C. See Organic Letters 2007, 9, 473–476 for oxidation conditions using methyltrioxorhenium and urea hydrogen peroxide.

As shown in Scheme 4 compounds of Formula 1 can be prepared by oxidation of dihydropyrroles of Formula 6 by methods well known to those skilled in the art. Oxidation is carried out with an oxidant, optionally in the presence of a catalyst and typically in the presence of a co-solvent. Suitable oxidants for the reaction include, but are not limited to, urea hydrogen peroxide, hydrogen peroxide, oxone, peracids such as m-chloroperbenzoic acid, oxaziridines such as 3-phenyl-2-(phenylsulfonyl)oxaziridine and dioxiranes such as dimethyldioxirane. Suitable catalysts for the reaction include, but are not limited to, sodium tungstate, selenium dioxide and methyltrioxorhenium. A wide variety of co-solvents are suitable for the reaction including, but not limited to, water, ethanol, methanol, acetone, acetonitrile, tetrahydrofuran, chloroform and dichloromethane. The reaction is conducted at temperatures ranging from–20 °C to the boiling point of the solvent, and typically from 0 to 50 °C. See Organic Letters 2013, 15, 326–329 for oxidation conditions using sodium tungstate and urea hydrogen peroxide. 15 Scheme 4

As shown in Scheme 5, compounds of Formula 1b (i.e. a compound of Formula 1 wherein J ² is other than -NR ^2b - or -O- and Y is O) can be obtained by reduction of compounds of Formula 7 and subsequent in situ cyclization of the resulting intermediate amine. A wide variety of methods for reduction of the aliphatic nitro group in compounds of Formula 7 are known in the literature. Methods include catalytic hydrogenation in the presence of palladium on carbon or Raney nickel and iron or zinc metal in acidic medium (see, for an example using iron metal, Synlett, 2015, 26, 846–850 and for an example using zinc metal, Tetrahedron, 2000, 56, 1889–1897). Alternatively sodium borohydride in the presence of a nickel catalyst such as nickel(II) acetate or nickel(II) chloride can be used (see for example, Angewandte Chemie, International Edition, 2013, 52, 5575–5579). The method of Scheme 5 utilizing zinc metal in the presence of ammonium chloride is illustrated by Step E of Synthesis Example 1. Scheme 5

Compounds of Formula 5a (i.e. a compound of Formula 5 wherein R ¹ is OR, NHR, NH ₂ R, SR or CN) can be synthesized from a compound of Formula 8 by the reaction shown in Scheme 6. The substitution reaction is carried out with an appropriate nucleophile, optionally in the presence of a base and typically in the presence of a co-solvent. Suitable nucleophiles for the reaction include, but are not limited to, alkyl alcohols, amines, alkyl thiols and cyanide salts. Suitable bases for the reaction include, but are not limited to, sodium hydride, sodium methoxide, sodium ethoxide, cesium carbonate, potassium carbonate or potassium tert-butoxide are employed. Typically the reaction is conducted in a solvent such as water, methanol, ethanol, tetrahydrofuran, dimethylsulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone and acetonitrile or a mixture thereof at temperatures ranging from ambient temperature to the reflux temperature of the solvent.

Scheme 6

As shown in Scheme 7, compounds of Formula 5b (i.e. a compound of Formula 5 wherein R ¹ is C ₁ -C ₆ alkylthio, C ₁ -C ₆ haloalkylthio, C ₃ -C ₈ cycloalkylthio ^; and Y is O) can be prepared by alkylation of compounds of Formula 9 with an appropriate alkylating agent optionally in the presence of a base. Suitable alkylating agents include, but are not limited to, trialkyloxonium tetrafluoroborates such as trimethyloxonium tetrafluoroborate and triethyloxonium tetrafluoroborate, alkyliodides, alkylbromides, and alkyl sulfonates. Suitable bases for the reaction include, but are not limited to, carbonates such as sodium and potassium carbonate and neutral nitrogen-containing bases such as triethylamine and 1,8-diazabicyclo[5.4.0]undec-7-ene. A wide variety of co-solvents are suitable for the reaction including, but not limited to, dimethylsulfoxide, N,N-dimethylformamide, N,N- dimethylacetamide, N-methylpyrrolidinone, acetonitrile, acetone and tetrahydrofuran. The reaction is conducted at temperatures ranging from–20 °C to the boiling point of the solvent, and typically from 0– 150 °C.

Scheme 7

As shown in Scheme 8, thiolactams of Formula 9 can be prepared by thiocarbonyl transfer to nitrones of Formula 10. The reaction is carried out with a thiocarbonyl transfer reagent, optionally in the presence of a co-solvent. Suitable thiocarbonyl transfer reagents for the reaction include, but are not limited to, 1,1’-thiocarbonyl-di-(1,2,4)-triazole, chlorodiphenylphosphine sulfide, phenylthiophosphoryl dichloride (Cl ₂ P(=S)Ph and thiophosphoryl chloride (Cl ₃ PS). A variety of co-solvents are suitable for the reaction including, but not limited to, benzene, toluene and tetrahydrofuran. The reaction is conducted at temperatures ranging from–20 °C to the boiling point of the solvent, and typically from 0 to 100 °C. See Canadian Journal of Chemistry, 1985, 63, 951–957 for conditions using 1,1’- thiocarbonyl-di-(1,2,4)-triazole. Scheme 8

As shown in Scheme 9, compounds of Formula 5c can be obtained by reduction of a compound of Formula 7 and subsequent in situ cyclization of the resulting intermediate amine. A wide variety of methods for reduction of the aliphatic nitro group in compounds of Formula 7 are known in the literature. Methods include catalytic hydrogenation in the presence of palladium on carbon or Raney nickel, iron or zinc metal in acidic medium (see, for an example using iron metal, Angewandte Chemie, International Edition, 2013, 52, 5575–5579 and for an example using zinc metal, Tetrahedron, 2000, 56, 1889–1897) and titanium(III) trichloride. Scheme 9

As shown in Scheme 10 a compound of Formula 2 can be prepared by hydrolysis of esters of Formula 11. Hydrolysis is carried out with aqueous base or aqueous acid, typically in the presence of a co-solvent. Suitable bases for the reaction include, but are not limited to, hydroxides such as sodium and potassium hydroxide and carbonates such as sodium and potassium carbonate. Suitable acids for the reaction include, but are not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid and sulfuric acid, and organic acids such as acetic acid and trifluoroacetic acid. A wide variety of co-solvents are suitable for the reaction including, but not limited to, methanol, ethanol and tetrahydrofuran. The reaction is conducted at temperatures ranging from–20 °C to the boiling point of the solvent, and typically from 0 – 100 °C. The method of Scheme 10 is illustrated by Step A of Synthesis Example 3

Scheme 10

As shown in Scheme 11, a compound of Formula 12 can be obtained by reduction of compounds of Formula 13 and subsequent in situ cyclization of the resulting intermediate amine. A wide variety of methods for reduction of the aliphatic nitro group in compounds of Formula 13 are known in the literature. Methods well known to those skilled in the art include catalytic hydrogenation in the presence of palladium on carbon or Raney nickel and iron or zinc metal in acidic medium (see, for an example using iron metal, Synlett, 2015, 26, 846–850 and for an example using zinc metal, Tetrahedron, 2000, 56, 1889–1897). Alternatively sodium borohydride in the presence of a nickel catalyst such as nickel(II) acetate or nickel(II) chloride can be used (see for example, Angewandte Chemie, International Edition, 2013, 52, 5575–5579). The method of Scheme 11 utilizing zinc metal in the presence of ammonium chloride is illustrated by Step B of Synthesis Example 2.

As shown in Scheme 12, compounds of Formula 14 can be obtained by reduction of compounds of Formula 13 and subsequent in situ cyclization of the resulting intermediate amine. A wide variety of methods for reduction of the aliphatic nitro group in compounds of Formula 13 are known in the literature. Methods include catalytic hydrogenation in the presence of palladium on carbon or Raney nickel, iron or zinc metal in acidic medium (see, for an example using iron metal, Angewandte Chemie, International Edition, 2013, 52, 5575– 5579 and for an example using zinc metal, Tetrahedron, 2000, 56, 1889–1897) and titanium(III) trichloride. 10 Scheme 12

As shown in Scheme 13, a compound of Formula 15 can be obtained by the conjugate addition of nitro-containing compounds of Formula 16 to an α,β-unsaturated carbonyl compound of Formula 17. The reaction can be conducted under base-promoted conditions, optionally in the presence of a co-solvent and a carboxylic acid. Suitable bases for the reaction include, but are not limited to, fluorides such as potassium fluoride, carbonates such as sodium and potassium carbonate, amines such as triethylamine and diethylamine, and phosphazenes such as 2-tert-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2- diazaphosphorine. A wide variety of co-solvents are suitable for the reaction including, but not limited to, methanol, ethanol, tetrahydrofuran and dichloromethane. The reaction is conducted at temperatures ranging from–20 °C to the boiling point of the solvent, and typically from 0– 100 °C. The method of Scheme 13 is illustrated by Step D of Synthesis Example 1 and Step A of Synthesis Example 2. The method of Scheme 13 utilizing zinc metal in the presence of ammonium chloride is illustrated by Step B of Synthesis Example 2. The conjugate addition can also be conducted using a suitable catalyst. Typically, these catalysts contain stereocenters and can be synthesized in high optical purity. The use of enantioenriched catalysts can result in the formation of enantioenriched compounds of Formula 15. A variety of suitable catalysts are well known in the literature: see Chemistry– A European Journal, 2014, 20, 979–982 for conditions using copper/ligand complexes, see Tetrahedron, 2014, 70, 8168–8173 for conditions using squaramides and see Chemistry– A European Journal, 2011, 17, 5931–5938 for conditions using thioureas. Compounds of Formula 16 and compounds of Formula 17 are commercially available or their preparation is known in the art. Scheme 13

As shown in Scheme 14, compounds of Formula 18 can be obtained by the ring expansion of a compound of Formula 19 using an appropriate promoter in an appropriate solvent. Suitable promoters include, but are not limited to, boron trifluoride etherate, iron(III) nitrate, sodium iodide and trimethylsilyl iodide. A variety of co-solvents are suitable for the reaction including, but not limited to, dimethylsulfoxide, N,N-dimethylformamide, N,N- dimethylacetamide, N-methylpyrrolidinone N,N-dimethylformamide, acetonitrile, acetone and tetrahydrofuran. The reaction is conducted at temperatures ranging from–20 °C to the boiling point of the solvent, and typically from 0– 100 °C. See Recueil des Travaux Chimiques des Pays-Bas, 1992, 111, 16–21 for ring expansion conditions using boron trifluoride etherate. N-Acyl aziridines of Formula 19 can readily be prepared by literature methods.

Scheme 14

As shown in Scheme 15, compounds of Formula 20 can be obtained by the reaction of aziridines of Formula 21 with imidoyl chlorides of Formula 22 and subsequent ring expansion. The reaction is typically conducted in the presence of a base with the optional use of a co- solvent. Suitable bases include, but are not limited to, alkylamines such as triethylamine and diethylamine, arylamines such as N,N-dimethylaniline, and pyridines such as 2,6-lutidine. A variety of co-solvents are suitable for the reaction including, but not limited to, dimethylsulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidinone N,N-dimethylformamide, acetonitrile, acetone and tetrahydrofuran. The reaction is conducted at temperatures ranging from–20 °C to the boiling point of the solvent, and typically from 0– 100 °C. See Journal of Organic Chemistry, 2011, 76, 2913–2919 for conditions using 2,6-lutidine in N,N-dimethylformamide. Imidoyl chlorides of Formula 22 can readily be prepared from amides by literataure methods. Aziridines of Formula 21 can readily be prepared by literature methods. Scheme 15

It is recognized by one skilled in the art that various functional groups can be converted into others to provide different compounds of Formula 1. For a valuable resource that illustrates the interconversion of functional groups in a simple and straightforward fashion, see Larock, R. C., Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Ed., Wiley-VCH, New York, 1999. For example, intermediates for the preparation of compounds of Formula 1 may contain aromatic nitro groups, which can be reduced to amino groups, and then be converted via reactions well known in the art such as the Sandmeyer reaction, to various halides, providing compounds of Formula 1. The above reactions can also in many cases be performed in alternate order.

It is recognized that some reagents and reaction conditions described above for preparing compounds of Formula 1 may not be compatible with certain functionalities present in the intermediates. In these instances, the incorporation of protection/deprotection sequences or functional group interconversions into the synthesis will aid in obtaining the desired products. The use and choice of the protecting groups will be apparent to one skilled in chemical synthesis (see, for example, Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 2nd ed.; Wiley: New York, 1991). One skilled in the art will recognize that, in some cases, after the introduction of a given reagent as depicted in any individual scheme, it may be necessary to perform additional routine synthetic steps not described in detail to complete the synthesis of compounds of Formula 1. One skilled in the art will also recognize that it may be necessary to perform a combination of the steps illustrated in the above schemes in an order other than that implied by the particular presented to prepare the compounds of Formula 1.

One skilled in the art will also recognize that compounds of Formula 1 and the intermediates described herein can be subjected to various electrophilic, nucleophilic, radical, organometallic, oxidation, and reduction reactions to add substituents or modify existing substituents.

Without further elaboration, it is believed that one skilled in the art using the preceding description can utilize the present disclosure to its fullest extent. The following non-limiting Examples are illustrative of the disclosure. Steps in the following Examples illustrate a procedure for each step in an overall synthetic transformation, and the starting material for each step may not have necessarily been prepared by a particular preparative run whose procedure is described in other Examples or Steps. Percentages are by weight except for chromatographic solvent mixtures or where otherwise indicated. Parts and percentages for chromatographic solvent mixtures are by volume unless otherwise indicated. ¹ H NMR spectra are reported in ppm downfield from tetramethylsilane;“s” means singlet,“d” means doublet, “t” means triplet,“q” means quartet,“m” means multiplet,“dd” means doublet of doublets, “dt” means doublet of triplets, and“br s” means broad singlet. SYNTHESIS EXAMPLE 1

Preparation of trans-3-(4-chlorophenyl)-N-(2,3-difluorophenyl)-3,4-dihydro- 5-methyl-2H-pyrrole-2-carboxamide 1-oxide (Compound 5) Step A: Preparation of dipotassium nitroacetate

A solution of potassium hydroxide (44.9 g, 0.68 mol) in water (22 mL) was heated to 70 °C. Nitromethane (12.2 g, 0.20 mol) was added dropwise over the course of 15 minutes, during which the internal temperature increased to 105 °C. The reaction mixture was heated in a 180 °C sand bath and held at a slow reflux for 1 h. The reaction was cooled to 23 °C and then filtered. The filter cake was washed with methanol (3 × 40 mL) and dried under vacuum to afford the title compound (13.2 g) as a beige solid.

Step B: Preparation of nitroacetic acid

A solution of (L)-tartaric acid (80.4 g, 0.54 mol) in water (150 mL) was cooled to 0 °C. A solution of dipotassium nitroacetate (i.e. the product of Step A, 11.3 g, 62 mmol) in water (40 mL) was cooled to–5 °C. The tartartic acid solution was added slowly to the dipotassium nitroacetate solution, keeping the internal temperature between–5 °C and 0 °C. The reaction mixture was stirred at 0 °C for 30 min. The mixture was filtered, and the filtrate was extracted with ice cold diethyl ether (3 × 100 mL). The organic layer was dried over MgSO ₄ and concentrated under reduced pressure in an ice bath to afford the title compound (6.0 g) as a pale yellow solid that was used immediately in the next step.

Step C: Preparation of N-(2,3-difluorophenyl)-2-nitroacetamide

A solution of nitroacetic acid (i.e. the product of Step B, 6.0 g, 57 mmol) and 2,3-difluoroaniline (5.8 mL, 57 mmol) in tetrahydrofuran (150 mL) was cooled to 0 °C. N,N’-Dicyclohexylcarbodiimide (13.0 g, 63 mmol) was added portionwise, keeping the temperature under 15 °C. The reaction mixture was stirred for 45 min at 0 °C. The reaction mixture was filtered, and the filtrate was concentrated to afford the crude product. The crude product was purified by column chromatography, eluting with 0% to 50% ethyl acetate in hexanes, to afford the title compound (3.0 g) as a pale yellow solid. Additional product (6.0-g, 45% pure by weight) was isolated as a mixture with N,N’-dicyclohexylurea.

1H NMR δ 8.59 (br s, 1H), 8.02–7.96 (m, 1H), 7.15–7.08 (m, 1H), 7.06–6.96 (m, 1H), 5.30 (s, 2H).

Step D: Preparation of 3-(4-chlorophenyl)-N-(2,3-difluorophenyl)-2-nitro-5-oxo- hexanamide

A mixture of N-(2,3-difluorophenyl)-2-nitroacetamide (i.e. the product of Step C, 0.93 mmol), (E)-4-(4-chlorophenyl)but-3-en-2-one (0.18 g, 1.02 mmol) and triethylamine (0.38 mL, 2.78 mmol) in tetrahydrofuran (0.9 mL) was refluxed for 1 h. The reaction mixture was cooled to 23 °C and diluted with ethyl acetate (50 mL). The organic layer was washed with 1M hydrochloric acid (2 × 15 mL), dried over MgSO ₄ , and concentrated to afford the crude product. The crude product was purified by column chromatography, eluting with 0% to 100% ethyl acetate in hexanes, to afford the title compound (0.20 g, 1:1 mixture of diastereomers) as a yellow oil.

1H NMR (2 diastereomers) δ 8.69 (br s, 1H), 8.26 (br s, 1H), 7.91–7.86 (m, 1H), 7.73–7.68 (m, 1H), 7.35–7.26 (m, 4H), 7.23–7.18 (m, 4H), 7.13–6.93 (m, 4H), 5.67 (d, J = 10.9 Hz, 1H), 5.57 (d, J = 8.8 Hz, 1H), 4.29–4.23 (m, 2H), 3.13–2.98 (m, 3H), 2.94–2.88 (m, 1H), 2.12 (s, 3H), 2.08 (s, 3H).

Step E: Preparation of trans-3-(4-chlorophenyl)-N-(2,3-difluorophenyl)-3,4-dihydro- 5-methyl-2H-pyrrole-2-carboxamide 1-oxide

To a solution of 3-(4-chlorophenyl)-N-(2,3-difluorophenyl)-2-nitro-5-oxo-hexa namide (i.e. the product of Step D, 0.20 g, 0.50 mmol) in tetrahydrofuran (2.5 mL) was added saturated ammonium chloride solution (2.5 mL). The mixture was cooled to 0 °C. Zinc dust (0.10 g, 1.50 mmol) was added, and the reaction was stirred vigorously at 0 °C for 30 min. The reaction mixture was filtered through Celite® diatomaceous filter aid, washing the filter cake with ethyl acetate (30 mL). The organic layer was separated, washed with saturated NaCl (10 mL), dried over MgSO ₄ , and concentrated to afford the crude product. The crude product was purified by column chromatography, eluting with 0% to 100% ethyl acetate in hexanes, to afford the title compound, a compound of the present disclosure, as a colorless solid (0.072 g).

1H NMR δ 11.66 (br s, 1H), 8.06–8.00 (m, 1H), 7.38–7.33 (m, 2H), 7.29–7.24 (m, 2H), 7.07– 7.00 (m, 1H), 6.94–6.87 (m, 1H), 4.78–4.71 (m, 1H), 4.20–4.14 (m, 1H), 3.32–3.22 (m, 1H), 2.87–2.78 (m, 1H), 2.25–2.21 (m, 3H). SYNTHESIS EXAMPLE 2

Preparation of trans-N-(2,3-difluorophenyl)-3,4-dihydro-5-methyl-3-[4- (trifluoromethyl)phenyl]-2H-pyrrole-2-carboxamide 1-oxide

(Compound 2)

Step A: Preparation of ethyl 2-nitro-5-oxo-3-[4-(trifluoromethyl)phenyl]hexanoate To a solution of ethyl nitroacetate (11.0 mL, 95 mmol) and (E)-4-[4- (trifluoromethyl)phenyl]but-3-en-2-one (17.0 g, 79 mmol) in tetrahydrofuran (36 mL) was added triethylamine (33.0 mL, 237 mmol) dropwise over 15 min. The reaction mixture was then refluxed for 3 h. The reaction mixture was cooled to 23 °C and diluted with ethyl acetate (300 mL). The organic layer was washed with 1 M hydrochloric acid (100 mL) and saturated sodium chloride (100 mL). The organic layer was dried over MgSO ₄ and concentrated to afford the crude product (28.9 g). The crude product was stirred in a 3:1 mixture of hexanes/1- chlorobutane (50 mL) for 45 min. The mixture was filtered to afford the title compound (19.4 g, 2.5:1 mixture of diastereomers) as a colorless solid. The filtrate was concentrated and triturated with hexanes (25 mL) to afford the title compound (4.7 g, minor diastereomer) as an orange solid.

1H NMR (major diastereomer) δ 7.60–7.55 (m, 2H), 7.43–7.38 (m, 2H), 5.44 (d, J = 8.5 Hz, 1H), 4.37–4.28 (m, 1H), 4.15–4.04 (m, 2H), 3.17–3.09 (m, 1H), 3.05–2.98 (m, 1H), 2.10 (s, 3H), 1.11–1.07 (m, 3H); (minor diastereomer) δ 7.60–7.55 (m, 2H), 7.43–7.38 (m, 2H), 5.51 (d, J = 9.6 Hz, 1H), 4.37–4.22 (m, 3H), 4.15–4.04 (m, 2H), 3.13–3.06 (m, 1H), 3.01–2.94 (m, 1H), 2.10 (s, 3H), 1.32–1.27 (m, 3H).

Step B: Preparation of ethyl 5-methyl-1-oxido-3-[4-(trifluoromethyl)phenyl]-3,4- dihydro-2H-pyrrol-1-ium-2-carboxylate

To a solution of ethyl 2-nitro-5-oxo-3-[4-(trifluoromethyl)phenyl]hexanoate (i.e. the product of Step A, 24.1 g, 69.4 mmol, 1.35:1 mixture of diastereomers) in tetrahydrofuran (115 mL) was added saturated ammonium chloride solution (115 mL). The mixture was cooled to 0 °C. Zinc dust (13.6 g, 208 mmol) was added portionwise keeping the temperature under 5 °C. After the addition, the reaction was stirred vigorously at 0 °C for 60 min. The reaction mixture was filtered through Celite® diatomaceous filter aid, and the filter cake was washed with ethyl acetate (150 mL). Ethyl acetate (150 mL) and water (150 mL) were added to the reaction mixture. The organic layer was separated, dried over MgSO ₄ , and concentrated to afford the crude product. The crude product was purified by column chromatography, eluting with 0% to 25% methanol in ethyl acetate, to afford the cis diastereomer of the title compound as a colorless solid (2.05 g) and the trans diastereomer of the title compound as a yellow oil (7.07 g).

1H NMR (major diastereomer, trans) δ 7.66–7.60 (m, 2H), 7.36–7.31 (m, 2H), 4.77–4.71 (m, 1H), 4.39–4.25 (m, 2H), 3.83–3.75 (m, 1H), 3.43–3.33 (m, 1H), 2.84–2.75 (m, 1H), 2.20– 2.16 (m, 3H), 1.35–1.29 (m, 3H); (minor diastereomer, cis) δ 7.64–7.57 (m, 2H), 7.44–7.38 (m, 2H), 4.95–4.89 (m, 1H), 4.19–4.10 (m, 1H), 3.93–3.84 (m, 1H), 3.82–3.73 (m, 1H), 3.41–3.31 (m, 1H), 3.10–3.01 (m, 1H), 2.27–2.21 (m, 3H), 0.85–0.78 (m, 3H).

Step C: Preparation of trans-5-methyl-1-oxido-3-[4-(trifluoromethyl)phenyl]-3,4- dihydro-2H-pyrrol-1-ium-2-carboxylic acid

To a solution of ethyl 5-methyl-1-oxido-3-[4-(trifluoromethyl)phenyl]-3,4-dihydro-2 H- pyrrol-1-ium-2-carboxylate (i.e. the product of Step B, 0.070 g, 0.22 mmol, trans diastereomer) in methanol (1.1 mL) was added 1M NaOH (0.44 mL, 0.44 mmol). The mixture was stirred vigorously at 23 °C for 2 h. The mixture was diluted with 1 M NaOH (3 mL) and washed with diethyl ether (10 mL). The organic layer was back extracted with 1M NaOH (2 mL). The combined aqueous layers were acidified to pH 1 with 1 M HCl, extracted with ethyl acetate (2 × 10 mL), dried over MgSO ₄ , and concentrated to afford to afford the trans diastereomer of the title compound as an orange oil (0.058 g).

1H NMR δ 7.68-7.62 (m, 2H), 7.51–7.44 (m, 2H), 4.69–4.62 (m, 1H), 4.10–4.01 (m, 1H), 3.33–3.22 (m, 1H), 3.01–2.90 (m, 1H), 2.29–2.22 (m, 3H),–CO ₂ H signal not observed. Step D: Preparation of trans-N-(2,3-difluorophenyl)-3,4-dihydro-5-methyl-3-[4- (trifluoromethyl)phenyl]-2H-pyrrole-2-carboxamide 1-oxide

To a solution of trans-5-methyl-1-oxido-3-[4-(trifluoromethyl)phenyl]-3,4-dih ydro-2H- pyrrol-1-ium-2-carboxylic acid (i.e. the product of Step C, 0.058 g, 0.20 mmol) in tetrahydrofuran (2.0 mL) was added 2,3-difluoroaniline (0.090 mL, 0.44 mmol), triethylamine (0.084 mL, 0.61 mmol), and propylphosphonic anhydride solution (50 wt. % in ethyl acetate, 0.072 mL, 0.24 mmol). The mixture allowed to stand at 23 °C for 35 min. The reaction mixture was directly purified by column chromatography, eluting with 0% to 100% ethyl acetate in hexanes, to afford the title compound, a compound of the present disclosure, as a colorless solid (0.025 g).

1H NMR δ 11.69 (br s, 1H), 8.06–8.00 (m, 1H), 7.68–7.63 (m, 2H), 7.50–7.42 (m, 2H), 7.08– 7.00 (m, 1H), 6.96–6.88 (m, 1H), 4.82–4.76 (m, 1H), 4.30–4.23 (m, 1H), 3.36–3.26 (m, 1H), 2.91–2.82 (m, 1H), 2.27–2.23 (m, 3H). SYNTHESIS EXAMPLE 3

Preparation of trans-N-(2-fluorophenyl)-3,4-dihydro-5-methyl-3-[4- (trifluoromethyl)phenyl]-2H-pyrrole-2-carboxamide 1-oxide

(Compound 26)

Step A: trans-N-(2-fluorophenyl)-3,4-dihydro-5-methyl-3-[4- (trifluoromethyl)phenyl]-2H-pyrrole-2-carboxamide 1-oxide

Ethyl 5-methyl-1-oxido-3-[4-(trifluoromethyl)phenyl]-3,4-dihydro-2 H-pyrrol-1-ium-2- carboxylate (i.e. the product of Example 2, Step B, 0.250 g, 0.79 mmol, trans diastereomer) was dissolved in anhydrous toluene (2.0 mL). In a separate vessel, trimethylaluminum solution (2.0 M in toluene, 0.44 mL, 0.87 mmol) was added dropwise over 10 min to a solution of 2-fluoroaniline (0.084 mL, 0.87 mmol) in anhydrous toluene (2.0 mL). The solution was stirred for 5 min at 23 °C. The solution of the ester was added to the aluminum amide solution. The resulting solution was stirred for 1 h at 100 °C. The reaction was cooled to 23 °C and carefully quenched with the addition of 1 M HCl. The mixture was diluted with water (50 mL) and extracted with ethyl acetate (100 mL). The organic layer was washed with saturated NaCl (50 mL) and adsorbed onto silica gel. This mixture was purified by column chromatography, eluting with 60% to 100% ethyl acetate in hexanes and then with 0-10% methanol in ethyl acetate, to afford the title compound, a compound of the present disclosure, as a colorless solid (0.160 g).

1H NMR δ 11.47 (br s, 1H), 8.30–8.22 (m, 1H), 7.60–7.62 (m, 2H), 7.52–7.43 (m, 2H), 7.17– 7.03 (m, 3H), 4.82–4.75 (m, 1H), 4.32–4.24 (m, 1H), 3.36–3.25 (m, 1H), 2.89–2.81 (m, 1H), 2.27–2.21 (m, 3H). SYNTHESIS EXAMPLE 4

Preparation of trans-N-(2,3-difluorophenyl)-3-(4,6-dimethoxypyrimidin-2-yl) -5-methyl-1- oxido-3,4-dihydro-2H-pyrrol-1-ium-2-carboxamide (Compound 59) Step A: Preparation of (E)-4-(4,6-dimethoxypyrimidin-2-yl)but-3-en-2-one

A mixture of 2-chloro-4,6-dimethoxy-pyrimidine (0.50 g, 2.9 mmol), methyl vinyl ketone (0.61 g, 8.7 mmol), tetrabutylammonium acetate (1.72 g, 5.7 mmol) and bis(tri-tert- butylphosphine)palladium(0) (0.11 g, 0.21 mmol) in 1,4-dioxane (2.0 mL) was heated to 100 °C in a microwave reactor for 30 minutes. The reaction mixture was cooled to 23 °C and then directly purified by column chromatography, eluting with 0% to 40% ethyl acetate in hexanes to afford the title compound as a colorless solid (0.20 g).

1H NMR δ 7.35–7.20 (m, 2H), 6.46 (s, 1H), 4.03 (s, 3H), 4.00 (s, 3H), 2.40 (s, 3H). Step B: Preparation of trans-N-(2,3-difluorophenyl)-3-(4,6-dimethoxypyrimidin-2- yl)-5-methyl-1-oxido-3,4-dihydro-2H-pyrrol-1-ium-2-carboxami de

A mixture of N-(2,3-difluorophenyl)-2-nitroacetamide (i.e. the product of Example 1, Step C, 0.46 g, 2.1 mmol), (E)-4-(4,6-dimethoxypyrimidin-2-yl)but-3-en-2-one (0.44 g, 2.1 mmol) and triethylamine (0.89 mL, 6.3 mmol) in tetrahydrofuran (8.0 mL) was refluxed for 2 h. The mixture was cooled to 0 °C and diluted with addition tetrahydrofuran (5 mL). Concentrated hydrochloric acid was added until the pH was adjusted to 6. Zinc dust (0.44 g, 6.3 mmol) was added, and the reaction was stirred vigorously at 0 °C for 1 h. A solution of 50% aqueous sodium hydroxide was added to adjust the pH to 13, and the reaction was stirred vigorously for 20 min. The reaction mixture was extracted with ethyl acetate (3 x 20 mL). The organic layer was washed with saturated NaCl (10 mL), dried over MgSO ₄ , and concentrated to afford the crude product. The crude product was twice purified by column chromatography, eluting with 0% to 100% ethyl acetate in hexanes to afford a colorless solid. The solid was triturated with diethyl ether to afford the title compound, a compound of the present disclosure, as a colorless solid (0.12 g).

1H NMR δ 11.93 (br s, 1H), 8.05–7.99 (m, 1H), 7.06–6.99 (m, 1H), 6.94–6.87 (m, 1H), 6.51 (s, 1H), 5.19–5.13 (m, 1H), 4.11–4.03 (m, 1H), 3.98 (s, 3H), 3.98 (s, 3H), 3.09–3.03 (m, 2H), 2.19 (m, 3H).

By the procedures described herein together with methods known in the art, the following compounds of Tables 1 to (960) can be prepared. The following abbreviations are used in the Tables which follow: t means tertiary, s means secondary, n means normal, i means iso, c means cyclo, Me means methyl, Et means ethyl, Pr means propyl, Bu means butyl, i-Pr means isopropyl, c-Pr cyclopropyl, t-Bu means tertiary butyl, Ph means phenyl, OMe means methoxy, OEt means ethoxy, SMe means methylthio, -CN means cyano, -NO ₂ means nitro, TMS means trimethylsilyl, SOMe means methylsulfinyl, C ₂ F ₅ means CF ₂ CF ₃ and SO ₂ Me means methylsulfonyl.

Y is O; J ² is -CH ₂ -; Q ² is Ph(2-F); and Q ¹ is

Q ¹ Q ¹ Q ¹

Ph(3-Cl) Ph(3-CN) 1H-Imidazol-2-yl(1-Me,5-F) Ph(3-F) ^Ph(3-NO ₂ ⁾ 2-Thienyl Ph(3-Br) Ph(3-Ph) 2-Thienyl(4-F) Ph(3-Me) Ph(3-COMe) 2-Thienyl(4-Cl) Ph(3-Et) Ph(3-OCOMe) 2-Thienyl(4-CF ₃ ) Ph(3-t-Bu) Ph(3-CO ₂ Me) 2-Thienyl(5-F) Ph(3-i-Pr) Ph(3-OCO ₂ Me) 2-Thienyl(5-Cl) Ph(3-c-Pr) Ph(3-TMS) 2-Thienyl(5-CF ₃ ) Ph(3-cyclohexyl) ^Ph(3-SF ₅ ⁾ Ph(4-Cl) Ph(3-CH═CH ₂ ) Ph[3-(1H-pyrazol-1-yl)] Ph(4-F)

P ^h(3-CF ₃ ⁾ Ph[3-(2H-1,2,3-triazol-2-yl)] Ph(4-Br) P ^h(3-CH ₂ ^CF ₃ ⁾ Ph[3-(1H-imidazol-1-yl)] Ph(4-Me) Ph(3-CHF ₂ ) Ph[3-(3-pyridinyl)] Ph(4-Et) Ph(3-CH ₂ F) Ph[3-(4-pyridinyl)] Ph(4-t-Bu) Ph(3-OCF ₃ ) Ph[3-(2-pyridinyl)] Ph(4-i-Pr) Ph(3-OCH ₂ F) 4-Pyridinyl(2-CF ₃ ) Ph(4-c-Pr) Ph(3-SCF ₃ ) 4-Pyridinyl(2-Cl) Ph(4-cyclohexyl) Ph(3-SMe) 4-Pyridinyl(2-F) Ph(4-CH═CH ₂ ) Ph(3-SOMe) 4-Pyridinyl(2-OCF ₃ ) ^Ph(4-CF ₃ ^{) 3-SO} ₂ ^Me 4-Pyridinyl(2-Me) ^Ph(4-CH ₂ ^CF ₃ ⁾ Ph(3-OSO ₂ Me) 4-Pyridinyl(2-Br) Ph(4-CHF ₂ ) Ph(3-C≡CH) 4-Pyridinyl Ph(4-CH ₂ F) Ph(3-OMe) 1H-Pyrazol-4-yl(1-Me) Ph(4-OCF ₃ ) Ph(3-OEt) 1H-Pyrazol-4-yl(1-CH ₂ CF ₃ ) Ph(4-OCH ₂ F) Ph(3-NHCO ₂ -t-Bu) 1H-Imidazol-2-yl(1-Me) Ph(4-SCF ₃ ) Ph(3-NHCOMe) 1H-Imidazol-2-yl(1-CH ₂ CF ₃ ) Ph(4-SMe) Ph(3-NHCOCF ₃ ) 1H-Imidazol-2-yl(1-Me,5-Cl) Ph(4-SOMe) Q ¹ Q ¹ Q ¹ Ph(4-SO ₂ Me) 1H-Pyrazol-3-yl(1-Me) Ph(3-F,4-CN) Ph(4-OSO ₂ Me) 1H-Pyrazol-3-yl(1-CH ₂ CF ₃ ) Ph(3-F,4-SF ₅ ) Ph(4-C≡CH) 1H-Pyrazol-3-yl(1-Me,4-F) Ph(3-Br,4-Cl) Ph(4-OMe) 1H-Pyrazol-3-yl(1-Me,4-Cl) Ph(3-Br,4-F) Ph(4-OEt) 1H-Imidazol-5-yl(1-Me) Ph(3,4-di-Br) Ph(4-NHCO ₂ -t-Bu) 1H-Imidazol-5-yl(1-CH ₂ CF ₃ ) Ph(3-Br,4-Me) Ph(4-NHCOMe) 1H-Imidazol-4-yl(1-Me) Ph(3-Br,4-c-Pr) Ph(4-NHCOCF ₃ ) 1H-Imidazol-4-yl(1-CH ₂ CF ₃ ) Ph(3-Br,4-CF ₃ ) Ph(4-CN) 3-Thienyl Ph(3-Br,4-CHF ₂ ) P ^h(4-NO ₂ ⁾ 3-Thienyl(5-F) Ph(3-Br,4-OCF ₃ ) Ph(4-Ph) 3-Thienyl(5-Cl) Ph(3-Br,4-OCHF ₂ ) Ph(4-COMe) 3-Thienyl(5-CF ₃ ) Ph(3-Br,4-SO ₂ Me) Ph(4-OCOMe) Ph(3,4-di-Cl) Ph(3-Br,4-TMS) Ph(4-CO ₂ Me) Ph(3-Cl,4-F) Ph(3-Br,4-CN) Ph(4-OCO ₂ Me) Ph(3-Cl,4-Br) Ph(3-Me,4-Cl) Ph(4-TMS) Ph(3-Cl,4-Me) Ph(3-Me,4-F) Ph(4-SF ₅ ) Ph(3-Cl,4-t-Bu) Ph(3-Me,4-Br) Ph(1H-pyrazol-1-yl) Ph(3-Cl,4-c-Pr) Ph(3,4-di-Me) Ph(2H-1,2,3-triazol-2-yl) Ph(3-Cl,4-CF ₃ ) Ph(3-Me,4-t-Bu) Ph(1H-imidazol-1-yl) Ph(3-Cl,4-CHF ₂ ) Ph(3-Me,4-c-Pr) Ph[4-(3-pyridinyl)] Ph(3-Cl,4-OCF ₃ ) Ph(3-Me,4-CF ₃ ) Ph[4-(4-pyridinyl)] Ph(3-Cl,4-OCHF ₂ ) Ph(3-Me,4-OCF ₃ ) Ph[4-(2-pyridinyl)] Ph(3-Cl,4-SO ₂ Me) Ph(3-Me,4-OCHF ₂ ) 3-Pyridinyl(5-CF ₃ ) Ph(3-Cl,4-TMS) Ph(3-Me,4-SO ₂ Me) 3-Pyridinyl(5-Cl) Ph(3-Cl,4-CN) Ph(3-Me,4-TMS) 3-Pyridinyl(5-F) Ph(3-F,4-Cl) Ph(3-Me,4-CN) 3-Pyridinyl(5-OCF ₃ ) Ph(3,4-di-F)* Ph(3-t-Bu,4-Cl) 3-Pyridinyl(5-Me) Ph(3-F,4-Br) Ph(3-t-Bu,4-F) 3-Pyridinyl(5-Br) Ph(3-F,4-Me) Ph(3-t-Bu,4-Br) 3-Pyridinyl(4-CF ₃ ) Ph(3-F,4-t-Bu) Ph(3-t-Bu,4-Me) 3-Pyridinyl(4-CHF ₂ ) Ph(3-F,4-c-Pr) Ph(3,4-di-t-Bu) 3-Pyridinyl(4-CH ₂ F) Ph(3-F,4-CF ₃ ) Ph(3-t-Bu,4-c-Pr) 3-Pyridinyl(4-Me) Ph(3-F,4-CHF ₂ ) Ph(3-t-Bu,4-CF ₃ ) 3-Pyridinyl(4-Cl) Ph(3-F,4-OCF ₃ ) Ph(3-t-Bu,4-CHF ₂ ) 3-Pyridinyl(4-Br) Ph(3-F,4-OCHF ₂ ) Ph(3-t-Bu,4-OCF ₃ ) 3-Pyridinyl(4-F) Ph(3-F,4-SO ₂ Me) Ph(3-t-Bu,4-OCHF ₂ ) 3-Pyridinyl Ph(3-F,4-TMS) Ph(3-t-Bu,4-SO ₂ Me) Q ¹ Q ¹ Q ¹ Ph(3-t-Bu,4-TMS) ^Ph(3-OCF ₃ ^,4-OCHF ₂ ⁾ Ph(3-CN,4-CHF ₂ ) Ph(3-t-Bu,4-CN) Ph(3-OCF ₃ ,4-SO ₂ Me) Ph(3-CN,4-OCF ₃ ) Ph(3-c-Pr,4-Cl) Ph(3-OCF ₃ ,4-TMS) Ph(3-CN,4-OCHF ₂ ) Ph(3-c-Pr,4-F) Ph(3-OCF ₃ ,4-CN) Ph(3-CN,4-SO ₂ Me) Ph(3-c-Pr,4-Br) Ph(3-SO ₂ Me,4-Cl) Ph(3-CN,4-TMS) Ph(3-c-Pr,4-Me) Ph(3-SO ₂ Me,4-F) Ph(3,4-di-CN) Ph(3-c-Pr,4-t-Bu) Ph(3-SO ₂ Me,4-Br) Ph(3-SF ₅ ,4-F) Ph(3,4-di-c-Pr) Ph(3-SO ₂ Me,4-Me) Ph(2-F,3-Cl,4-Cl) Ph(3-c-Pr,4-CF ₃ ) Ph(3-SO ₂ Me,4-t-Bu) Ph(2-F,3-Cl,4-F) Ph(3-c-Pr,4-CHF ₂ ) Ph(3-SO ₂ Me,4-c-Pr) Ph(2-F,3-Cl,4-Br) Ph(3-c-Pr,4-OCF ₃ ) ^Ph(3-SO ₂ ^Me,4-CF ₃ ⁾ Ph(2-F,3-Cl,4-Me) Ph(3-c-Pr,4-OCHF ₂ ) ^Ph(3-SO ₂ ^Me,4-CHF ₂ ⁾ Ph(2-F,3-Cl,4-t-Bu) Ph(3-c-Pr,4-SO ₂ Me) ^Ph(3-SO ₂ ^Me,4-OCF ₃ ⁾ Ph(2-F,3-Cl,4-c-Pr) Ph(3-c-Pr,4-TMS) ^Ph(3-SO ₂ ^Me,4-OCHF ₂ ⁾ Ph(2-F,3-Cl,4-CF ₃ ) Ph(3-c-Pr,4-CN) Ph(3,4-di-SO ₂ Me) Ph(2-F,3-Cl,4-CHF ₂ ) Ph(3-CF ₃ ,4-Cl) Ph(3-SO ₂ Me,4-TMS) Ph(2-F,3-Cl,4-OCF ₃ ) Ph(3-CF ₃ ,4-F) Ph(3-SO ₂ Me,4-CN) Ph(2-F,3-Cl,4-OCHF ₂ ) Ph(3-CF ₃ ,4-Br) Ph(3-CHF ₂ ,4-Cl) Ph(2-F,3-Cl,4-SO ₂ Me) Ph(3-CF ₃ ,4-Me) Ph(3-CHF ₂ ,4-F) Ph(2-F,3-Cl,4-TMS) Ph(3-CF ₃ ,4-t-Bu) Ph(3-CHF ₂ ,4-Br) Ph(2-F,3-Cl,4-CN) Ph(3-CF ₃ ,4-c-Pr) Ph(3-CHF ₂ ,4-Me) Ph(2-F,3-F,4-Cl) Ph(3,4-di-CF ₃ ) Ph(3-CHF ₂ ,4-t-Bu) Ph(2-F,3-F,4-F) ^Ph(3-CF ₃ ^,4-CHF ₂ ⁾ Ph(3-CHF ₂ ,4-c-Pr) Ph(2-F,3-F,4-Br) P ^h(3-CF ₃ ^,4-OCF ₃ ^{) Ph(3-CHF} ₂ ^,4-CF ₃ ⁾ Ph(2-F,3-F,4-Me) ^Ph(3-CF ₃ ^,4-OCHF ₂ ^{) Ph(3-CHF} ₂ ^,4-CHF ₂ ⁾ Ph(2-F,3-F,4-t-Bu) ^Ph(3-CF ₃ ^,4-SO ₂ ^{Me) Ph(3-CHF} ₂ ^,4-OCF ₃ ⁾ Ph(2-F,3-F,4-c-Pr) Ph(3-CF ₃ ,4-TMS) Ph(3-CHF ₂ ,4-OCHF ₂ ) Ph(2-F,3-F,4-CF ₃ ) Ph(3-CF ₃ ,4-CN) Ph(3-CHF ₂ ,4-SO ₂ Me) Ph(2-F,3-F,4-CHF ₂ ) Ph(3-OCF ₃ ,4-Cl) Ph(3-CHF ₂ ,4-TMS) Ph(2-F,3-F,4-OCF ₃ ) Ph(3-OCF ₃ ,4-F) Ph(3-CHF ₂ ,4-CN) Ph(2-F,3-F,4-OCHF ₂ ) Ph(3-OCF ₃ ,4-Br) Ph(3-CN,4-Cl) Ph(2-F,3-F,4-SO ₂ Me) Ph(3-OCF ₃ ,4-Me) Ph(3-CN,4-F) Ph(2-F,3-F,4-TMS) Ph(3-OCF ₃ ,4-t-Bu) Ph(3-CN,4-Br) Ph(2-F,3-F,4-CN) Ph(3-OCF ₃ ,4-c-Pr) Ph(3-CN,4-Me) Ph(2-F,3-Br,4-Cl) ^Ph(3-OCF ₃ ^-4-CF ₃ ⁾ Ph(3-CN,4-t-Bu) Ph(2-F,3-Br,4-F) ^Ph(3-OCF ₃ ^,4-CHF ₂ ⁾ Ph(3-CN,4-c-Pr) Ph(2-F,3-Br,4-Br) Ph(3,4-di-OCF ₃ ) Ph(3-CN,4-CF ₃ ) Ph(2-F,3-Br,4-Me) Q ¹ Q ¹ Q ¹

Ph(2-F,3-Br,4-t-Bu) Ph(2-F,3-c-Pr,4-Me) Ph(2-F,3-SO ₂ Me,4-F) Ph(2-F,3-Br,4-c-Pr) Ph(2-F,3-c-Pr,4-t-Bu) Ph(2-F,3-SO ₂ Me,4-Br) Ph(2-F,3-Br,4-CF ₃ ) Ph(2-F,3,4-di-c-Pr) Ph(2-F,3-SO ₂ Me,4-Me) Ph(2-F,3-Br,4-CHF ₂ ) Ph(2-F,3-c-Pr,4-CF ₃ ) Ph(2-F,3-SO ₂ Me,4-t-Bu) Ph(2-F,3-Br,4-OCF ₃ ) Ph(2-F,3-c-Pr,4-CHF ₂ Ph(2-F,3-SO ₂ Me,4-c-Pr) Ph(2-F,3-Br,4-OCHF ₂ ) Ph(2-F,3-c-Pr,4-OCF ₃ ) Ph(2-F,3-SO ₂ Me,4-CF ₃ ) Ph(2-F,3-Br,4-SO ₂ Me) Ph(2-F,3-c-Pr,4-OCHF ₂ ) Ph(2-F,3-SO ₂ Me,4-CHF ₂ ) Ph(2-F,3-Br,4-TMS) Ph(2-F,3-c-Pr,4-SO ₂ Me) Ph(2-F,3-SO ₂ Me,4-OCF ₃ ) Ph(2-F,3-Br,4-CN) Ph(2-F,3-c-Pr,4-TMS) Ph(2-F,3-SO ₂ Me,4-OCHF ₂ ) Ph(2-F,3-Me,4-Cl) Ph(2-F,3-c-Pr,4-CN) Ph(2-F,3,4-di-SO ₂ Me) Ph(2-F,3-Me,4-F) Ph(2-F,3-CF ₃ ,4-Cl) Ph(2-F,3-SO ₂ Me,4-TMS) Ph(2-F,3-Me,4-Br) Ph(2-F,3-CF ₃ ,4-F) Ph(2-F,3-SO ₂ Me,4-CN) Ph(2-F,3-Me,4-Me) Ph(2-F,3-CF ₃ ,4-Br) Ph(2-F,3-CHF ₂ ,4-Cl) Ph(2-F,3-Me,4-t-Bu) Ph(2-F,3-CF ₃ ,4-Me) Ph(2-F,3-CHF ₂ ,4-F) Ph(2-F,3-Me,4-CF ₃ ) Ph(2-F,3-CF ₃ ,4-t-Bu) Ph(2-F,3-CHF ₂ ,4-Br) Ph(2-F,3-Me,4-CHF ₂ ) Ph(2-F,3-CF ₃ ,4-c-Pr) Ph(2-F,3-CHF ₂ ,4-Me) Ph(2-F,3-Me,4-OCF ₃ ) Ph(2-F,3-CF ₃ ,4-CF ₃ ) Ph(2-F,3-CHF ₂ ,4-t-Bu) Ph(2-F,3-Me,4-OCHF ₂ ) Ph(2-F,3-CF ₃ ,4-CHF ₂ ) Ph(2-F,3-CHF ₂ ,4-c-Pr) Ph(2-F,3-Me,4-SO ₂ Me) Ph(2-F,3-CF ₃ ,4-OCF ₃ ) Ph(2-F,3-CHF ₂ ,4-CF ₃ ) Ph(2-F,3-Me,4-TMS) Ph(2-F,3-CF ₃ ,4-OCHF ₂ ) Ph(2-F,3-CHF ₂ ,4-CHF ₂ ) Ph(2-F,3-Me,4-CN) Ph(2-F,3-CF ₃ ,4-SO ₂ Me) Ph(2-F,3-CHF ₂ ,4-OCF ₃ ) Ph(2-F,3-t-Bu,4-Cl) Ph(2-F,3-CF ₃ ,4-TMS) Ph(2-F,3-CHF ₂ ,4-OCHF ₂ ) Ph(2-F,3-t-Bu,4-F) Ph(2-F,3-CF ₃ ,4-CN) Ph(2-F,3-CHF ₂ ,4-SO ₂ Me) Ph(2-F,3-t-Bu,4-Br) Ph(2-F,3-OCF ₃ ,4-Cl) Ph(2-F,3-CHF ₂ ,4-TMS) Ph(2-F,3-t-Bu,4-Me) Ph(2-F,3-OCF ₃ ,4-F) Ph(2-F,3-CHF ₂ ,4-CN) Ph(2-F,3-t-Bu,4-t-Bu) Ph(2-F,3-OCF ₃ ,4-Br) Ph(2-F,3-CN,4-Cl) Ph(2-F,3-t-Bu,4-c-Pr) Ph(2-F,3-OCF ₃ ,4-Me) Ph(2-F,3-CN,4-F) Ph(2-F,3-t-Bu,4-CF ₃ ) Ph(2-F,3-OCF ₃ ,4-t-Bu) Ph(2-F,3-CN,4-Br) Ph(2-F,3-t-Bu,4-CHF ₂ ) Ph(2-F,3-OCF ₃ ,4-c-Pr) Ph(2-F,3-CN,4-Me) Ph(2-F,3-t-Bu,4-OCF ₃ ) Ph(2-F,3-OCF ₃ ,4-CF ₃ ) Ph(2-F,3-CN,4-t-Bu) Ph(2-F,3-t-Bu,4-OCHF ₂ ) Ph(2-F,3-OCF ₃ ,4-CHF ₂ ) Ph(2-F,3-CN,4-c-Pr) Ph(2-F,3-t-Bu,4-SO ₂ Me) Ph(2-F,3-OCF ₃ ,4-OCF ₃ ) Ph(2-F,3-CN,4-CF ₃ ) Ph(2-F,3-t-Bu,4-TMS) Ph(2-F,3-OCF ₃ ,4-OCHF ₂ ) Ph(2-F,3-CN,4-CHF ₂ ) Ph(2-F,3-t-Bu,4-CN) Ph(2-F,3-OCF ₃ ,4-SO ₂ Me) Ph(2-F,3-CN,4-OCF ₃ ) Ph(2-F,3-c-Pr,4-Cl) Ph(2-F,3-OCF ₃ ,4-TMS) Ph(2-F,3-CN,4-OCHF ₂ ) Ph(2-F,3-c-Pr,4-F) Ph(2-F,3-OCF ₃ ,4-CN) Ph(2-F,3-CN,4-SO ₂ Me) Ph(2-F,3-c-Pr,4-Br) Ph(2-F,3-SO ₂ Me,4-Cl) Ph(2-F,3-CN,4-TMS) Q ¹ Q ¹ Q ¹ Ph(2-F,3-CN,4-CN) Ph(2-cyclohexyl) ^Ph(2-OC ₂ ^F ₅ ⁾ Ph(2-F,4-Cl) Ph(2-CH═CH ₂ ) Ph(2-OCH ₂ CF ₃ ) Ph(2-F,4-F) Ph(2-CF ₃ ) Ph(2-OCH ₂ C≡CH) Ph(2-F,4-Br) ^Ph(2-CH ₂ ^CF ₃ ⁾ Ph(2-OCH ₂ C ^≡CCF ₃ ) Ph(2-F,4-Me) Ph(2-CF ₂ H) ^Ph(2-OCH ₂ ^C≡CCF ₂ ^H) Ph(2-F,4-t-Bu) Ph(2-CH ₂ F) ^Ph(2-OCH ₂ ^C≡CCH ₃ ⁾ Ph(2-F,4-c-Pr) Ph(2-OCF ₃ ) Ph(2-OCH ₂ C≡C-c-Pr) Ph(2-F,4-CF ₃ ) Ph(2-OCH ₂ F) Ph(2-C≡CCF ₂ H) Ph(2-F,4-CHF ₂ ) Ph(2-OCF ₂ H) Ph(2-C≡CCH ₃ ) Ph(2-F,4-OCF ₃ ) Ph(2-SCF ₃ ) Ph(2-C≡C-c-Pr) Ph(2-F,4-OCHF ₂ ) Ph(2-SMe) Ph(2-OPh) Ph(2-F,4-SO ₂ Me) Ph(2-SOMe) Ph(2-C≡CCF ₃ ) Ph(2-F,4-TMS) Ph(2-SO ₂ Me) Ph(2-CH═CF ₂ ) Ph(2-F,4-CN) Ph(2-OSO ₂ Me) Ph(2-CH═CCl ₂ ) Ph(2-F,3-Cl) Ph(2-C≡CH) Ph(2-CH═CBr ₂ ) Ph(2-F,3-F) Ph(2-OMe) Ph(2-OCH═CH ₂ ) Ph(2-F,3-Br) Ph(2-OEt) Ph(2-OCH═CF ₂ ) Ph(2-F,3-Me) Ph(2-NHCO ₂ -t-Bu) Ph(2-OCH═CCl ₂ ) Ph(2-F,3-t-Bu) Ph(2-NHCOMe) Ph(2-OCH═CBr ₂ ) Ph(2-F,3-c-Pr) Ph(2-NHCOCF ₃ ) ^Ph(2-CH ₂ ^CH═CH ₂ ⁾ Ph(2-F,3-CF ₃ ) Ph(2-CN) ^Ph(2-CH ₂ ^CH═CF ₂ ⁾ Ph(2-F,3-CHF ₂ ) ^Ph(2-NO ₂ ^{) Ph(2-CH} ₂ ^CH═CCl ₂ ⁾ Ph(2-F,3-OCF ₃ ) Ph(2-Ph) ^Ph(2-CH ₂ ^CH═CBr ₂ ⁾ Ph(2-F,3-OCHF ₂ ) Ph(2-COMe) ^Ph(2-OCH ₂ ^CH═CH ₂ ⁾ Ph(2-F,3-SO ₂ Me) Ph(2-OCOMe) ^Ph(2-OCH ₂ ^CH═CF ₂ ⁾ Ph(2-F,3-TMS) Ph(2-CO ₂ Me) ^Ph(2-OCH ₂ ^CH═CCl ₂ ⁾ Ph(2-F,3-CN) Ph(2-OCO ₂ Me) Ph(2-OCH ₂ CH═CBr ₂ ) Ph(2-Cl) Ph(2-TMS) Ph(2-SCF ₂ H) Ph(2-F) Ph[2-(1H-pyrazol-1-yl)] Ph(2-SCF ₂ CF ₂ H) Ph(2-Br) Ph[2-(2H-1,2,3-triazol-2-yl)] Ph(3-I) Ph(2-I) Ph[2-(1H-imidazol-1-yl)] Ph(3-n-Pr) Ph(2-Me) Ph[2-(3-pyridinyl)] Ph(3-CF ₂ H) Ph(2-Et) Ph[2-(4-pyridinyl)] Ph(3-OCF ₂ H) Ph(2-n-Pr) Ph[2-(2-pyridinyl)] Ph(3-SO ₂ Me) Ph(2-t-Bu) ^Ph(2-C ₂ ^F ₅ ^{) Ph(3-C} ₂ ^F ₅ ⁾ Ph(2-i-Pr) ^Ph(2-CF ₂ ^CF ₂ ^{H) Ph(3-CF} ₂ ^CF ₂ ^H) Ph(2-c-Pr) ^Ph(2-OCF ₂ ^CF ₂ ^{H) Ph(3-OCF} ₂ ^CF ₂ ^H) Q ¹ Q ¹ Q ¹

P ^h(3-OC ₂ ^F ₅ ⁾ Ph(2-Cl,3-i-Pr) ^Ph(2-Cl,3-C ₂ ^F ₅ ⁾ Ph(3-OCH ₂ CF ₃ ) Ph(2-Cl,3-c-Pr) Ph(2-Cl,3-CF ₂ CF ₂ H) Ph(3-OCH ₂ C≡CH) Ph(2-Cl,3-cyclohexyl) Ph(2-Cl,3-OCF ₂ CF ₂ H) Ph(3-OCH ₂ C ^≡CCF ₃ ) Ph(2-Cl,3-CH═CH ₂ ) Ph(2-Cl,3-OC ₂ F ₅ ) ^Ph(3-OCH ₂ ^C≡CCF ₂ ^H) Ph(2-Cl,3-CF ₃ ) ^{Ph(2-Cl,3-OCH} ₂ ^CF ₃ ^{) Ph(3-OCH} ₂ ^C≡CCH ₃ ^{) Ph(2-Cl,3-CH} ₂ ^CF ₃ ⁾ Ph(2-Cl,3-OCH ₂ C≡CH) Ph(3-OCH ₂ C≡C-c-Pr) Ph(2-Cl,3-CF ₂ H) Ph(2-Cl,3-OCH ₂ C≡CCF ₃ ) Ph(3-C≡CCF ₂ H) Ph(2-Cl,3-CH ₂ F) Ph(2-Cl,3-OCH ₂ C≡CCF ₂ H) Ph(3-C≡CCH ₃ ) Ph(2-Cl,3-OCF ₃ ) Ph(2-Cl,3-OCH ₂ C≡CCH ₃ ) Ph(3-C≡C-c-Pr) Ph(2-Cl,3-OCH ₂ F) Ph(2-Cl,3-OCH ₂ C≡C-c-Pr) Ph(3-OPh) Ph(2-Cl,3-OCF ₂ H) Ph(2-Cl,3-C≡CCF ₂ H) Ph(3-C≡CCF ₃ ) Ph(2-Cl,3-SCF ₃ ) Ph(2-Cl,3-C≡CCH ₃ ) Ph(3-CH═CF ₂ ) Ph(2-Cl,3-SMe) Ph(2-Cl,3-C≡C-c-Pr) Ph(3-CH═CCl ₂ ) Ph(2-Cl,3-SOMe) Ph(2-Cl,3-OPh) Ph(3-CH═CBr ₂ ) Ph(2-Cl,3-SO ₂ Me) Ph(2-Cl,3-C≡CCF ₃ ) Ph(3-OCH═CH ₂ ) Ph(2-Cl,3-OSO ₂ Me) Ph(2-Cl,3-CH═CF ₂ ) Ph(3-OCH═CF ₂ ) Ph(2-Cl,3-C≡CH) Ph(2-Cl,3-CH═CCl ₂ ) Ph(3-OCH═CCl ₂ ) Ph(2-Cl,3-OMe) Ph(2-Cl,3-CH═CBr ₂ ) Ph(3-OCH═CBr ₂ ) Ph(2-Cl,3-OEt) Ph(2-Cl,3-OCH═CH ₂ ) P ^h(3-CH ₂ ^CH═CH ₂ ⁾ Ph(2-Cl,3-NHCO ₂ -t-Bu) Ph(2-Cl,3-OCH═CF ₂ ) P ^h(3-CH ₂ ^CH═CF ₂ ⁾ Ph(2-Cl,3-NHCOMe) Ph(2-Cl,3-OCH═CCl ₂ ) P ^h(3-CH ₂ ^CH═CCl ₂ ⁾ Ph(2-Cl,3-NHCOCF ₃ ) Ph(2-Cl,3-OCH═CBr ₂ ) P ^h(3-CH ₂ ^CH═CBr ₂ ⁾ Ph(2-Cl,3-CN) Ph(2-Cl,3-CH ₂ CH═CH ₂ ) ^Ph(3-OCH ₂ ^CH═CH ₂ ⁾ Ph(2-Cl,3-NO ₂ ) Ph(2-Cl,3-CH ₂ CH═CF ₂ ) ^Ph(3-OCH ₂ ^CH═CF ₂ ⁾ Ph(2-Cl,3-Ph) Ph(2-Cl,3-CH ₂ CH═CCl ₂ ) ^Ph(3-OCH ₂ ^CH═CCl ₂ ⁾ Ph(2-Cl,3-COMe) Ph(2-Cl,3-CH ₂ CH═CBr ₂ ) Ph(3-OCH ₂ CH═CBr ₂ ) Ph(2-Cl,3-OCOMe) Ph(2-Cl,3-OCH ₂ CH═CH ₂ ) Ph(3-SCF ₂ H) Ph(2-Cl,3-CO ₂ Me) Ph(2-Cl,3-OCH ₂ CH═CF ₂ ) Ph(3-SCF ₂ CF ₂ H) Ph(2-Cl,3-OCO ₂ Me) Ph(2-Cl,3-OCH ₂ CH═CCl ₂ ) Ph(2-Cl,3-Cl) Ph(2-Cl,3-TMS) Ph(2-Cl,3-OCH ₂ CH═CBr ₂ ) Ph(2-Cl,3-F) Ph[3-(2-Cl,1H-pyrazol-1-yl)] Ph(2-Cl,3-SCF ₂ H) Ph(2-Cl,3-Br) Ph[3-(2-Cl,2H-1,2,3-triazol-2- ^{Ph(2-Cl,3-SCF} ₂ ^CF ₂ ^H) Ph(2-Cl,3-I) yl)] Ph(2-F,3-F) Ph(2-Cl,3-Me) Ph[3-(2-Cl,1H-imidazol-1-yl)] Ph(2-F,3-Br) Ph(2-Cl,3-Et) Ph[3-(2-Cl,3-pyridinyl)] Ph(2-F,3-I) Ph(2-Cl,3-n-Pr) Ph[3-(2-Cl,4-pyridinyl)] Ph(2-F,3-Me) Ph(2-Cl,3-t-Bu) Ph[3-(2-Cl,2-pyridinyl)] Ph(2-F,3-Et) Q ¹ Q ¹ Q ¹

Ph(2-F,3-n-Pr) Ph(2-F,3-OCH ₂ C≡CH) 2-Thienyl(4-OCF ₂ CF ₂ H) Ph(2-F,3-t-Bu) Ph(2-F,3-OCH ₂ C≡CCF ₃ ) 2-Thienyl(5-Me) Ph(2-F,3-i-Pr) Ph(2-F,3-OCH ₂ C≡CCF ₂ H) 2-Thienyl(5-Et) Ph(2-F,3-cyclohexyl) Ph(2-F,3-OCH ₂ C ^≡CCH ₃ ) 2-Thienyl(5-i-Pr) Ph(2-F,3-CH═CH ₂ ) Ph(2-F,3-OCH ₂ C≡C-c-Pr) 2-Thienyl(5-c-Pr) Ph(2-F,3-CF ₃ ) Ph(2-F,3-C≡CCF ₂ H) 2-Thienyl(5-CF ₂ H) P ^h(2-F,3-CH ₂ ^CF ₃ ⁾ Ph(2-F,3-C≡CCH ₃ ) 2-Thienyl(5-OCF ₂ H) Ph(2-F,3-CF ₂ H) Ph(2-F,3-C≡C-c-Pr) 2-Thienyl(5-OCF ₂ CF ₂ H) Ph(2-F,3-CH ₂ F) Ph(2-F,3-OPh) ^{2-Thienyl(5-OC} ₂ ^F ₅ ⁾ Ph(2-F,3-OCH ₂ F) Ph(2-F,3-C≡CCF ₃ ) 2-Furanyl(4-F) Ph(2-F,3-OCF ₂ H) Ph(2-F,3-CH═CF ₂ ) 2-Furanyl(4-Cl) Ph(2-F,3-SCF ₃ ) Ph(2-F,3-CH═CCl ₂ ) 2-Furanyl(4-CF ₃ ) Ph(2-F,3-SMe) Ph(2-F,3-CH═CBr ₂ ) 2-Furanyl(5-F) Ph(2-F,3-SOMe) Ph(2-F,3-OCH═CH ₂ ) 2-Furanyl(5-Cl) Ph(2-F,3-SO ₂ Me) Ph(2-F,3-OCH═CF ₂ ) 2-Furanyl(5-CF ₃ ) Ph(2-F,3-OSO ₂ Me) Ph(2-F,3-OCH═CCl ₂ ) 2-Furanyl(4-Me) Ph(2-F,3-C≡CH) Ph(2-F,3-OCH═CBr ₂ ) 2-Furanyl(4-Et) Ph(2-F,3-OMe) ^Ph(2-F,3-CH ₂ ^CH═CH ₂ ⁾ 2-Furanyl(4-i-Pr) Ph(2-F,3-OEt) ^Ph(2-F,3-CH ₂ ^CH═CF ₂ ⁾ 2-Furanyl(4-c-Pr) Ph(2-F,3-NHCO ₂ -t-Bu) Ph(2-F,3-CH ₂ CH═CCl ₂ ) 2-Furanyl(4-CF ₂ H) Ph(2-F,3-NHCOMe) Ph(2-F,3-CH ₂ CH═CBr ₂ ) 2-Furanyl(4-OCF ₂ H) Ph(2-F,3-NHCOCF ₃ ) Ph(2-F,3-OCH ₂ CH═CH ₂ ) 2-Furanyl(4-OCF ₂ CF ₂ H) Ph(2-F,3-NO ₂ ) Ph(2-F,3-OCH ₂ CH═CF ₂ ) 2-Furanyl(5-Me) Ph(2-F,3-Ph) Ph(2-F,3-OCH ₂ CH═CCl ₂ ) 2-Furanyl(5-Et) Ph(2-F,3-COMe) Ph(2-F,3-OCH ₂ CH═CBr ₂ ) 2-Furanyl(5-i-Pr) Ph(2-F,3-OCOMe) Ph(2-F,3-SCF ₂ H) 2-Furanyl(5-c-Pr) Ph(2-F,3-CO ₂ Me) Ph(2-F,3-SCF ₂ CF ₂ H) 2-Furanyl(5-CF ₂ H) Ph(2-F,3-OCO ₂ Me) Ph(2-F,3-SF ₅ ) 2-Furanyl(5-OCF ₂ H) Ph[3-(2-F,1H-imidazol-1-yl)] 4-Pyridinyl(5-OCF ₂ H) 2-Furanyl(5-OCF ₂ CF ₂ H) Ph[3-(2-F,3-pyridinyl)] 4-Pyridinyl(5-CF ₂ H) ^{2-Furanyl(5-OC} ₂ ^F ₅ ⁾ Ph[3-(2-F,4-pyridinyl)] 4-Pyridinyl(5-OCF ₂ CF ₂ H) Ph(4-I) Ph[3-(2-F,2-pyridinyl)] 2-Thienyl(4-Me) Ph(4-n-Pr) P ^h(2-F,3-C ₂ ^F ₅ ⁾ 2-Thienyl(4-Et) Ph(4-OCHF ₂ ) P ^h(2-F,3-CF ₂ ^CF ₂ ^H) 2-Thienyl(4-i-Pr) ^Ph(4-C ₂ ^F ₅ ^{) Ph(2-F,3-OCF} ₂ ^CF ₂ ^H) 2-Thienyl(4-c-Pr) ^Ph(4-CF ₂ ^CF ₂ ^{H) Ph(2-F,3-OC} ₂ ^F ₅ ⁾ 2-Thienyl(4-CF ₂ H) ^Ph(4-OCF ₂ ^CF ₂ ^{H) Ph(2-F,3-OCH} ₂ ^CF ₃ ⁾ 2-Thienyl(4-OCF ₂ H) ^Ph(4-OC ₂ ^F ₅ ⁾ Q ¹ Q ¹ Q ¹

P ^h(4-OCH ₂ ^CF ₃ ⁾ Ph(2-Cl,4-c-Pr) Ph(2-Cl,4-OCH ₂ C≡CCH ₃ ) Ph(4-OCH ₂ C≡CH) Ph(2-Cl,4-cyclohexyl) Ph(2-Cl,4-OCH ₂ C≡C-c-Pr) Ph(4-OCH ₂ C≡CCF ₃ ) Ph(2-Cl,4-CH═CH ₂ ) Ph(2-Cl,4-C≡CCF ₂ H) Ph(4-OCH ₂ C ^≡CCF ₂ H) Ph(2-Cl,4-CF ₃ ) Ph(2-Cl,4-C ^≡CCH ₃ ) ^Ph(4-OCH ₂ ^C≡CCH ₃ ^{) Ph(2-Cl,4-CH} ₂ ^CF ₃ ⁾ Ph(2-Cl,4-C≡C-c-Pr) Ph(4-OCH ₂ C≡C-c-Pr) Ph(2-Cl,4-CHF ₂ ) Ph(2-Cl,4-OPh) Ph(4-C≡CCF ₂ H) Ph(2-Cl,4-CH ₂ F) Ph(2-Cl,4-C≡CCF ₃ ) Ph(4-C≡CCH ₃ ) Ph(2-Cl,4-OCF ₃ ) Ph(2-Cl,4-CH═CF ₂ ) Ph(4-C≡C-c-Pr) Ph(2-Cl,4-OCH ₂ F) Ph(2-Cl,4-CH═CCl ₂ ) Ph(4-OPh) Ph(2-Cl,4-OCHF ₂ ) Ph(2-Cl,4-CH═CBr ₂ ) Ph(4-C≡CCF ₃ ) Ph(2-Cl,4-SCF ₃ ) Ph(2-Cl,4-OCH═CH ₂ ) Ph(4-CH═CF ₂ ) Ph(2-Cl,4-SMe) Ph(2-Cl,4-OCH═CF ₂ ) Ph(4-CH═CCl ₂ ) Ph(2-Cl,4-SOMe) Ph(2-Cl,4-OCH═CCl ₂ ) Ph(4-CH═CBr ₂ ) Ph(2-Cl,4-SO ₂ Me) Ph(2-Cl,4-OCH═CBr ₂ ) Ph(4-OCH═CH ₂ ) Ph(2-Cl,4-OSO ₂ Me) Ph(2-Cl,4-CH ₂ CH═CH ₂ ) Ph(4-OCH═CF ₂ ) Ph(2-Cl,4-C≡CH) Ph(2-Cl,4-CH ₂ CH═CF ₂ ) Ph(4-OCH═CCl ₂ ) Ph(2-Cl,4-OMe) Ph(2-Cl,4-CH ₂ CH═CCl ₂ ) Ph(4-OCH═CBr ₂ ) Ph(2-Cl,4-OEt) Ph(2-Cl,4-CH ₂ CH═CBr ₂ ) P ^h(4-CH ₂ ^CH═CH ₂ ⁾ Ph(2-Cl,4-NHCO ₂ -t-Bu) Ph(2-Cl,4-OCH ₂ CH═CH ₂ ) P ^h(4-CH ₂ ^CH═CF ₂ ⁾ Ph(2-Cl,4-NHCOMe) Ph(2-Cl,4-OCH ₂ CH═CF ₂ ) P ^h(4-CH ₂ ^CH═CCl ₂ ⁾ Ph(2-Cl,4-NHCOCF ₃ ) Ph(2-Cl,4-OCH ₂ CH═CCl ₂ ) P ^h(4-CH ₂ ^CH═CBr ₂ ⁾ Ph(2-Cl,4-CN) Ph(2-Cl,4-OCH ₂ CH═CBr ₂ ) ^Ph(4-OCH ₂ ^CH═CH ₂ ⁾ Ph(2-Cl,4-NO ₂ ) Ph(2-Cl,4-SCF ₂ H) ^Ph(4-OCH ₂ ^CH═CF ₂ ⁾ Ph(2-Cl,4-Ph) ^{Ph(2-Cl,4-SCF} ₂ ^CF ₂ ^{H) Ph(4-OCH} ₂ ^CH═CCl ₂ ⁾ Ph(2-Cl,4-COMe) Ph(2-F,4-Cl) ^Ph(4-OCH ₂ ^CH═CBr ₂ ⁾ Ph(2-Cl,4-OCOMe) Ph(2,4-di-F)

Ph(4-SCF ₂ H) Ph(2-Cl,4-CO ₂ Me) Ph(2-F,4-Br) Ph(4-SCF ₂ CF ₂ H) Ph(2-Cl,4-OCO ₂ Me) Ph(2-F,4-I)

Ph(2,4-di-Cl) Ph(2-Cl,4-TMS) Ph(2-F,4-Me) Ph(2-Cl,4-F) ^Ph(2-Cl,4-C ₂ ^F ₅ ⁾ Ph(2-F,4-Et) Ph(2-Cl,4-Br) ^Ph(2-Cl,4-CF ₂ ^CF ₂ ^H) Ph(2-F,4-n-Pr) Ph(2-Cl,4-I) ^{Ph(2-Cl,4-OCF} ₂ ^CF ₂ ^H) Ph(2-F,4-t-Bu) Ph(2-Cl,4-Me) ^Ph(2-Cl,4-OC ₂ ^F ₅ ⁾ Ph(2-F,4-i-Pr) Ph(2-Cl,4-Et) ^{Ph(2-Cl,4-OCH} ₂ ^CF ₃ ⁾ Ph(2-F,4-cyclohexyl) Ph(2-Cl,4-n-Pr) Ph(2-Cl,4-OCH ₂ C≡CH) Ph(2-F,4-CH═CH ₂ ) Ph(2-Cl,4-t-Bu) Ph(2-Cl,4-OCH ₂ C≡CCF ₃ ) Ph(2-F,4-CF ₃ ) Ph(2-Cl,4-i-Pr) Ph(2-Cl,4-OCH ₂ C≡CCF ₂ H) ^Ph(2-F,4-CH ₂ ^CF ₃ ⁾ Q ¹ Q ¹ Q ¹

Ph(2-F,4-CHF ₂ ) Ph(2-F,4-C≡CCF ₃ ) 3-Furanyl(4-CF ₂ H) Ph(2-F,4-CH ₂ F) Ph(2-F,4-CH═CF ₂ ) 3-Furanyl(4-OCF ₂ H) Ph(2-F,4-OCF ₃ ) Ph(2-F,4-CH═CCl ₂ ) 3-Furanyl(4-OCF ₂ CF ₂ H) Ph(2-F,4-OCH ₂ F) Ph(2-F,4-CH═CBr ₂ ) 3-Furanyl(4-OC ₂ F ₅ ) Ph(2-F,4-OCHF ₂ ) Ph(2-F,4-OCH═CH ₂ ) Ph(3-Cl,4-I) Ph(2-F,4-SCF ₃ ) Ph(2-F,4-OCH═CF ₂ ) Ph(3-Cl,4-Et) Ph(2-F,4-SMe) Ph(2-F,4-OCH═CCl ₂ ) Ph(3-Cl,4-n-Pr) Ph(2-F,4-SOMe) Ph(2-F,4-OCH═CBr ₂ ) Ph(3-Cl,4-i-Pr) Ph(2-F,4-SO ₂ Me) ^Ph(2-F,4-CH ₂ ^CH═CH ₂ ^{) Ph(3-Cl,4-C} ₂ ^F ₅ ⁾ Ph(2-F,4-OSO ₂ Me) ^Ph(2-F,4-CH ₂ ^CH═CF ₂ ^{) Ph(3-Cl,4-CF} ₂ ^CF ₂ ^H) Ph(2-F,4-C≡CH) Ph(2-F,4-CH ₂ CH═CCl ₂ ) Ph(3-Cl,4-CF ₂ H) Ph(2-F,4-OMe) Ph(2-F,4-CH ₂ CH═CBr ₂ ) Ph(3-Cl,4-OMe) Ph(2-F,4-OEt) Ph(2-F,4-OCH ₂ CH═CH ₂ ) ^{Ph(3-Cl,4-OCF} ₂ ^CF ₂ ^H) Ph(2-F,4-NHCO ₂ -t-Bu) Ph(2-F,4-OCH ₂ CH═CF ₂ ) ^Ph(3-Cl,4-OC ₂ ^F ₅ ⁾ Ph(2-F,4-NHCOMe) Ph(2-F,4-OCH ₂ CH═CCl ₂ ) Ph(3,4-di-F) Ph(2-F,4-NHCOCF ₃ ) Ph(2-F,4-OCH ₂ CH═CBr ₂ ) Ph(3-F,4-I) Ph(2-F,4-CN) Ph(2-F,4-SCF ₂ H) Ph(3-F,4-Et) Ph(2-F,4-NO ₂ ) ^Ph(2-F,4-SCF ₂ ^CF ₂ ^H) Ph(3-F,4-n-Pr) Ph(2-F,4-Ph) Ph(2-F,4-SF ₅ ) Ph(3-F,4-i-Pr) Ph(2-F,4-COMe) 3-Pyridinyl(5-OCF ₂ H) ^Ph(3-F,4-C ₂ ^F ₅ ⁾ Ph(2-F,4-OCOMe) 3-Pyridinyl(5-CF ₂ H) ^Ph(3-F,4-CF ₂ ^CF ₂ ^H) Ph(2-F,4-CO ₂ Me) 3-Pyridinyl(5-OCF ₂ CF ₂ H) Ph(3-F,4-CF ₂ H) Ph(2-F,4-OCO ₂ Me) 3-Thienyl(4-Me) Ph(3-F,4-OMe) P ^h(2-F,4-C ₂ ^F ₅ ⁾ 3-Thienyl(4-Et) ^Ph(3-F,4-OCF ₂ ^CF ₂ ^{H) Ph(2-F,4-CF} ₂ ^CF ₂ ^H) 3-Thienyl(4-i-Pr) ^Ph(3-F,4-OC ₂ ^F ₅ ^{) Ph(2-F,4-OCF} ₂ ^CF ₂ ^H) 3-Thienyl(4-c-Pr) Ph(3-Br,4-I) Ph(2-F,4-OC ₂ F ₅ ) 3-Thienyl(4-CF ₂ H) Ph(3-Br,4-Et) Ph(2-F,4-OCH ₂ CF ₃ ) 3-Thienyl(4-OCF ₂ H) Ph(3-Br,4-n-Pr) Ph(2-F,4-OCH ₂ C ^≡CH) 3-Thienyl(4-OCF ₂ CF ₂ H) Ph(3-Br,4-t-Bu) Ph(2-F,4-OCH ₂ C≡CCF ₃ ) ^{3-Thienyl(4-OC} ₂ ^F ₅ ⁾ Ph(3-Br,4-i-Pr) Ph(2-F,4-OCH ₂ C≡CCF ₂ H) 3-Furanyl(5-F) ^Ph(3-Br,4-C ₂ ^F ₅ ⁾ Ph(2-F,4-OCH ₂ C≡CCH ₃ ) 3-Furanyl(5-Cl) ^Ph(3-Br,4-CF ₂ ^CF ₂ ^H) Ph(2-F,4-OCH ₂ C≡C-c-Pr) 3-Furanyl(5-CF ₃ ) Ph(3-Br,4-CF ₂ H) Ph(2-F,4-C≡CCF ₂ H) 3-Furanyl(4-Me) Ph(3-Br,4-OMe) Ph(2-F,4-C≡CCH ₃ ) 3-Furanyl(4-Et) ^{Ph(3-Br,4-OCF} ₂ ^CF ₂ ^H) Ph(2-F,4-C≡C-c-Pr) 3-Furanyl(4-i-Pr) ^Ph(3-Br,4-OC ₂ ^F ₅ ⁾ Ph(2-F,4-OPh) 3-Furanyl(4-c-Pr) Ph(3-I,4-Cl) Q ¹ Q ¹ Q ¹

Ph(3-I,4-F) Ph(3-Et,4-n-Pr) Ph(3-n-Pr,4-CN) Ph(3-I,4-Br) Ph(3-Et,4-t-Bu) Ph(3-t-Bu,4-I) Ph(3,4-di-I) Ph(3-Et,4-i-Pr) Ph(3-t-Bu,4-Et) Ph(3-I,4-Me) Ph(3-Et,4-c-Pr) Ph(3-t-Bu,4-n-Pr) Ph(3-I,4-Et) Ph(3-Et,4-CF ₃ ) Ph(3-t-Bu,4-i-Pr) Ph(3-I,4-n-Pr) ^Ph(3-Et,4-C ₂ ^F ₅ ^{) Ph(3-t-Bu,4-C} ₂ ^F ₅ ⁾ Ph(3-I,4-t-Bu) ^Ph(3-Et,4-CF ₂ ^CF ₂ ^H) Ph(3-t-Bu,4-CF ₂ CF ₂ H) Ph(3-I,4-i-Pr) Ph(3-Et,4-CF ₂ H) Ph(3-t-Bu,4-CF ₂ H) Ph(3-I,4-c-Pr) Ph(3-Et,4-OMe) Ph(3-t-Bu,4-OMe) Ph(3-I,4-CF ₃ ) Ph(3-Et,4-OCF ₃ ) Ph(3-t-Bu,4-OCF ₂ CF ₂ H) P ^h(3-I,4-C ₂ ^F ₅ ⁾ Ph(3-Et,4-OCHF ₂ ) ^{Ph(3-t-Bu,4-OC} ₂ ^F ₅ ^{) Ph(3-I,4-CF} ₂ ^CF ₂ ^{H) Ph(3-Et,4-OCF} ₂ ^CF ₂ ^H) Ph(3-i-Pr,4-Cl) Ph(3-I,4-CF ₂ H) ^Ph(3-Et,4-OC ₂ ^F ₅ ⁾ Ph(3-i-Pr,4-F) Ph(3-I,4-OMe) Ph(3-Et,4-SO ₂ Me) Ph(3-i-Pr,4-Br) Ph(3-I,4-OCF ₃ ) Ph(3-Et,4-TMS) Ph(3-i-Pr,4-I) Ph(3-I,4-OCHF ₂ ) Ph(3-Et,4-CN) Ph(3-i-Pr,4-Me) Ph(3-I,4-OCF ₂ CF ₂ H) Ph(3-n-Pr,4-Cl) Ph(3-i-Pr,4-Et) P ^h(3-I,4-OC ₂ ^F ₅ ⁾ Ph(3-n-Pr,4-F) Ph(3-i-Pr,4-n-Pr) Ph(3-I,4-SO ₂ Me) Ph(3-n-Pr,4-Br) Ph(3-i-Pr,4-t-Bu) Ph(3-I,4-TMS) Ph(3-n-Pr,4-I) Ph(3,4-di-i-Pr) Ph(3-I,4-CN) Ph(3-n-Pr,4-Me) Ph(3-i-Pr,4-c-Pr) Ph(3-Me,4-I) Ph(3-n-Pr,4-Et) Ph(3-i-Pr,4-CF ₃ ) Ph(3-Me,4-Et) Ph(3,4-di-n-Pr) ^{Ph(3-i-Pr,4-C} ₂ ^F ₅ ⁾ Ph(3-Me,4-n-Pr) Ph(3-n-Pr,4-t-Bu) Ph(3-i-Pr,4-CF ₂ CF ₂ H) Ph(3-Me,4-i-Pr) Ph(3-n-Pr,4-i-Pr) Ph(3-i-Pr,4-CF ₂ H) P ^h(3-Me,4-C ₂ ^F ₅ ⁾ Ph(3-n-Pr,4-c-Pr) Ph(3-i-Pr,4-OMe) Ph(3-Me,4-CF ₂ CF ₂ H) Ph(3-n-Pr,4-CF ₃ ) Ph(3-i-Pr,4-OCF ₃ ) Ph(3-Me,4-CF ₂ H) Ph(3-n-Pr,4-C ₂ F ₅ ) Ph(3-i-Pr,4-OCHF ₂ ) Ph(3-Me,4-OMe) Ph(3-n-Pr,4-CF ₂ CF ₂ H) Ph(3-i-Pr,4-OCF ₂ CF ₂ H) ^{Ph(3-Me,4-OCF} ₂ ^CF ₂ ^H) Ph(3-n-Pr,4-CF ₂ H) ^{Ph(3-i-Pr,4-OC} ₂ ^F ₅ ^{) Ph(3-Me,4-OC} ₂ ^F ₅ ⁾ Ph(3-n-Pr,4-OMe) Ph(3-i-Pr,4-SO ₂ Me) Ph(3-Et,4-Cl) Ph(3-n-Pr,4-OCF ₃ ) Ph(3-i-Pr,4-TMS) Ph(3-Et,4-F) Ph(3-n-Pr,4-OCHF ₂ ) Ph(3-i-Pr,4-CN) Ph(3-Et,4-Br) Ph(3-n-Pr,4-OCF ₂ CF ₂ H) Ph(3-c-Pr,4-I) Ph(3-Et,4-I) ^{Ph(3-n-Pr,4-OC} ₂ ^F ₅ ⁾ Ph(3-c-Pr,4-Et) Ph(3-Et,4-Me) Ph(3-n-Pr,4-SO ₂ Me) Ph(3-c-Pr,4-n-Pr) Ph(3,4-di-Et) Ph(3-n-Pr,4-TMS) Ph(3-c-Pr,4-i-Pr) Q ¹ Q ¹ Q ¹

P ^h(3-c-Pr,4-C ₂ ^F ₅ ^{) Ph(3-C} ₂ ^F ₅ ^,4-TMS) Ph(3,4-di-CF ₂ H) Ph(3-c-Pr,4-CF ₂ CF ₂ H) Ph(3-C ₂ F ₅ ,4-CN) Ph(3-CF ₂ H,4-OMe) Ph(3-c-Pr,4-CF ₂ H) Ph(3-CF ₂ CF ₂ H,4-Cl) Ph(3-CF ₂ H,4-OCF ₃ ) Ph(3-c-Pr,4-OMe) Ph(3-CF ₂ CF ₂ H,4-F) Ph(3-CF ₂ H,4-OCHF ₂ ) Ph(3-c-Pr,4-OCF ₂ CF ₂ H) ^Ph(3-CF ₂ ^CF ₂ ^{H,4-Br) Ph(3-CF} ₂ ^H,4-OCF ₂ ^CF ₂ ^{H) Ph(3-c-Pr,4-OC} ₂ ^F ₅ ^{) Ph(3-CF} ₂ ^CF ₂ ^{H,4-I) Ph(3-CF} ₂ ^H,4-OC ₂ ^F ₅ ⁾ Ph(3-CF ₃ ,4-I) ^Ph(3-CF ₂ ^CF ₂ ^{H,4-Me) Ph(3-CF} ₂ ^H,4-SO ₂ ^Me) Ph(3-CF ₃ ,4-Et) ^Ph(3-CF ₂ ^CF ₂ ^H,4-Et) Ph(3-CF ₂ H,4-TMS) Ph(3-CF ₃ ,4-n-Pr) Ph(3-CF ₂ CF ₂ H,4-n-Pr) Ph(3-CF ₂ H,4-CN) Ph(3-CF ₃ ,4-i-Pr) Ph(3-CF ₂ CF ₂ H,4-t-Bu) Ph(3-OMe,4-Cl) P ^h(3-CF ₃ ^,4-C ₂ ^F ₅ ⁾ Ph(3-CF ₂ CF ₂ H,4-i-Pr) Ph(3-OMe,4-F) P ^h(3-CF ₃ ^,4-CF ₂ ^CF ₂ ^H) Ph(3-CF ₂ CF ₂ H,4-c-Pr) Ph(3-OMe,4-Br) P ^h(3-CF ₃ ^,4-CF ₂ ^{H) Ph(3-CF} ₂ ^CF ₂ ^H,4-CF ₃ ⁾ Ph(3-OMe,4-I) Ph(3-CF ₃ ,4-OMe) ^Ph(3-CF ₂ ^CF ₂ ^H,4-C ₂ ^F ₅ ⁾ Ph(3-OMe,4-Me) Ph(3-CF ₃ ,4-OCF ₂ CF ₂ H) Ph(3,4-di-CF ₂ CF ₂ H) Ph(3-OMe,4-Et) P ^h(3-CF ₃ ^,4-OC ₂ ^F ₅ ⁾ Ph(3-CF ₂ CF ₂ H,4-CF ₂ H) Ph(3-OMe,4-n-Pr) Ph(3-CF ₃ ,4-TMS) Ph(3-CF ₂ CF ₂ H,4-OMe) Ph(3-OMe,4-t-Bu) P ^h(3-C ₂ ^F ₅ ^{,4-Cl) Ph(3-CF} ₂ ^CF ₂ ^H,4-OCF ₃ ⁾ Ph(3-OMe,4-i-Pr) P ^h(3-C ₂ ^F ₅ ^{,4-F) Ph(3-CF} ₂ ^CF ₂ ^H,4-OCHF ₂ ⁾ Ph(3-OMe,4-c-Pr) P ^h(3-C ₂ ^F ₅ ^{,4-Br) Ph(3-CF} ₂ ^CF ₂ ^H,4-OCF ₂ ^CF ₂ ^H) Ph(3-OMe,4-CF ₃ ) P ^h(3-C ₂ ^F ₅ ^{,4-I) Ph(3-CF} ₂ ^CF ₂ ^H,4-OC ₂ ^F ₅ ^{) Ph(3-OMe,4-C} ₂ ^F ₅ ^{) Ph(3-C} ₂ ^F ₅ ^{,4-Me) Ph(3-CF} ₂ ^CF ₂ ^H,4-SO ₂ ^{Me) Ph(3-OMe,4-CF} ₂ ^CF ₂ ^{H) Ph(3-C} ₂ ^F ₅ ^{,4-Et) Ph(3-CF} ₂ ^CF ₂ ^H,4-TMS) Ph(3-OMe,4-CF ₂ H) P ^h(3-C ₂ ^F ₅ ^{,4-n-Pr) Ph(3-CF} ₂ ^CF ₂ ^H,4-CN) Ph(3,4-di-OMe) P ^h(3-C ₂ ^F ₅ ^,4-t-Bu) Ph(3-CF ₂ H,4-Cl) Ph(3-OMe,4-OCF ₃ ) P ^h(3-C ₂ ^F ₅ ^,4-i-Pr) Ph(3-CF ₂ H,4-F) Ph(3-OMe,4-OCHF ₂ ) Ph(3-C ₂ F ₅ ,4-c-Pr) Ph(3-CF ₂ H,4-Br) Ph(3-OMe,4-OCF ₂ CF ₂ H) P ^h(3-C ₂ ^F ₅ ^CF ₃ ^,4-CF ₃ ⁾ Ph(3-CF ₂ H,4-I) Ph(3-OMe,4-OC ₂ F ₅ ) Ph(3,4-di-C ₂ F ₅ ) Ph(3-CF ₂ H,4-Me) Ph(3-OMe,4-SO ₂ Me) ^Ph(3-C ₂ ^F ₅ ^,4-CF ₂ ^CF ₂ ^H) Ph(3-CF ₂ H,4-Et) Ph(3-OMe,4-TMS) P ^h(3-C ₂ ^F ₅ ^,4-CF ₂ ^H) Ph(3-CF ₂ H,4-n-Pr) Ph(3-OMe,4-CN) P ^h(3-C ₂ ^F ₅ ^,4-OMe) Ph(3-CF ₂ H,4-t-Bu) Ph(3-OCF ₃ ,4-I) P ^h(3-C ₂ ^F ₅ ^,4-OCF ₃ ⁾ Ph(3-CF ₂ H,4-i-Pr) Ph(3-OCF ₃ ,4-Et) P ^h(3-C ₂ ^F ₅ ^,4-OCHF ₂ ⁾ Ph(3-CF ₂ H,4-c-Pr) Ph(3-OCF ₃ ,4-n-Pr) ^Ph(3-C ₂ ^F ₅ ^,4-OCF ₂ ^CF ₂ ^{H) Ph(3-CF} ₂ ^H,4-CF ₃ ⁾ Ph(3-OCF ₃ ,4-i-Pr) P ^h(3-C ₂ ^F ₅ ^,4-OC ₂ ^F ₅ ^{) Ph(3-CF} ₂ ^H,4-C ₂ ^F ₅ ^{) Ph(3-OCF} ₃ ^,4-CF ₃ ^{) Ph(3-C} ₂ ^F ₅ ^,4-SO ₂ ^{Me) Ph(3-CF} ₂ ^H,4-CF ₂ ^CF ₂ ^{H) Ph(3-OCF} ₃ ^,4-C ₂ ^F ₅ ⁾ Q ¹ Q ¹ Q ¹

P ^h(3-OCF ₃ ^,4-CF ₂ ^CF ₂ ^{H) Ph(3-OCF} ₂ ^CF ₂ ^H,4-CF ₃ ^{) Ph(3-SO} ₂ ^MeCF ₃ ^,4-CF ₃ ⁾ Ph(3-OCF ₃ ,4-CF ₂ H) ^Ph(3-OCF ₂ ^CF ₂ ^H,4-C ₂ ^F ₅ ^{) Ph(3-SO} ₂ ^Me,4-C ₂ ^F ₅ ⁾ Ph(3-OCF ₃ ,4-OMe) ^Ph(3-OCF ₂ ^CF ₂ ^H,4-CF ₂ ^CF ₂ ^H) Ph(3-SO ₂ Me,4-CF ₂ CF ₂ H) Ph(3-OCF ₃ ,4-OCF ₂ CF ₂ H) Ph(3-OCF ₂ CF ₂ H,4-CF ₂ H) Ph(3-SO ₂ Me,4-CF ₂ H) P ^h(3-OCF ₃ ^,4-OC ₂ ^F ₅ ⁾ Ph(3-OCF ₂ CF ₂ H,4-OMe) Ph(3-SO ₂ Me,4-OMe) Ph(3-OCHF ₂ ,4-Cl) ^Ph(3-OCF ₂ ^CF ₂ ^H,4-OCF ₃ ^{) Ph(3-SO} ₂ ^Me,4-OCF ₂ ^CF ₂ ^H) Ph(3-OCHF ₂ ,4-F) ^Ph(3-OCF ₂ ^CF ₂ ^H,4-OCHF ₂ ^{) Ph(3-SO} ₂ ^Me,4-OC ₂ ^F ₅ ⁾ Ph(3-OCHF ₂ ,4-Br) ^{Ph(3,4-di-OCF} ₂ ^CF ₂ ^H) Ph(3-TMS,4-Cl) Ph(3-OCHF ₂ ,4-I) ^Ph(3-OCF ₂ ^CF ₂ ^H,4-OC ₂ ^F ₅ ⁾ Ph(3-TMS,4-F) Ph(3-OCHF ₂ ,4-Me) ^Ph(3-OCF ₂ ^CF ₂ ^H,4-SO ₂ ^Me) Ph(3-TMS,4-Br) Ph(3-OCHF ₂ ,4-Et) Ph(3-OCF ₂ CF ₂ H,4-TMS) Ph(3-TMS,4-I) Ph(3-OCHF ₂ ,4-n-Pr) ^Ph(3-OCF ₂ ^CF ₂ ^H,4-CN) Ph(3-TMS,4-Me) Ph(3-OCHF ₂ ,4-t-Bu) ^Ph(3-OC ₂ ^F ₅ ^,4-Cl) Ph(3-TMS,4-Et) Ph(3-OCHF ₂ ,4-i-Pr) ^Ph(3-OC ₂ ^F ₅ ^,4-F) Ph(3-TMS,4-n-Pr) Ph(3-OCHF ₂ ,4-c-Pr) Ph(3-OC ₂ F ₅ ,4-Br) Ph(3-TMS,4-t-Bu) Ph(3-OCHF ₂ CF ₃ ,4-CF ₃ ) Ph(3-OC ₂ F ₅ ,4-I) Ph(3-TMS,4-i-Pr) P ^h(3-OC ₂ ^F ₅ ^,4-C ₂ ^F ₅ ⁾ Ph(3-OC ₂ F ₅ ,4-Me) Ph(3-TMS,4-c-Pr) ^Ph(3-OCHF ₂ ^,4-CF ₂ ^CF ₂ ^{H) Ph(3-OC} ₂ ^F ₅ ^,4-Et) Ph(3-TMS,4-CF ₃ ) P ^h(3-OCHF ₂ ^,4-CF ₂ ^{H) Ph(3-OC} ₂ ^F ₅ ^{,4-n-Pr) Ph(3-TMS,4-C} ₂ ^F ₅ ⁾ Ph(3-OCHF ₂ ,4-OMe) ^Ph(3-OC ₂ ^F ₅ ^{,4-t-Bu) Ph(3-TMS,4-CF} ₂ ^CF ₂ ^{H) Ph(3-OCHF} ₂ ^,4-OCF ₃ ^{) Ph(3-OC} ₂ ^F ₅ ^,4-i-Pr) Ph(3-TMS,4-CF ₂ H) Ph(3,4-di-OCHF ₂ ) ^Ph(3-OC ₂ ^F ₅ ^,4-c-Pr) Ph(3-TMS,4-OMe) ^Ph(3-OCHF ₂ ^,4-OCF ₂ ^CF ₂ ^{H) Ph(3-OC} ₂ ^F ₅ ^CF ₃ ^,4-CF ₃ ⁾ Ph(3-TMS,4-OCF ₃ ) P ^h(3-OCHF ₂ ^,4-OC ₂ ^F ₅ ^{) Ph(3-OC} ₂ ^F ₅ ^,4-CF ₂ ^CF ₂ ^H) Ph(3-TMS,4-OCHF ₂ ) P ^h(3-OCHF ₂ ^,4-SO ₂ ^{Me) Ph(3-OC} ₂ ^F ₅ ^,4-CF ₂ ^H) Ph(3-TMS,4-OCF ₂ CF ₂ H) Ph(3-OCHF ₂ ,4-TMS) ^Ph(3-OC ₂ ^F ₅ ^{,4-OMe) Ph(3-TMS,4-OC} ₂ ^F ₅ ⁾ Ph(3-OCHF ₂ ,4-CN) ^Ph(3-OC ₂ ^F ₅ ^,4-OCF ₃ ⁾ Ph(3-TMS,4-SO ₂ Me) Ph(3-OCF ₂ CF ₂ H,4-Cl) ^Ph(3-OC ₂ ^F ₅ ^,4-OCHF ₂ ⁾ Ph(3,4-di-TMS) Ph(3-OCF ₂ CF ₂ H,4-F) ^Ph(3-OC ₂ ^F ₅ ^,4-OCF ₂ ^CF ₂ ^H) Ph(3-TMS,4-CN) P ^h(3-OCF ₂ ^CF ₂ ^{H,4-Br) Ph(3,4-di-OC} ₂ ^F ₅ ⁾ Ph(3-CN,4-I) P ^h(3-OCF ₂ ^CF ₂ ^{H,4-I) Ph(3-OC} ₂ ^F ₅ ^,4-SO ₂ ^Me) Ph(3-CN,4-Et) P ^h(3-OCF ₂ ^CF ₂ ^{H,4-Me) Ph(3-OC} ₂ ^F ₅ ^,4-TMS) Ph(3-CN,4-n-Pr) P ^h(3-OCF ₂ ^CF ₂ ^{H,4-Et) Ph(3-OC} ₂ ^F ₅ ^,4-CN) Ph(3-CN,4-i-Pr) Ph(3-OCF ₂ CF ₂ H,4-n-Pr) Ph(3-SO ₂ Me,4-I) ^Ph(3-CN,4-C ₂ ^F ₅ ⁾ Ph(3-OCF ₂ CF ₂ H,4-t-Bu) Ph(3-SO ₂ Me,4-Et) ^Ph(3-CN,4-CF ₂ ^CF ₂ ^H) Ph(3-OCF ₂ CF ₂ H,4-i-Pr) Ph(3-SO ₂ Me,4-n-Pr) Ph(3-CN,4-CF ₂ H) Ph(3-OCF ₂ CF ₂ H,4-c-Pr) Ph(3-SO ₂ Me,4-i-Pr) Ph(3-CN,4-OMe) Q ¹ Q ¹ Q ^{1 Ph(3-CN,4-OCF} ₂ ^CF ₂ ^H) Ph(3-F,5-CF ₂ H) Ph(3-I,5-n-Pr) Ph(3-CN,4-OC ₂ F ₅ ) Ph(3-F,5-OMe) Ph(3-I,5-t-Bu) Ph(3,5-di-Cl) Ph(3-F,5-OCF ₃ ) Ph(3-I,5-i-Pr) Ph(3-Cl,5-F) Ph(3-F,5-OCHF ₂ ) Ph(3-I,5-c-Pr) Ph(3-Cl,5-Br) ^Ph(3-F,5-OCF ₂ ^CF ₂ ^H) Ph(3-I,5-CF ₃ ) Ph(3-Cl,5-I) ^Ph(3-F,5-OC ₂ ^F ₅ ^{) Ph(3-I,5-C} ₂ ^F ₅ ⁾ Ph(3-Cl,5-Me) Ph(3-F,5-SO ₂ Me) ^Ph(3-I,5-CF ₂ ^CF ₂ ^H) Ph(3-Cl,5-Et) Ph(3-F,5-TMS) Ph(3-I,5-CF ₂ H) Ph(3-Cl,5-n-Pr) Ph(3-F,5-CN) Ph(3-I,5-OMe) Ph(3-Cl,5-t-Bu) Ph(3-Br,5-Cl) Ph(3-I,5-OCF ₃ ) Ph(3-Cl,5-i-Pr) Ph(3-Br,5-F) Ph(3-I,5-OCHF ₂ ) Ph(3-Cl,5-c-Pr) Ph(3,5-di-Br) ^Ph(3-I,5-OCF ₂ ^CF ₂ ^H) Ph(3-Cl,5-CF ₃ ) Ph(3-Br,5-I) ^Ph(3-I,5-OC ₂ ^F ₅ ^{) Ph(3-Cl,5-C} ₂ ^F ₅ ⁾ Ph(3-Br,5-Me) Ph(3-I,5-SO ₂ Me) Ph(3-Cl,5-CF ₂ CF ₂ H) Ph(3-Br,5-Et) Ph(3-I,5-TMS) Ph(3-Cl,5-CF ₂ H) Ph(3-Br,5-n-Pr) Ph(3-I,5-CN) Ph(3-Cl,5-OMe) Ph(3-Br,5-t-Bu) Ph(3-Me,5-Cl) Ph(3-Cl,5-OCF ₃ ) Ph(3-Br,5-i-Pr) Ph(3-Me,5-F) Ph(3-Cl,5-OCHF ₂ ) Ph(3-Br,5-c-Pr) Ph(3-Me,5-Br) ^{Ph(3-Cl,5-OCF} ₂ ^CF ₂ ^H) Ph(3-Br,5-CF ₃ ) Ph(3-Me,5-I) P ^h(3-Cl,5-OC ₂ ^F ₅ ^{) Ph(3-Br,5-C} ₂ ^F ₅ ⁾ Ph(3,5-di-Me) Ph(3-Cl,5-SO ₂ Me) ^Ph(3-Br,5-CF ₂ ^CF ₂ ^H) Ph(3-Me,5-Et) Ph(3-Cl,5-TMS) Ph(3-Br,5-CF ₂ H) Ph(3-Me,5-n-Pr) Ph(3-Cl,5-CN) Ph(3-Br,5-OMe) Ph(3-Me,5-t-Bu) Ph(3-F,5-Cl) Ph(3-Br,5-OCF ₃ ) Ph(3-Me,5-i-Pr) Ph(3,5-di-F) Ph(3-Br,5-OCHF ₂ ) Ph(3-Me,5-c-Pr) Ph(3-F,5-Br) Ph(3-Br,5-OCF ₂ CF ₂ H) Ph(3-Me,5-CF ₃ ) Ph(3-F,5-I) Ph(3-Br,5-OC ₂ F ₅ ) Ph(3-Me,5-C ₂ F ₅ ) Ph(3-F,5-Me) Ph(3-Br,5-SO ₂ Me) Ph(3-Me,5-CF ₂ CF ₂ H) Ph(3-F,5-Et) Ph(3-Br,5-TMS) Ph(3-Me,5-CF ₂ H) Ph(3-F,5-n-Pr) Ph(3-Br,5-CN) Ph(3-Me,5-OMe) Ph(3-F,5-t-Bu) Ph(3-I,5-Cl) Ph(3-Me,5-OCF ₃ ) Ph(3-F,5-i-Pr) Ph(3-I,5-F) Ph(3-Me,5-OCHF ₂ ) Ph(3-F,5-c-Pr) Ph(3-I,5-Br) ^{Ph(3-Me,5-OCF} ₂ ^CF ₂ ^H) Ph(3-F,5-CF ₃ ) Ph(3,5-di-I) ^Ph(3-Me,5-OC ₂ ^F ₅ ^{) Ph(3-F,5-C} ₂ ^F ₅ ⁾ Ph(3-I,5-Me) Ph(3-Me,5-SO ₂ Me) P ^h(3-F,5-CF ₂ ^CF ₂ ^H) Ph(3-I,5-Et) Ph(3-Me,5-TMS) Q ¹ Q ¹ Q ¹

Ph(3-Me,5-CN) Ph(3-n-Pr,5-OMe) Ph(3-i-Pr,5-t-Bu) Ph(3-Et,5-Cl) Ph(3-n-Pr,5-OCF ₃ ) Ph(3,5-di-i-Pr) Ph(3-Et,5-F) Ph(3-n-Pr,5-OCHF ₂ ) Ph(3-i-Pr,5-c-Pr) Ph(3-Et,5-Br) Ph(3-n-Pr,5-OCF ₂ CF ₂ H) Ph(3-i-Pr,5-CF ₃ ) Ph(3-Et,5-I) ^{Ph(3-n-Pr,5-OC} ₂ ^F ₅ ^{) Ph(3-i-Pr,5-C} ₂ ^F ₅ ⁾ Ph(3-Et,5-Me) Ph(3-n-Pr,5-SO ₂ Me) Ph(3-i-Pr,5-CF ₂ CF ₂ H) Ph(3,5-di-Et) Ph(3-n-Pr,5-TMS) Ph(3-i-Pr,5-CF ₂ H) Ph(3-Et,5-n-Pr) Ph(3-n-Pr,5-CN) Ph(3-i-Pr,5-OMe) Ph(3-Et,5-t-Bu) Ph(3-t-Bu,5-Cl) Ph(3-i-Pr,5-OCF ₃ ) Ph(3-Et,5-i-Pr) Ph(3-t-Bu,5-F) Ph(3-i-Pr,5-OCHF ₂ ) Ph(3-Et,5-c-Pr) Ph(3-t-Bu,5-Br) Ph(3-i-Pr,5-OCF ₂ CF ₂ H) Ph(3-Et,5-CF ₃ ) Ph(3-t-Bu,5-I) ^{Ph(3-i-Pr,5-OC} ₂ ^F ₅ ^{) Ph(3-Et,5-C} ₂ ^F ₅ ⁾ Ph(3-t-Bu,5-Me) Ph(3-i-Pr,5-SO ₂ Me) P ^h(3-Et,5-CF ₂ ^CF ₂ ^H) Ph(3-t-Bu,5-Et) Ph(3-i-Pr,5-TMS) Ph(3-Et,5-CF ₂ H) Ph(3-t-Bu,5-n-Pr) Ph(3-i-Pr,5-CN) Ph(3-Et,5-OMe) Ph(3,5-di-t-Bu) Ph(3-c-Pr,5-Cl) Ph(3-Et,5-OCF ₃ ) Ph(3-t-Bu,5-i-Pr) Ph(3-c-Pr,5-F) Ph(3-Et,5-OCHF ₂ ) Ph(3-t-Bu,5-c-Pr) Ph(3-c-Pr,5-Br) ^{Ph(3-Et,5-OCF} ₂ ^CF ₂ ^H) Ph(3-t-Bu,5-CF ₃ ) Ph(3-c-Pr,5-I) P ^h(3-Et,5-OC ₂ ^F ₅ ^{) Ph(3-t-Bu,5-C} ₂ ^F ₅ ⁾ Ph(3-c-Pr,5-Me) Ph(3-Et,5-SO ₂ Me) Ph(3-t-Bu,5-CF ₂ CF ₂ H) Ph(3-c-Pr,5-Et) Ph(3-Et,5-TMS) Ph(3-t-Bu,5-CF ₂ H) Ph(3-c-Pr,5-n-Pr) Ph(3-Et,5-CN) Ph(3-t-Bu,5-OMe) Ph(3-c-Pr,5-t-Bu) Ph(3-n-Pr,5-Cl) Ph(3-t-Bu,5-OCF ₃ ) Ph(3-c-Pr,5-i-Pr) Ph(3-n-Pr,5-F) Ph(3-t-Bu,5-OCHF ₂ ) Ph(3,5-di-c-Pr) Ph(3-n-Pr,5-Br) Ph(3-t-Bu,5-OCF ₂ CF ₂ H) Ph(3-c-Pr,5-CF ₃ ) Ph(3-n-Pr,5-I) Ph(3-t-Bu,5-OC ₂ F ₅ ) Ph(3-c-Pr,5-C ₂ F ₅ ) Ph(3-n-Pr,5-Me) Ph(3-t-Bu,5-SO ₂ Me) Ph(3-c-Pr,5-CF ₂ CF ₂ H) Ph(3-n-Pr,5-Et) Ph(3-t-Bu,5-TMS) Ph(3-c-Pr,5-CF ₂ H) Ph(3,5-di-n-Pr) Ph(3-t-Bu,5-CN) Ph(3-c-Pr,5-OMe) Ph(3-n-Pr,5-t-Bu) Ph(3-i-Pr,5-Cl) Ph(3-c-Pr,5-OCF ₃ ) Ph(3-n-Pr,5-i-Pr) Ph(3-i-Pr,5-F) Ph(3-c-Pr,5-OCHF ₂ ) Ph(3-n-Pr,5-c-Pr) Ph(3-i-Pr,5-Br) Ph(3-c-Pr,5-OCF ₂ CF ₂ H) Ph(3-n-Pr,5-CF ₃ ) Ph(3-i-Pr,5-I) ^{Ph(3-c-Pr,5-OC} ₂ ^F ₅ ^{) Ph(3-n-Pr,5-C} ₂ ^F ₅ ⁾ Ph(3-i-Pr,5-Me) Ph(3-c-Pr,5-SO ₂ Me) Ph(3-n-Pr,5-CF ₂ CF ₂ H) Ph(3-i-Pr,5-Et) Ph(3-c-Pr,5-TMS) Ph(3-n-Pr,5-CF ₂ H) Ph(3-i-Pr,5-n-Pr) Ph(3-c-Pr,5-CN) Q ¹ Q ¹ Q ¹

Ph(3-CF ₃ ,5-Cl) ^Ph(3-C ₂ ^F ₅ ^,5-OCF ₃ ⁾ Ph(3-CF ₂ H,5-i-Pr) Ph(3-CF ₃ ,5-F) ^Ph(3-C ₂ ^F ₅ ^,5-OCHF ₂ ⁾ Ph(3-CF ₂ H,5-c-Pr) Ph(3-CF ₃ ,5-Br) ^Ph(3-C ₂ ^F ₅ ^,5-OCF ₂ ^CF ₂ ^H) Ph(3-CF ₂ H,5-CF ₃ ) Ph(3-CF ₃ ,5-I) ^Ph(3-C ₂ ^F ₅ ^,5-OC ₂ ^F ₅ ^{) Ph(3-CF} ₂ ^H,5-C ₂ ^F ₅ ⁾ Ph(3-CF ₃ ,5-Me) ^Ph(3-C ₂ ^F ₅ ^,5-SO ₂ ^{Me) Ph(3-CF} ₂ ^H,5-CF ₂ ^CF ₂ ^H) Ph(3-CF ₃ ,5-Et) ^Ph(3-C ₂ ^F ₅ ^,5-TMS) Ph(3,5-di-CF ₂ H) Ph(3-CF ₃ ,5-n-Pr) ^Ph(3-C ₂ ^F ₅ ^,5-CN) Ph(3-CF ₂ H,5-OMe) Ph(3-CF ₃ ,5-t-Bu) ^Ph(3-CF ₂ ^CF ₂ ^{H,5-Cl) Ph(3-CF} ₂ ^H,5-OCF ₃ ⁾ Ph(3-CF ₃ ,5-i-Pr) ^Ph(3-CF ₂ ^CF ₂ ^{H,5-F) Ph(3-CF} ₂ ^H,5-OCHF ₂ ⁾ Ph(3-CF ₃ ,5-c-Pr) ^Ph(3-CF ₂ ^CF ₂ ^{H,5-Br) Ph(3-CF} ₂ ^H,5-OCF ₂ ^CF ₂ ^H) Ph(3,5-di-CF ₃ ) ^Ph(3-CF ₂ ^CF ₂ ^{H,5-I) Ph(3-CF} ₂ ^H,5-OC ₂ ^F ₅ ^{) Ph(3-CF} ₃ ^,5-C ₂ ^F ₅ ^{) Ph(3-CF} ₂ ^CF ₂ ^{H,5-Me) Ph(3-CF} ₂ ^H,5-SO ₂ ^{Me) Ph(3-CF} ₃ ^,5-CF ₂ ^CF ₂ ^{H) Ph(3-CF} ₂ ^CF ₂ ^H,5-Et) Ph(3-CF ₂ H,5-TMS) P ^h(3-CF ₃ ^,5-CF ₂ ^H) Ph(3-CF ₂ CF ₂ H,5-n-Pr) Ph(3-CF ₂ H,5-CN) Ph(3-CF ₃ ,5-OMe) Ph(3-CF ₂ CF ₂ H,5-t-Bu) Ph(3-OMe,5-Cl) Ph(3-CF ₃ ,5-OCF ₃ ) Ph(3-CF ₂ CF ₂ H,5-i-Pr) Ph(3-OMe,5-F) Ph(3-CF ₃ ,5-OCHF ₂ ) Ph(3-CF ₂ CF ₂ H,5-c-Pr) Ph(3-OMe,5-Br) ^Ph(3-CF ₃ ^,5-OCF ₂ ^CF ₂ ^{H) Ph(3-CF} ₂ ^CF ₂ ^H,5-CF ₃ ⁾ Ph(3-OMe,5-I) P ^h(3-CF ₃ ^,5-OC ₂ ^F ₅ ^{) Ph(3-CF} ₂ ^CF ₂ ^H,5-C ₂ ^F ₅ ⁾ Ph(3-OMe,5-Me) P ^h(3-CF ₃ ^,5-SO ₂ ^{Me) Ph(3,5-di-CF} ₂ ^CF ₂ ^H) Ph(3-OMe,5-Et) Ph(3-CF ₃ ,5-TMS) ^Ph(3-CF ₂ ^CF ₂ ^H,5-CF ₂ ^H) Ph(3-OMe,5-n-Pr) Ph(3-CF ₃ ,5-CN) ^Ph(3-CF ₂ ^CF ₂ ^H,5-OMe) Ph(3-OMe,5-t-Bu) P ^h(3-C ₂ ^F ₅ ^{,5-Cl) Ph(3-CF} ₂ ^CF ₂ ^H,5-OCF ₃ ⁾ Ph(3-OMe,5-i-Pr) P ^h(3-C ₂ ^F ₅ ^{,5-F) Ph(3-CF} ₂ ^CF ₂ ^H,5-OCHF ₂ ⁾ Ph(3-OMe,5-c-Pr) P ^h(3-C ₂ ^F ₅ ^{,5-Br) Ph(3-CF} ₂ ^CF ₂ ^H,5-OCF ₂ ^CF ₂ ^{H) Ph(3-OMeCF} ₃ ^,5-CF ₃ ^{) Ph(3-C} ₂ ^F ₅ ^{,5-I) Ph(3-CF} ₂ ^CF ₂ ^H,5-OC ₂ ^F ₅ ^{) Ph(3-OMe,5-C} ₂ ^F ₅ ⁾ Ph(3-C ₂ F ₅ ,5-Me) Ph(3-CF ₂ CF ₂ H,5-SO ₂ Me) Ph(3-OMe,5-CF ₂ CF ₂ H) Ph(3-C ₂ F ₅ ,5-Et) Ph(3-CF ₂ CF ₂ H,5-TMS) Ph(3-OMe,5-CF ₂ H) Ph(3-C ₂ F ₅ ,5-n-Pr) Ph(3-CF ₂ CF ₂ H,5-CN) Ph(3,5-di-OMe) P ^h(3-C ₂ ^F ₅ ^,5-t-Bu) Ph(3-CF ₂ H,5-Cl) Ph(3-OMe,5-OCF ₃ ) P ^h(3-C ₂ ^F ₅ ^,5-i-Pr) Ph(3-CF ₂ H,5-F) Ph(3-OMe,5-OCHF ₂ ) P ^h(3-C ₂ ^F ₅ ^,5-c-Pr) Ph(3-CF ₂ H,5-Br) Ph(3-OMe,5-OCF ₂ CF ₂ H) P ^h(3-C ₂ ^F ₅ ^CF ₃ ^,5-CF ₃ ⁾ Ph(3-CF ₂ H,5-I) ^{Ph(3-OMe,5-OC} ₂ ^F ₅ ^{) Ph(3,5-di-C} ₂ ^F ₅ ⁾ Ph(3-CF ₂ H,5-Me) Ph(3-OMe,5-SO ₂ Me) ^Ph(3-C ₂ ^F ₅ ^,5-CF ₂ ^CF ₂ ^H) Ph(3-CF ₂ H,5-Et) Ph(3-OMe,5-TMS) P ^h(3-C ₂ ^F ₅ ^,5-CF ₂ ^H) Ph(3-CF ₂ H,5-n-Pr) Ph(3-OMe,5-CN) P ^h(3-C ₂ ^F ₅ ^,5-OMe) Ph(3-CF ₂ H,5-t-Bu) Ph(3-OCF ₃ ,5-Cl) Q ¹ Q ¹ Q ¹

Ph(3-OCF ₃ ,5-F) Ph(3,5-di-OCHF ₂ ) ^Ph(3-OC ₂ ^F ₅ ^,5-c-Pr) Ph(3-OCF ₃ ,5-Br) Ph(3-OCHF ₂ ,5-OCF ₂ CF ₂ H) ^Ph(3-OC ₂ ^F ₅ ^CF ₃ ^,5-CF ₃ ⁾ Ph(3-OCF ₃ ,5-I) ^Ph(3-OCHF ₂ ^,5-OC ₂ ^F ₅ ^{) Ph(3-OC} ₂ ^F ₅ ^,5-CF ₂ ^CF ₂ ^H) Ph(3-OCF ₃ ,5-Me) Ph(3-OCHF ₂ ,5-SO ₂ Me) ^Ph(3-OC ₂ ^F ₅ ^,5-CF ₂ ^H) Ph(3-OCF ₃ ,5-Et) Ph(3-OCHF ₂ ,5-TMS) ^Ph(3-OC ₂ ^F ₅ ^,5-OMe) Ph(3-OCF ₃ ,5-n-Pr) Ph(3-OCHF ₂ ,5-CN) ^Ph(3-OC ₂ ^F ₅ ^,5-OCF ₃ ⁾ Ph(3-OCF ₃ ,5-t-Bu) ^Ph(3-OCF ₂ ^CF ₂ ^{H,5-Cl) Ph(3-OC} ₂ ^F ₅ ^,5-OCHF ₂ ⁾ Ph(3-OCF ₃ ,5-i-Pr) ^Ph(3-OCF ₂ ^CF ₂ ^{H,5-F) Ph(3,5-di-OC} ₂ ^F ₅ ⁾ Ph(3-OCF ₃ ,5-c-Pr) ^Ph(3-OCF ₂ ^CF ₂ ^{H,5-Br) Ph(3,5-di-OC} ₂ ^F ₅ ^{) Ph(3-OCF} ₃ ^,5-CF ₃ ^{) Ph(3-OCF} ₂ ^CF ₂ ^{H,5-I) Ph(3-OC} ₂ ^F ₅ ^,5-SO ₂ ^{Me) Ph(3-OCF} ₃ ^,5-C ₂ ^F ₅ ^{) Ph(3-OCF} ₂ ^CF ₂ ^{H,5-Me) Ph(3-OC} ₂ ^F ₅ ^{,5-TMS) Ph(3-OCF} ₃ ^,5-CF ₂ ^CF ₂ ^{H) Ph(3-OCF} ₂ ^CF ₂ ^{H,5-Et) Ph(3-OC} ₂ ^F ₅ ^{,5-CN) Ph(3-OCF} ₃ ^,5-CF ₂ ^H) Ph(3-OCF ₂ CF ₂ H,5-n-Pr) Ph(3-SO ₂ Me,5-Cl) Ph(3-OCF ₃ ,5-OMe) Ph(3-OCF ₂ CF ₂ H,5-t-Bu) Ph(3-SO ₂ Me,5-F) Ph(3,5-di-OCF ₃ ) Ph(3-OCF ₂ CF ₂ H,5-i-Pr) Ph(3-SO ₂ Me,5-Br) Ph(3-OCF ₃ ,5-OCHF ₂ ) Ph(3-OCF ₂ CF ₂ H,5-c-Pr) Ph(3-SO ₂ Me,5-I) Ph(3-OCF ₃ ,5-OCF ₂ CF ₂ H) Ph(3-OCF ₂ CF ₂ H,5-CF ₃ ) Ph(3-SO ₂ Me,5-Me) P ^h(3-OCF ₃ ^,5-OC ₂ ^F ₅ ^{) Ph(3-OCF} ₂ ^CF ₂ ^H,5-C ₂ ^F ₅ ⁾ Ph(3-SO ₂ Me,5-Et) P ^h(3-OCF ₃ ^,5-SO ₂ ^{Me) Ph(3-OCF} ₂ ^CF ₂ ^H,5-CF ₂ ^CF ₂ ^H) Ph(3-SO ₂ Me,5-n-Pr) Ph(3-OCF ₃ ,5-TMS) ^Ph(3-OCF ₂ ^CF ₂ ^H,5-CF ₂ ^H) Ph(3-SO ₂ Me,5-t-Bu) Ph(3-OCF ₃ ,5-CN) Ph(3-OCF ₂ CF ₂ H,5-OMe) Ph(3-SO ₂ Me,5-i-Pr) Ph(3-OCHF ₂ ,5-Cl) ^Ph(3-OCF ₂ ^CF ₂ ^H,5-OCF ₃ ⁾ Ph(3-SO ₂ Me,5-c-Pr) Ph(3-OCHF ₂ ,5-F) ^Ph(3-OCF ₂ ^CF ₂ ^H,5-OCHF ₂ ^{) Ph(3-SO} ₂ ^MeCF ₃ ^,5-CF ₃ ⁾ Ph(3-OCHF ₂ ,5-Br) ^{Ph(3,5-di-OCF} ₂ ^CF ₂ ^{H) Ph(3-SO} ₂ ^Me,5-C ₂ ^F ₅ ⁾ Ph(3-OCHF ₂ ,5-I) ^Ph(3-OCF ₂ ^CF ₂ ^H,5-OC ₂ ^F ₅ ^{) Ph(3-SO} ₂ ^Me,5-CF ₂ ^CF ₂ ^H) Ph(3-OCHF ₂ ,5-Me) ^Ph(3-OCF ₂ ^CF ₂ ^H,5-SO ₂ ^{Me) Ph(3-SO} ₂ ^Me,5-CF ₂ ^H) Ph(3-OCHF ₂ ,5-Et) Ph(3-OCF ₂ CF ₂ H,5-TMS) Ph(3-SO ₂ Me,5-OMe) Ph(3-OCHF ₂ ,5-n-Pr) Ph(3-OCF ₂ CF ₂ H,5-CN) Ph(3-SO ₂ Me,5-OCF ₃ ) Ph(3-OCHF ₂ ,5-t-Bu) Ph(3-OC ₂ F ₅ ,5-Cl) Ph(3-SO ₂ Me,5-OCHF ₂ ) Ph(3-OCHF ₂ ,5-i-Pr) ^Ph(3-OC ₂ ^F ₅ ^{,5-F) Ph(3-SO} ₂ ^Me,5-OCF ₂ ^CF ₂ ^H) Ph(3-OCHF ₂ ,5-c-Pr) ^Ph(3-OC ₂ ^F ₅ ^{,5-Br) Ph(3-SO} ₂ ^Me,5-OC ₂ ^F ₅ ^{) Ph(3-OCHF} ₂ ^CF ₃ ^,5-CF ₃ ^{) Ph(3-OC} ₂ ^F ₅ ^,5-I) Ph(3,5-di-SO ₂ Me) P ^h(3-OC ₂ ^F ₅ ^,5-C ₂ ^F ₅ ^{) Ph(3-OC} ₂ ^F ₅ ^,5-Me) Ph(3-SO ₂ Me,5-TMS) ^Ph(3-OCHF ₂ ^,5-CF ₂ ^CF ₂ ^{H) Ph(3-OC} ₂ ^F ₅ ^,5-Et) Ph(3-SO ₂ Me,5-CN) P ^h(3-OCHF ₂ ^,5-CF ₂ ^{H) Ph(3-OC} ₂ ^F ₅ ^,5-n-Pr) Ph(3-TMS,5-Cl) Ph(3-OCHF ₂ ,5-OMe) ^Ph(3-OC ₂ ^F ₅ ^,5-t-Bu) Ph(3-TMS,5-F) P ^h(3-OCHF ₂ ^,5-OCF ₃ ^{) Ph(3-OC} ₂ ^F ₅ ^,5-i-Pr) Ph(3-TMS,5-Br) Q ¹ Q ¹ Q ¹

Ph(3-TMS,5-I) ^Ph(3-CN,5-OC ₂ ^F ₅ ^{) Ph(2-Cl,3-F,4-C} ₂ ^F ₅ ⁾ Ph(3-TMS,5-Me) Ph(3-CN,5-SO ₂ Me) Ph(2-Cl,3-F,4-CF ₂ CF ₂ H) Ph(3-TMS,5-Et) Ph(3-CN,5-TMS) Ph(2-Cl,3-F,4-CF ₂ H) Ph(3-TMS,5-n-Pr) Ph(3,5-di-CN) Ph(2-Cl,3-F,4-OMe) Ph(3-TMS,5-t-Bu) Ph(2,3,4-tri-Cl) Ph(2-Cl,3-F,4-OCF ₃ ) Ph(3-TMS,5-i-Pr) Ph(2-Cl,3-Cl,4-F) Ph(2-Cl,3-F,4-OCHF ₂ ) Ph(3-TMS,5-c-Pr) Ph(2-Cl,3-Cl,4-Br) Ph(2-Cl,3-F,4-OCF ₂ CF ₂ H) Ph(3-TMS,5-CF ₃ ) Ph(2-Cl,3-Cl,4-I) Ph(2-Cl,3-F,4-OC ₂ F ₅ ) P ^h(3-TMS,5-C ₂ ^F ₅ ⁾ Ph(2-Cl,3-Cl,4-Me) Ph(2-Cl,3-F,4-SO ₂ Me) ^{Ph(3-TMS,5-CF} ₂ ^CF ₂ ^H) Ph(2-Cl,3-Cl,4-Et) Ph(2-Cl,3-F,4-TMS) Ph(3-TMS,5-CF ₂ H) Ph(2-Cl,3-Cl,4-n-Pr) Ph(2-Cl,3-F,4-CN) Ph(3-TMS,5-OMe) Ph(2-Cl,3-Cl,4-t-Bu) Ph(2-Cl,3-Br,4-Cl) Ph(3-TMS,5-OCF ₃ ) Ph(2-Cl,3-Cl,4-i-Pr) Ph(2-Cl,3-Br,4-F) Ph(3-TMS,5-OCHF ₂ ) Ph(2-Cl,3-Cl,4-c-Pr) Ph(2-Cl,3,4-di-Br) Ph(3-TMS,5-OCF ₂ CF ₂ H) Ph(2-Cl,3-Cl,4-CF ₃ ) Ph(2-Cl,3-Br,4-I) Ph(3-TMS,5-OC ₂ F ₅ ) Ph(2-Cl,3-Cl,4-C ₂ F ₅ ) Ph(2-Cl,3-Br,4-Me) Ph(3-TMS,5-SO ₂ Me) Ph(2-Cl,3-Cl,4-CF ₂ CF ₂ H) Ph(2-Cl,3-Br,4-Et) Ph(3,5-di-TMS) Ph(2-Cl,3-Cl,4-CF ₂ H) Ph(2-Cl,3-Br,4-n-Pr) Ph(3-TMS,5-CN) Ph(2-Cl,3-Cl,4-OMe) Ph(2-Cl,3-Br,4-t-Bu) Ph(3-CN,5-Cl) Ph(2-Cl,3-Cl,4-OCF ₃ ) Ph(2-Cl,3-Br,4-i-Pr) Ph(3-CN,5-F) Ph(2-Cl,3-Cl,4-OCHF ₂ ) Ph(2-Cl,3-Br,4-c-Pr) Ph(3-CN,5-Br) Ph(2-Cl,3-Cl,4-OCF ₂ CF ₂ H) Ph(2-Cl,3-Br,4-CF ₃ ) Ph(3-CN,5-I) Ph(2-Cl,3-Cl,4-OC ₂ F ₅ ) Ph(2-Cl,3-Br,4-C ₂ F ₅ ) Ph(3-CN,5-Me) Ph(2-Cl,3-Cl,4-SO ₂ Me) Ph(2-Cl,3-Br,4-CF ₂ CF ₂ H) Ph(3-CN,5-Et) Ph(2-Cl,3-Cl,4-TMS) Ph(2-Cl,3-Br,4-CF ₂ H) Ph(3-CN,5-n-Pr) Ph(2-Cl,3-Cl,4-CN) Ph(2-Cl,3-Br,4-OMe) Ph(3-CN,5-t-Bu) Ph(2-Cl,3-F,4-Cl) Ph(2-Cl,3-Br,4-OCF ₃ ) Ph(3-CN,5-i-Pr) Ph(2-Cl,3,4-di-F) Ph(2-Cl,3-Br,4-OCHF ₂ ) Ph(3-CN,5-c-Pr) Ph(2-Cl,3-F,4-Br) Ph(2-Cl,3-Br,4-OCF ₂ CF ₂ H) Ph(3-CN,5-CF ₃ ) Ph(2-Cl,3-F,4-I) Ph(2-Cl,3-Br,4-OC ₂ F ₅ ) P ^h(3-CN,5-C ₂ ^F ₅ ⁾ Ph(2-Cl,3-F,4-Me) Ph(2-Cl,3-Br,4-SO ₂ Me) P ^h(3-CN,5-CF ₂ ^CF ₂ ^H) Ph(2-Cl,3-F,4-Et) Ph(2-Cl,3-Br,4-TMS) Ph(3-CN,5-CF ₂ H) Ph(2-Cl,3-F,4-n-Pr) Ph(2-Cl,3-Br,4-CN) Ph(3-CN,5-OMe) Ph(2-Cl,3-F,4-t-Bu) Ph(2-Cl,3-I,4-Cl) Ph(3-CN,5-OCF ₃ ) Ph(2-Cl,3-F,4-i-Pr) Ph(2-Cl,3-I,4-F) Ph(3-CN,5-OCHF ₂ ) Ph(2-Cl,3-F,4-c-Pr) Ph(2-Cl,3-I,4-Br) ^{Ph(3-CN,5-OCF} ₂ ^CF ₂ ^H) Ph(2-Cl,3-F,4-CF ₃ ) Ph(2-Cl,3,4-di-I) Q ¹ Q ¹ Q ¹

Ph(2-Cl,3-I,4-Me) Ph(2-Cl,3-Me,4-SO ₂ Me) Ph(2-Cl,3-n-Pr,4-CF ₂ CF ₂ H) Ph(2-Cl,3-I,4-Et) Ph(2-Cl,3-Me,4-TMS) Ph(2-Cl,3-n-Pr,4-CF ₂ H) Ph(2-Cl,3-I,4-n-Pr) Ph(2-Cl,3-Me,4-CN) Ph(2-Cl,3-n-Pr,4-OMe) Ph(2-Cl,3-I,4-t-Bu) Ph(2-Cl,3-Et,4-Cl) Ph(2-Cl,3-n-Pr,4-OCF ₃ ) Ph(2-Cl,3-I,4-i-Pr) Ph(2-Cl,3-Et,4-F) Ph(2-Cl,3-n-Pr,4-OCHF ₂ ) Ph(2-Cl,3-I,4-c-Pr) Ph(2-Cl,3-Et,4-Br) Ph(2-Cl,3-n-Pr,4-OCF ₂ CF ₂ H) Ph(2-Cl,3-I,4-CF ₃ ) Ph(2-Cl,3-Et,4-I) Ph(2-Cl,3-n-Pr,4-OC ₂ F ₅ ) P ^{h(2-Cl,3-I,4-C} ₂ ^F ₅ ⁾ Ph(2-Cl,3-Et,4-Me) Ph(2-Cl,3-n-Pr,4-SO ₂ Me) Ph(2-Cl,3-I,4-CF ₂ CF ₂ H) Ph(2-Cl,3,4-di-Et) Ph(2-Cl,3-n-Pr,4-TMS) Ph(2-Cl,3-I,4-CF ₂ H) Ph(2-Cl,3-Et,4-n-Pr) Ph(2-Cl,3-n-Pr,4-CN) Ph(2-Cl,3-I,4-OMe) Ph(2-Cl,3-Et,4-t-Bu) Ph(2-Cl,3-t-Bu,4-Cl) Ph(2-Cl,3-I,4-OCF ₃ ) Ph(2-Cl,3-Et,4-i-Pr) Ph(2-Cl,3-t-Bu,4-F) Ph(2-Cl,3-I,4-OCHF ₂ ) Ph(2-Cl,3-Et,4-c-Pr) Ph(2-Cl,3-t-Bu,4-Br) Ph(2-Cl,3-I,4-OCF ₂ CF ₂ H) Ph(2-Cl,3-Et,4-CF ₃ ) Ph(2-Cl,3-t-Bu,4-I) Ph(2-Cl,3-I,4-OC ₂ F ₅ ) Ph(2-Cl,3-Et,4-C ₂ F ₅ ) Ph(2-Cl,3-t-Bu,4-Me) Ph(2-Cl,3-I,4-SO ₂ Me) Ph(2-Cl,3-Et,4-CF ₂ CF ₂ H) Ph(2-Cl,3-t-Bu,4-Et) Ph(2-Cl,3-I,4-TMS) Ph(2-Cl,3-Et,4-CF ₂ H) Ph(2-Cl,3-t-Bu,4-n-Pr) Ph(2-Cl,3-I,4-CN) Ph(2-Cl,3-Et,4-OMe) Ph(2-Cl,3,4-di-t-Bu) Ph(2-Cl,3-Me,4-Cl) Ph(2-Cl,3-Et,4-OCF ₃ ) Ph(2-Cl,3-t-Bu,4-i-Pr) Ph(2-Cl,3-Me,4-F) Ph(2-Cl,3-Et,4-OCHF ₂ ) Ph(2-Cl,3-t-Bu,4-c-Pr) Ph(2-Cl,3-Me,4-Br) Ph(2-Cl,3-Et,4-OCF ₂ CF ₂ H) Ph(2-Cl,3-t-Bu,4-CF ₃ ) Ph(2-Cl,3-Me,4-I) Ph(2-Cl,3-Et,4-OC ₂ F ₅ ) Ph(2-Cl,3-t-Bu,4-C ₂ F ₅ ) Ph(2-Cl,3,4-di-Me) Ph(2-Cl,3-Et,4-SO ₂ Me) Ph(2-Cl,3-t-Bu,4-CF ₂ CF ₂ H) Ph(2-Cl,3-Me,4-Et) Ph(2-Cl,3-Et,4-TMS) Ph(2-Cl,3-t-Bu,4-CF ₂ H) Ph(2-Cl,3-Me,4-n-Pr) Ph(2-Cl,3-Et,4-CN) Ph(2-Cl,3-t-Bu,4-OMe) Ph(2-Cl,3-Me,4-t-Bu) Ph(2-Cl,3-n-Pr,4-Cl) Ph(2-Cl,3-t-Bu,4-OCF ₃ ) Ph(2-Cl,3-Me,4-i-Pr) Ph(2-Cl,3-n-Pr,4-F) Ph(2-Cl,3-t-Bu,4-OCHF ₂ ) Ph(2-Cl,3-Me,4-c-Pr) Ph(2-Cl,3-n-Pr,4-Br) Ph(2-Cl,3-t-Bu,4-OCF ₂ CF ₂ H) Ph(2-Cl,3-Me,4-CF ₃ ) Ph(2-Cl,3-n-Pr,4-I) Ph(2-Cl,3-t-Bu,4-OC ₂ F ₅ ) Ph(2-Cl,3-Me,4-C ₂ F ₅ ) Ph(2-Cl,3-n-Pr,4-Me) Ph(2-Cl,3-t-Bu,4-SO ₂ Me) Ph(2-Cl,3-Me,4-CF ₂ CF ₂ H) Ph(2-Cl,3-n-Pr,4-Et) Ph(2-Cl,3-t-Bu,4-TMS) Ph(2-Cl,3-Me,4-CF ₂ H) Ph(2-Cl,3,4-di-n-Pr) Ph(2-Cl,3-t-Bu,4-CN) Ph(2-Cl,3-Me,4-OMe) Ph(2-Cl,3-n-Pr,4-t-Bu) Ph(2-Cl,3-i-Pr,4-Cl) Ph(2-Cl,3-Me,4-OCF ₃ ) Ph(2-Cl,3-n-Pr,4-i-Pr) Ph(2-Cl,3-i-Pr,4-F) Ph(2-Cl,3-Me,4-OCHF ₂ ) Ph(2-Cl,3-n-Pr,4-c-Pr) Ph(2-Cl,3-i-Pr,4-Br) Ph(2-Cl,3-Me,4-OCF ₂ CF ₂ H) Ph(2-Cl,3-n-Pr,4-CF ₃ ) Ph(2-Cl,3-i-Pr,4-I) Ph(2-Cl,3-Me,4-OC ₂ F ₅ ) Ph(2-Cl,3-n-Pr,4-C ₂ F ₅ ) Ph(2-Cl,3-i-Pr,4-Me) Q ¹ Q ¹ Q ¹

Ph(2-Cl,3-i-Pr,4-Et) Ph(2-Cl,3-c-Pr,4-TMS) ^Ph(2-Cl,3-C ₂ ^F ₅ ^,4-CF ₂ ^H) Ph(2-Cl,3-i-Pr,4-n-Pr) Ph(2-Cl,3-c-Pr,4-CN) Ph(2-Cl,3-C ₂ F ₅ ,4-OMe) Ph(2-Cl,3-i-Pr,4-t-Bu) Ph(2-Cl,3-CF ₃ ,4-Cl) Ph(2-Cl,3-C ₂ F ₅ ,4-OCF ₃ ) Ph(2-Cl,3,4-di-i-Pr) Ph(2-Cl,3-CF ₃ ,4-F) Ph(2-Cl,3-C ₂ F ₅ ,4-OCHF ₂ ) Ph(2-Cl,3-i-Pr,4-c-Pr) Ph(2-Cl,3-CF ₃ ,4-Br) ^Ph(2-Cl,3-C ₂ ^F ₅ ^,4-OCF ₂ ^CF ₂ ^H) Ph(2-Cl,3-i-Pr,4-CF ₃ ) Ph(2-Cl,3-CF ₃ ,4-I) ^Ph(2-Cl,3-C ₂ ^F ₅ ^,4-OC ₂ ^F ₅ ⁾ Ph(2-Cl,3-i-Pr,4-C ₂ F ₅ ) Ph(2-Cl,3-CF ₃ ,4-Me) ^Ph(2-Cl,3-C ₂ ^F ₅ ^,4-SO ₂ ^Me) Ph(2-Cl,3-i-Pr,4-CF ₂ CF ₂ H) Ph(2-Cl,3-CF ₃ ,4-Et) Ph(2-Cl,3-C ₂ F ₅ ,4-TMS) Ph(2-Cl,3-i-Pr,4-CF ₂ H) Ph(2-Cl,3-CF ₃ ,4-n-Pr) Ph(2-Cl,3-C ₂ F ₅ ,4-CN) Ph(2-Cl,3-i-Pr,4-OMe) Ph(2-Cl,3-CF ₃ ,4-t-Bu) Ph(2-Cl,3-CF ₂ CF ₂ H,4-Cl) Ph(2-Cl,3-i-Pr,4-OCF ₃ ) Ph(2-Cl,3-CF ₃ ,4-i-Pr) Ph(2-Cl,3-CF ₂ CF ₂ H,4-F) Ph(2-Cl,3-i-Pr,4-OCHF ₂ ) Ph(2-Cl,3-CF ₃ ,4-c-Pr) Ph(2-Cl,3-CF ₂ CF ₂ H,4-Br) Ph(2-Cl,3-i-Pr,4-OCF ₂ CF ₂ H) Ph(2-Cl,3,4-di-CF ₃ ) Ph(2-Cl,3-CF ₂ CF ₂ H,4-I) Ph(2-Cl,3-i-Pr,4-OC ₂ F ₅ ) ^Ph(2-Cl,3-CF ₃ ^,4-C ₂ ^F ₅ ⁾ Ph(2-Cl,3-CF ₂ CF ₂ H,4-Me) Ph(2-Cl,3-i-Pr,4-SO ₂ Me) Ph(2-Cl,3-CF ₃ ,4-CF ₂ CF ₂ H) Ph(2-Cl,3-CF ₂ CF ₂ H,4-Et) Ph(2-Cl,3-i-Pr,4-TMS) Ph(2-Cl,3-CF ₃ ,4-CF ₂ H) Ph(2-Cl,3-CF ₂ CF ₂ H,4-n-Pr) Ph(2-Cl,3-i-Pr,4-CN) Ph(2-Cl,3-CF ₃ ,4-OMe) Ph(2-Cl,3-CF ₂ CF ₂ H,4-t-Bu) Ph(2-Cl,3-c-Pr,4-Cl) Ph(2-Cl,3-CF ₃ ,4-OCF ₃ ) Ph(2-Cl,3-CF ₂ CF ₂ H,4-i-Pr) Ph(2-Cl,3-c-Pr,4-F) Ph(2-Cl,3-CF ₃ ,4-OCHF ₂ ) Ph(2-Cl,3-CF ₂ CF ₂ H,4-c-Pr) Ph(2-Cl,3-c-Pr,4-Br) ^Ph(2-Cl,3-CF ₃ ^,4-OCF ₂ ^CF ₂ ^{H) Ph(2-Cl,3-CF} ₂ ^CF ₂ ^H,4-CF ₃ ⁾ Ph(2-Cl,3-c-Pr,4-I) ^Ph(2-Cl,3-CF ₃ ^,4-OC ₂ ^F ₅ ^{) Ph(2-Cl,3-CF} ₂ ^CF ₂ ^H,4-C ₂ ^F ₅ ⁾ Ph(2-Cl,3-c-Pr,4-Me) Ph(2-Cl,3-CF ₃ ,4-SO ₂ Me) Ph(2-Cl,3,4-di-CF ₂ CF ₂ H) Ph(2-Cl,3-c-Pr,4-Et) Ph(2-Cl,3-CF ₃ ,4-TMS) ^Ph(2-Cl,3-CF ₂ ^CF ₂ ^H,4-CF ₂ ^H) Ph(2-Cl,3-c-Pr,4-n-Pr) Ph(2-Cl,3-CF ₃ ,4-CN) Ph(2-Cl,3-CF ₂ CF ₂ H,4-OMe) Ph(2-Cl,3-c-Pr,4-t-Bu) Ph(2-Cl,3-C ₂ F ₅ ,4-Cl) ^Ph(2-Cl,3-CF ₂ ^CF ₂ ^H,4-OCF ₃ ⁾ Ph(2-Cl,3-c-Pr,4-i-Pr) ^Ph(2-Cl,3-C ₂ ^F ₅ ^{,4-F) Ph(2-Cl,3-CF} ₂ ^CF ₂ ^H,4- Ph(2-Cl,3,4-di-c-Pr) Ph(2-Cl,3-C ₂ F ₅ ,4-Br) OCHF ₂ )

Ph(2-Cl,3-c-Pr,4-CF ₃ ) Ph(2-Cl,3-C ₂ F ₅ ,4-I) Ph(2-Cl,3-CF ₂ CF ₂ H,4- Ph(2-Cl,3-c-Pr,4-C ₂ F ₅ ) Ph(2-Cl,3-C ₂ F ₅ ,4-Me) ^OCF ₂ ^CF ₂ ^H) Ph(2-Cl,3-c-Pr,4-CF ₂ CF ₂ H) Ph(2-Cl,3-C ₂ F ₅ ,4-Et) ^Ph(2-Cl,3-CF ₂ ^CF ₂ ^H,4-OC ₂ ^F ₅ ⁾ Ph(2-Cl,3-c-Pr,4-CF ₂ H) Ph(2-Cl,3-C ₂ F ₅ ,4-n-Pr) ^Ph(2-Cl,3-CF ₂ ^CF ₂ ^H,4- Ph(2-Cl,3-c-Pr,4-OMe) Ph(2-Cl,3-C ₂ F ₅ ,4-t-Bu) ^SO ₂ ^Me)

Ph(2-Cl,3-c-Pr,4-OCF ₃ ) Ph(2-Cl,3-C ₂ F ₅ ,4-i-Pr) Ph(2-Cl,3-CF ₂ CF ₂ H,4-TMS) Ph(2-Cl,3-c-Pr,4-OCHF ₂ ) Ph(2-Cl,3-C ₂ F ₅ ,4-c-Pr) Ph(2-Cl,3-CF ₂ CF ₂ H,4-CN) Ph(2-Cl,3-c-Pr,4-OCF ₂ CF ₂ H) ^Ph(2-Cl,3-C ₂ ^F ₅ ^CF ₃ ^,4-CF ₃ ⁾ Ph(2-Cl,3-CF ₂ H,4-Cl) Ph(2-Cl,3-c-Pr,4-OC ₂ F ₅ ) Ph(2-Cl,3,4-di-C ₂ F ₅ ) Ph(2-Cl,3-CF ₂ H,4-F) Ph(2-Cl,3-c-Pr,4-SO ₂ Me) ^Ph(2-Cl,3-C ₂ ^F ₅ ^,4-CF ₂ ^CF ₂ ^H) Ph(2-Cl,3-CF ₂ H,4-Br) Q ¹ Q ¹ Q ¹

Ph(2-Cl,3-CF ₂ H,4-I) Ph(2-Cl,3-OMe,4-OCF ₂ CF ₂ H) Ph(2-Cl,3-OCHF ₂ ,4-c-Pr) Ph(2-Cl,3-CF ₂ H,4-Me) Ph(2-Cl,3-OMe,4-OC ₂ F ₅ ) Ph(2-Cl,3-OCHF ₂ CF ₃ ,4-CF ₃ ) Ph(2-Cl,3-CF ₂ H,4-Et) Ph(2-Cl,3-OMe,4-SO ₂ Me) ^Ph(2-Cl,3-OC ₂ ^F ₅ ^,4-C ₂ ^F ₅ ⁾ Ph(2-Cl,3-CF ₂ H,4-n-Pr) Ph(2-Cl,3-OMe,4-TMS) Ph(2-Cl,3-OCHF ₂ ,4- Ph(2-Cl,3-CF ₂ H,4-t-Bu) Ph(2-Cl,3-OMe,4-CN) ^CF ₂ ^CF ₂ ^H) Ph(2-Cl,3-CF ₂ H,4-i-Pr) Ph(2-Cl,3-OCF ₃ ,4-Cl) Ph(2-Cl,3-OCHF ₂ ,4-CF ₂ H) Ph(2-Cl,3-CF ₂ H,4-c-Pr) Ph(2-Cl,3-OCF ₃ ,4-F) Ph(2-Cl,3-OCHF ₂ ,4-OMe) Ph(2-Cl,3-CF ₂ H,4-CF ₃ ) Ph(2-Cl,3-OCF ₃ ,4-Br) Ph(2-Cl,3-OCHF ₂ ,4-OCF ₃ ) P ^h(2-Cl,3-CF ₂ ^H,4-C ₂ ^F ₅ ⁾ Ph(2-Cl,3-OCF ₃ ,4-I) Ph(2-Cl,3,4-di-OCHF ₂ ) ^Ph(2-Cl,3-CF ₂ ^H,4-CF ₂ ^CF ₂ ^H) Ph(2-Cl,3-OCF ₃ ,4-Me) Ph(2-Cl,3-OCHF ₂ ,4- Ph(2-Cl,3,4-di-CF ₂ H) Ph(2-Cl,3-OCF ₃ ,4-Et) ^OCF ₂ ^CF ₂ ^H) Ph(2-Cl,3-CF ₂ H,4-OMe) Ph(2-Cl,3-OCF ₃ ,4-n-Pr) ^{Ph(2-Cl,3-OCHF} ₂ ^,4-OC ₂ ^F ₅ ⁾ Ph(2-Cl,3-CF ₂ H,4-OCF ₃ ) Ph(2-Cl,3-OCF ₃ ,4-t-Bu) Ph(2-Cl,3-OCHF ₂ ,4-SO ₂ Me) Ph(2-Cl,3-CF ₂ H,4-OCHF ₂ ) Ph(2-Cl,3-OCF ₃ ,4-i-Pr) Ph(2-Cl,3-OCHF ₂ ,4-TMS) Ph(2-Cl,3-CF ₂ H,4- Ph(2-Cl,3-OCF ₃ ,4-c-Pr) Ph(2-Cl,3-OCHF ₂ ,4-CN) O ^CF ₂ ^CF ₂ ^H) Ph(2-Cl,3-OCF ₃ ,4-CF ₃ ) Ph(2-Cl,3-OCF ₂ CF ₂ H,4-Cl) Ph(2-Cl,3-CF ₂ H,4-OC ₂ F ₅ ) Ph(2-Cl,3-OCF ₃ ,4-C ₂ F ₅ ) Ph(2-Cl,3-OCF ₂ CF ₂ H,4-F) Ph(2-Cl,3-CF ₂ H,4-SO ₂ Me) ^{Ph(2-Cl,3-OCF} ₃ ^,4-CF ₂ ^CF ₂ ^H) Ph(2-Cl,3-OCF ₂ CF ₂ H,4-Br) Ph(2-Cl,3-CF ₂ H,4-TMS) Ph(2-Cl,3-OCF ₃ ,4-CF ₂ H) Ph(2-Cl,3-OCF ₂ CF ₂ H,4-I) Ph(2-Cl,3-CF ₂ H,4-CN) Ph(2-Cl,3-OCF ₃ ,4-OMe) Ph(2-Cl,3-OCF ₂ CF ₂ H,4-Me) Ph(2-Cl,3-OMe,4-Cl) Ph(2-Cl,3,4-di-OCF ₃ ) Ph(2-Cl,3-OCF ₂ CF ₂ H,4-Et) Ph(2-Cl,3-OMe,4-F) Ph(2-Cl,3-OCF ₃ ,4-OCHF ₂ ) Ph(2-Cl,3-OCF ₂ CF ₂ H,4-n-Pr) Ph(2-Cl,3-OMe,4-Br) Ph(2-Cl,3-OCF ₃ ,4- Ph(2-Cl,3-OCF ₂ CF ₂ H,4-t-Bu) Ph(2-Cl,3-OMe,4-I) ^OCF ₂ ^CF ₂ ^H) Ph(2-Cl,3-OCF ₂ CF ₂ H,4-i-Pr) Ph(2-Cl,3-OMe,4-Me) ^{Ph(2-Cl,3-OCF} ₃ ^,4-OC ₂ ^F ₅ ⁾ Ph(2-Cl,3-OCF ₂ CF ₂ H,4-c-Pr) Ph(2-Cl,3-OMe,4-Et) Ph(2-Cl,3-OCF ₃ ,4-SO ₂ Me) ^{Ph(2-Cl,3-OCF} ₂ ^CF ₂ ^H,4-CF ₃ ⁾ Ph(2-Cl,3-OMe,4-n-Pr) Ph(2-Cl,3-OCF ₃ ,4-TMS) ^{Ph(2-Cl,3-OCF} ₂ ^CF ₂ ^H,4-C ₂ ^F ₅ ⁾ Ph(2-Cl,3-OMe,4-t-Bu) Ph(2-Cl,3-OCF ₃ ,4-CN) Ph(2-Cl,3-OCF ₂ CF ₂ H,4- Ph(2-Cl,3-OMe,4-i-Pr) Ph(2-Cl,3-OCHF ₂ ,4-Cl) ^CF ₂ ^CF ₂ ^H) Ph(2-Cl,3-OMe,4-c-Pr) Ph(2-Cl,3-OCHF ₂ ,4-F) Ph(2-Cl,3-OCF ₂ CF ₂ H,4- Ph(2-Cl,3-OMe,4-CF ₃ ) Ph(2-Cl,3-OCHF ₂ ,4-Br) ^CF ₂ ^H)